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Summary 
Sophorolipids (SL) are amphiphilic biosurfactant molecules consisting of a disaccharide 
sophorose with one fatty acid at the C1 position and optional acetylation at the C6’and C6” 
positions. They exist in a closed ring lactonic (LSL) or open acidic (ASL) structure. 
Sophorolipids are produced in crude mixtures in economically viable amounts by the 
yeast Starmerella bombicola and used in a variety of consumer products. Varying levels of 
anti- proliferative and anti-cancer activity of crude sophorolipid mixtures are described in a 
number of tumour cell lines in vitro. However, significant inter-study variation exists in the 
composition of SL species as well as other biologically active compounds in these mixtures, 
which makes interpretation of in vitro and in vivo studies difficult. It is hard to truly assess 
the anti-cancer action of SL due to the lack of in vivo studies. To date, only one other study 
evaluates the ability of a crude SL preparation to reduced tumour growth in a cervical cancer 
xenograft model.  This thesis aims to evaluate the ability of two SL congeners, produced by 
Starmerella bombicola, which have been highly purified and well characterised against the 
colorectal cancer cell growth in vitro and the ability to regulate the development of pre-
cancerous polyps in vivo.  
This thesis first evaluated and compared the biological activity of a 96% pure preparation of 
C18:1 LSL and a 94% pure C18:1 ASL preparation against CRC cells (HT29, HT115, 
HCT116, Caco2, LS180) and two normal cell lines CCD-841-CoN (colonic epithelial) and 
MRC5 (lung fibroblast) in vitro by assessing their ability to modulate cell viability via a MTT 
assay and the regulate the metastatic properties of these cells by assessing changes to 
migration and invasion in culture. The overall consensus of the data suggest that LSL induce 
cytotoxicity in CRC cells but also induces cytotoxity in the normal colonic CCD-841-CoN 
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cells at lower concentrations; results are detailed further in chapter three. In comparison, ASL 
reduced the viability of the CRC cell lines at low concentrations but proved non-toxic to the 
normal colonic cell line; results of these studies are detailed further in chapter four. 
In the latter portions of chapter three and four respectively, the biological activity of both 
congers were assessed in wt c57 mice and Apcmin+/- mice, a recognised animal model of 
Familial adenomatous polyposis (FAP) by first ensuring both LSL and ASL were well 
tolerated at doses of 0.5, 5 and 50mg/kg when administered orally. Next the ability of SL 
congeners to mediate adenomatous polyp growth was measured by counting the number of 
polyps present in the intestinal tract of Apcmin+/-  after 70 days of SL treatment compared to 
the vehicle-only treated control mice. In addition, parameters such as spleen weight and 
haematocrit levels were also measured as a method to evaluate the ability of SL to regulate 
the secondary side-effects associated with reducing the life-span of the Apcmin+/-.  In 
summary, LSL resulted in exacerbated polyp growth in Apcmin+/- with a further decrease in 
haematocrit in addition to splenomegaly. ASL had no effect on tumour number of size but 
increased haematocrit levels and reduced the spleen size of the treated Apcmin+/-  mice 
compared to vehicle control.   
The final experimental chapter of this thesis explored the possible mechanisms of action of 
SL in vitro. The CRC cancer cell line HT29 was used to assess SL induced alterations to lipid 
raft expression, changes to tight junctions and SL congener specific changes to mitochondrial 
membrane potential and reactive oxygen species production in vitro, as described in chapter 
five.     
In summary, contrary to current literature, purified ASL appears to have an advantage over 
the LSL as a potential therapeutic agent due to its ability to selectively reduce viability of 
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CRC cells without inducing toxicity at equivalent doses in normal colonic epithelial and lung 
fibroblasts form in vitro. Although ASL did not disrupt the tumour growth in the Apcmin+/-  
mice, they improved the haematocrit levels and decreased spleen size which could result in 
an increase in life-span to these mice as they are known to succumb to the effects of intestinal 
bleeding in the 5th – 6th month of life.  To date, this is the first study to investigate the effects 
of a highly purified LSL and ASL preparation across a wide range of CRC cells in vitro and 
the first study to investigate the anti-cancer of purified preparation in vivo. 
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Thesis overview 
The aim of this thesis was to investigate the anti-cancer potential of two purified 
sophorolipid congeners against colorectal cancer growth in vitro and in vivo. 
This literature review gives an insight into the origin, production and current uses of 
biosurfactants with a specific focus on sophorolipids, a glucolipid produced by the yeast 
Starmerella bombicola, are reviewed.  
We explore and discuss the potential use of sophorolipids in biomedical applications 
focusing on the biology and interactions of sophorolipids as anti-cancer compounds. This 
introduction provides a comprehensive review on the development of human colorectal 
cancer, in addition to comparing and contrasting the use of human cancer cell lines in 
vitro and relevant animal models. In particular, we detail the use of the Apcmin+/- mouse 
to determine whether purified preparations of sophorolipid congeners inhibit growth and 
progression in this pre-clinical model of FAP progression.  
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1.1 Surfactants 
Surfactants, a term coined in the 1940’s (Gerhard and Heinz, 1940), are chemical products 
which have surface-interface tension reducing activity (Young and Coons, 1945) and are 
predominantly derived from petrochemicals (Deleu and Paquot, 2004). Surfactants are 
further classified by charge: being anionic, cationic, non-ionic or zwitterionic (Kume et 
al., 2008). The majority of surfactants are non-ionic, followed closely in total numbers by 
anionic which have greater functional properties compared to the cationic and 
zwitterionic, which are restricted to comparatively smaller niche markets (Deleu and 
Paquot, 2004). 
The functional properties of surfactants include their use as detergents, emulsifiers, 
foaming agents, lubricants, wetting agents, rheology modifiers and starch retrogradation 
inhibitors (agents which reduce the staling process of baked goods) (Jacobson and 
BeMiller, 1998).  Surfactant products are produced on a world-wide scale (10 million 
tons per annum) (Zana and Xia, 2003), with approximately half used in laundry and house 
hold detergents [4.9 million tonnes] and the remainder employed in the chemical [0.1], 
food [0.3] (Garti, 2002), textile [0.8], environmental [0.5], agricultural [0.6], health care 
and cosmetic industries [2.0] (Holmberg et al., 2003).  
However, surfactants are petroleum based, with a major disadvantage being their lack of 
biodegradability and biocompatibility, which adversely affects the environment as they 
accumulate in water sources and cause toxicity to marine based organisms. (Schröder, 
1993). The non-biodegradability of surfactants can cause contamination of soils and water 
sources which can be taken up by cows resulting in surfactant bioaccumulation in the beef 
– which is then eaten by humans. Beef contaminated with the surfactant perfluoroalkyl 
has been reported by Lupton et al and serve as a potential severe health risk due to its link 
with hepatocellular hypertrophy and reproduction dysfunction (Lupton et al., 2014).    
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In order to reduce the dependency on petroleum based surfactants, various formulations 
based on raw-material surfactants produced from fats, oil and organic carbon sourced 
from fossils were developed (Scott and Jones, 2000). 
The use of surfactants derived from raw materials greatly reduced greenhouse gas 
emission levels compared to petrochemical sources (Patel, 2003). However, a study 
carried out under the European Climate Change Programme (ECCP) recommended that 
surfactants produced by micro-organisms would further reduce greenhouse gas emissions 
and improve biocompatibility (Schroeder, 2009).  Thus, the search for naturally produced 
surfactants, which are economically viable and can be separated via extraction, 
precipitation or distillation from micro-organisms, plants, invertebrates or animals has 
been an area of intense research. 
 
 
 
 
 
 
 
 
 
1.2 Biosurfactants 
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Biosurfactants (BS) are a class of natural surfactants produced from renewable resources 
via biotechnological methods and were first discovered in the late 1960’s. BS are 
produced by a variety of microorganisms as secondary metabolites, forming emulsions 
that reduce both interfacial and surface tension (Mulligan, 2005) when grown on water-
miscible or oily substrates. They are either secreted into culture broth during production 
or may remain adhered to microbial surfaces. BS are classified as either glycolipids, 
lipopeptides, phospholipids, fatty acids or polymeric compounds (Table 1.1). The natural 
physiological role for BS secreted by micro-organisms in the environment is not yet fully 
understood. It is hypothesised that they facilitate the growth of microbes on water 
immiscible substrates, increase adhesion to insoluble substrates or aid in the interaction 
with metals in the environment. Other studies have also shown that they play an important 
role in quorum sensing in bacteria (Ron, 2001). 
BS have clear advantages over chemical surfactants which include increased 
biodegradability, low toxicity and the ability to exert their effects at extreme temperatures 
and pH levels (Rodrigues and Teixeira, 2010); they prove versatile for a wide range of 
biomedical and industrial applications (Fracchia et al., 2012). Currently, a range of 
microbial biosurfactants are used in cleaning supplies (Bognolo, 1999), pesticides 
(Finnerty, 1994), textiles (Montoneri et al., 2009) and cosmetics (Kralova and Sjöblom, 
2009) while petroleum derived surfactants are still used in food products (Nitschke and 
Costa, 2007) and over-the-counter creams (Levin and Miller, 2011). BS have also been 
shown to have biological activity for use as antibiotics (Nielsen et al., 2002), fungicides 
(Stanghellini and Miller, 1997), anti-viral/immunoregulators (Vollenbroich et al., 1997) 
and enzymatic inhibitors (Cameotra and Makkar, 2004).  
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1.3 Sophorolipids 
Table 1.1: Types of major BS 
Name Type Species Producing Potential Applications 
Lipopeptide 
(Morikawa et al., 
1993) 
Surfactan Bacteria- Bacillus sp. 
Anti-microbial, anti-
viral  
Phospholipids 
(Todd et al., 2010) 
  
Bacteria - 
Thiobaccillus 
thioxidans 
Lowering surface 
tension, Anti-
microbial  
Fatty acids 
(Mulligan et 
al,.2001) 
Corynomycolic acid Cornebacterium lepus Environmental 
Spiculisporic acid 
Penicillium 
spiculisporum 
Heavy Metal 
decontamination 
Polymeric 
Compounds 
(Torchilin et al., 
2001) 
Emuslan/Alasan Acinetobacter sp Emisfying agent 
Liposan Candida lipolytica Emulsifier 
Glycolipids 
(Banat et al., 2000 
Sophorolipids 
Starmenella 
Bombicola  
Anti-microbial, anti-
viral, anti-cancer 
Rhamolipids Pseduomonas sp 
Anti-microbial, 
environmental 
Mannosylerythriol Candida sp. 
Anti-microbial, 
environmental 
Trehalolipids Mycobacterium 
Anti-microbial, 
environmental 
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The sophorolipid (SL) class of biosurfactants were first described in the early 1960’s by 
Gorin et al, as extracellular glycolipids synthesized from the non-pathogenic yeast – 
Candida apicola (Gorin et al., 1961). In the same decade, SL synthesized from 
Rhodotorula bogoriensis and Starmerella bombicola were also discovered, proving that 
production is not limited to a singular species, but to a number of related micro-organisms 
(Spencer et al., 1970). SL have many attractive properties for large scale industrial 
production, such as low production costs, minimal toxicity and biodegradability 
(degraded 61% after 8hrs post-production). 
Naturally found SL mixtures are made up of eight major components and composed of a 
hydrophobic fatty acid (C16- C18) tail and a hydrophilic carbohydrate head. The fatty 
acid tail can have one or more unsaturated bonds while the head is composed of a 
disaccharide sophorose with a β-1, 2 bond which is acetylated on the 6’ and/or 6’’ 
position. The structure of SLs is dependent on a terminal or sub-terminal hydroxylated 
fatty acid, which is linked β-glycosidically to the sophorose. The fatty acids’ carboxylic 
end can be free, giving rise to the acidic structure (Fig 1a) (Cavalero and Cooper, 2003b) 
or can be esterified at the 4’’ position giving rise to the lactonic ring structure (Fig. 1b).  
 
 
 
 
 
 
 
Figure 1.1: The structure of SL 
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1.3.1 SL synthesis and production 
a 
b 
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SL synthesis relies on both a glucose and a fatty acid supply, which can be supplemented 
in the production medium. Biosynthesis of SL occurs as follows: 
Fatty acids are converted to either a terminal or sub-terminal hydroxyl fatty acid. This 
occurs via membrane bound action of a NADP dependent mono-oxygenase enzyme – 
cytochrome P450. Next glucose is coupled glycosidically to the C1 position of the 
hydroxyl group of the fatty acid via glycosyltransferase I. This reaction requires a 
nucleotide-activated glucose as a glucosyl donor. A second glucose is then coupled to the 
C2 position of the first large glucose molecule via glycosyltransferase II. SL obtained at 
this point is classed as non-acetylated acidic molecules. A majority of the molecules 
formed continue on in the fermentation process and are further modified via esterification 
(lactonization) or acetylation of the carbohydrate head forming Lactonic SL. Most LSL 
are esterified at the 4’’ position. A minute percentage is esterified at the 6’ or 6’’ position 
which is carried out by a further step involves the use of acetyl co-enzyme A (Coates et 
al, 2007) dependent acetyl transferase. 
The process of biosynthesis of sophorolipids (described above) occurs during 
fermentation of Candida bombicola  (Van Bogaert et al., 2007). An important aspect of 
fermentation are the culture conditions. The optimal temperature for the culture of SL 
producing strains is 28.8°C which produces the highest yields from the Candida 
Bombicola strain used in this thesis and allows the initiation of the exponential growth 
phase. A drop of pH from seven to two can often be seen here, however for high yield 
output at pH of 3.5 is best for our strain of SL producing Candida Bombicola (Roelants 
et al., 2016). This can be achieved with the addition of NaOH.  It is important that there 
is a good supply of oxygen during the exponential phase of growth. An oxygen transfer 
rate of 50 – 80mM O2/l h-1 is also a necessity for a high SL yield.  
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The production of SL is also highly dependent on the culture medium composition. The 
main components of culture medium needed for SL synthesis include glucose (first 
glycidic carbon source), yeast extract (nitrogen source) and urea (Casas and García-
Ochoa, 1999). However, product yields can be greatly increased with the addition of a 
second carbon source of a lipophilic carbon source nature. This usually involves the 
addition of an oil or fatty acid such as vegetable oils (sunflower, safflower or soybean). 
Rapeseed oil was used as the secondary carbon source in this thesis as it produces a higher 
yield of SL (Daniel et al., 1998). 
The final stage of SL production involves the extraction of SL from the culture broth 
which is a vital step in order to produce a highly pure preparation. This can be achieved 
by the addition of an organic solvent such as ethyl acetate. However, this allows residual 
lipidic carbon sources to also be extracted which can be problematic during purification. 
Therefore, hexane extraction is also employed (ethyl:hexane 1:1) (Baccile et al., 2013). 
Newer techniques applied to SL separation includes a simple centrifugation, as SL is 
heavier than water, excess medium can be simply decanted, which is beneficial for large 
volumes (Casas and García-Ochoa, 1999).  
Over the years of SL production, C. bombicola and Wickerhamiella domercqiae; were 
classed as the preferred stain due to the high yield (400g/l). However further strain 
characterising tests revealed that the SL producing stain of Wickerhamiella domercqiae 
is actually Starmerella bombicola CGMCC 1576 (Chen et al., 2006, Li et al., 2016b, Li 
et al., 2016a). C. bombicola strains have now been listed as microorganisms that are 
technologically beneficial and generally recognised as safe (GRAS) (Bourdichon et al., 
2012).   
It has been proposed that the application of SL is directly related the structure of the 
mixture used (highly purified or high percentage of LSL or ASL) (de Oliveira et al., 
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2015). One the attractive features of SL are their ability to be chemically modified. During 
the fermentation process, alongside LSL and ASL, four other SL derivatives are formed 
which differ by structure which include ethyl ester (EE), ethyl ester monoacetate (EEM), 
ethyl ester diacetate (EED), methyl ester (ME). A common modification occurs at the 
carboxylic end of the fatty acid forming alkyl esters (Azim et al., 2006, Sleiman et al., 
2009). LSL have been shown to possess better biomedical properties such as anti-
bacterial (De Rienzo et al., 2015), anti-cancer and spermicidal in comparison to ASL and 
SL derivatives but prove difficult to solubilise. ASL prove better in foaming agents such 
as cleaning agents and their solubility makes them more suitable in food and cosmetic 
applications (K Morya et al., 2013) as they can be dissolved in non-toxic solutions such 
as saline (Van Bogaert et al., 2007) while SL derivatives mixtures have also been shown 
to have strong anti-viral activity compared to both LSL and ASL (Borsanyiova et al., 
2016). 
It has been hypothesised that further investigation could lead to the production of SL 
congers to target specific diseases; i.e. LSL compounds as anti-bacterial agents, ASL for 
cleaning agents and derivatives for the use as anti-viral agents (Zhang et al., 2004). 
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1.3.2 SL applications 
SL already have widespread uses in world today particularly in cleaning products and 
pesticides (de Oliveira et al., 2015). They are employed in the formulation of beauty and 
personal care products such as acne pads, anti-dandruff shampoo, lipstick and toothpaste 
(Shete et al., 2006). The use of SL are favoured over petroleum based surfactants due to 
their low toxicity and their potential biomedical enhancing properties including their 
ability to stimulate human cell growth such as fibroblasts, induce collagen production and 
activate macrophages for wound healing (Maingault, 1999).  The main applications of SL 
in the commercial sector and for potential biomedical use are described below. 
Agricultural, environmental and oil recovery uses of SL 
SL mixtures derived from Candida bombicola with a high percentage (>50%) of ASL (de 
Oliveira et al., 2015) have biocidal properties against phytopathogens such as 
Phytophthora sp when used as an herbicidal adjuvant with lemongrass oil (LGO), an 
organic herbicide, due to their ability to adhere to the plant surface thus resulting in an 
increased penetration (Giessler-Blank et al., 2010). SL demonstrate anti-fungal potency 
against soil borne pathogens such as Pythium sp. which can cause root disease infecting 
seeds, leaves and stems via the formation of zoospores (Yoo et al., 2005). SL has the 
ability to inhibit mycelial growth and motility and can result in the lysis of the zoospores.  
Although the process of oil production has been well-established over the years, there is 
still 67% of residual oil left behind in reservoirs after mining. To increase oil recovery, 
microbial enhanced oil recovery (MEOR) is applied to increase the overall quantity of oil 
harvested (Nerurkar et al., 2012). SL is attractive for the use in MEOR due to their ability 
to reduce interfacial tension resulting in improved drainage, reduction of oil viscosity and 
clearing oil flooded capillaries, increasing the quantity of oil harvested. SL can also aid 
in the cleaning up of oil spill related accidents due to their ability to bind and degrade 
 13 
 
hydrocarbons such as 2-methylnapthalene and hexadecane in less than 7 days (Elshafie 
et al., 2015). SL has been shown to be one of the best non-ionic BS for soil washing due 
to its ability to degrade aliphatic and aromatic hydrocarbons by 85-97% under laboratory 
conditions (Kang et al., 2010). 
Cleaning products 
SL can be used in the production of detergents and stabilizers due to their ability to lower 
surface tension of liquids from 72 mN/m to 35mN/m (Ma et al., 2012). SL demonstrate 
the ability to form micelles, a key feature of surfactants, at low concentrations (e.g. 40-
100mg/L, defined as the critical micelle concentration CMC), have a hydrophilic balance 
of 10-13 and foam forming capabilities. These characteristics render SL as a good wetting 
agent thus making them ideal for use as dishwasher agents and for cleaning hard surfaces 
(Develter and Lauryssen, 2010). 
Food 
Surfactants have been used in the food industry for many years in products such as salad 
creams and deserts as they can contribute to creaminess, texture and palatability. The use 
of natural BS such as SL is more appealing to the food industry as they can improve the 
quality of wheat flour by promoting volume, appearance and shelf-life of baked goods 
(Nitschke and Costa, 2007). The anti-microbial and germicidal properties of SL are also 
an attractive feature to the food industry. Formulations which include as little as 1% of 
SL have been shown to kill organisms such as E. coli, Samonella typhi and Shigella 
dysenteriae (de Oliveira et al., 2015) which are known to play a role in food spoilage and 
food borne disease. 
 
Anti-microbial 
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The antimicrobial properties of SL are not just limited to bacteria. They also demonstrate 
anti-mycoplasma and anti-algal properties (Van Bogaert et al., 2007). The extent of anti-
microbial activity is dependent of the chemical structure of SL and structure of the target 
bacterium, for example, LSL show a greater extent of inhibition against gram positive 
bacteria such as Bacillus subtilis, Staphylococcus epidermidis, Streptococcus faecium, 
and Propionibacterium acnes all of which are associated with skin infections (Lang et 
al., 1989). Potency of LSL against these bacterial strains opens up the possibility of their 
use in skin creams, cosmetics and hygienic products (K Morya et al., 2013). It is believed 
that SL exert their anti-microbial effect via the destabilization of the bacterial membrane 
resulting in a change in permeability, thus allowing membrane rupture and expulsion of 
cellular contents (Azim et al., 2006). 
The advantages of SL as a primary antimicrobial agent in comparison to current 
antibiotics used to treat clinical relevant bacteria are unclear.  A number of studies has 
been carried out to test the antibacterial effect of SL. These tests are usually carried out 
in bacteria which classified as GRAS. An alternative solution has been suggested to 
combat the reduced potency of SL. Studies have shown the synergistic properties of SL 
when used as an antibiotic adjuvant enhancing the activity of antibiotics such as 
tetracycline and cefaclor against S. aureus and E.Coli  (Joshi-Navare and Prabhune, 
2013).  
 
 
Anti-viral and spermicide 
SL have shown great promise as spermicidal and anti-HIV agents (Gross et al., 2004) in 
vitro. These biological effects are highly dependent on their structure with short carbon 
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chain SL have a higher viral potency (C11-13), while long chain SL structures (C15-18) 
show anti-spermicidal activity LSL demonstrated superior spermicidal, cytotoxic and 
inflammatory activity however the addition of an acetyl groups lower the hydrophilicity 
of SL thus improving antiviral and cytokine stimulating effects. Unfortunately, SL 
mixtures also exhibit toxicity against the VK-2/E6E7, an epithelial vaginal cell line, at 
doses of 23µg/ml or greater when tested in vitro (Shah et al., 2005) which could prove 
problematic for possible clinical translation. 
Immuno-modulatory 
The use of SL as immune-modulatory agents has been widely researched in septic shock 
model’s due to their anti-microbial, anti-viral and anti-inflammatory properties 
(Napolitano, 2006). The use of animal models of sepsis have become popular to test 
immuno-modulatory agents (Bluth et al., 2006). Gram negative bacterial-induced sepsis 
is exacerbated by the induction of a cytokine cascade which in-turn activates the 
coagulation and apoptosis cascade resulting in organ damage and intravascular 
coagulation (Cohen, 2002). The administration of SL mixtures in a rat model of sepsis 
decreased macrophage numbers, nitric oxide production and pro-inflammatory 
cytokines which is thought to contribute to the overall reduction in mortality rates 
(Bluth et al., 2006). Similarly, the administration of SL mixtures at concentrations 
ranging from 0.1-100µg/ml results in an immune-modulatory effect by reducing IgE 
production, both in U266 myeloma cells in vitro as well as in a mouse model of asthma 
in vivo (Hagler et al., 2007).   
 
Drug delivery systems 
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The ability of SL to self-assemble into different congeners as well as the extent of their 
amphiphilicity, (both of which are dependent on production methods, temperature and 
pH levels) makes them an ideal target for their use as a drug delivery system (Faivre and 
Rosilio, 2010). ASL can be used as a vehicle for mogroside V, a drug with promising 
anti-atherosclerotic, anti-cancer and anti-diabetic properties, enhancing penetration of the 
drug through the skin thus increasing its efficacy (Imura et al., 2013). SL have also been 
shown to enhance drug penetration. When coupled with Lactoferrin, a compound used to 
stimulate wound re-epithelialization when tested in human dermal fibroblasts (HDFn) in 
vitro, SL has been shown to increase the expression of tropoelastan resulting in increased 
cell proliferation and collagen synthesis in an in vitro model of transdermal absorption 
(Ishii et al., 2012). This also shows that SL is non-toxic to normal cells. 
Anti-cancer 
SL, isolated from Candida bombicola, have been reported to possess anti-cancer 
properties (Chen et al., 2006b), with crude LSL enriched preparations showing potent 
cytotoxicity against human liver (HT7402), lung (A549), breast (MDA-MB-231), 
cervical (HeLa & CaSki) and leukemic (HL60 & K562) cancer cell lines (Chen et al., 
2006b). Crude preparations of SL with undisclosed LSL/ASL ratio percentages have also 
been reported to show dose-dependent, anti-proliferative and pro- apoptotic activity 
against pancreatic cancer (H7402, HPAC) and esophageal cancer (KYSE450, KYSE109) 
cell lines (Shao et al., 2012).  
A number of hypotheses have been proposed to explain the mechanisms by which SL 
exert their anti-cancer potency; these hypotheses differ depending on which cell line is 
used. SL (defined by the authors as a mixture of LSL and ASL), induced differentiation 
of both leukaemia and glioma cell lines (Joshi‐Navare et al., 2011) while Fu et al., 2008 
demonstrated the induction of necrosis measured by LDH release in pancreatic cancer 
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HPAC cells in vitro. The cytotoxic effects of SL mixtures (with an undisclosed proportion 
of ASL/LSL congeners) have been observed in the liver cancer line H7402. This cytotoxic 
effect is mediated by blocking the cell cycle at G1 and S phase, increasing intracellular 
Ca2+ resulting in the induction of the caspase cascade and induction of apoptosis (Chen 
et al., 2006a).  
Conclusions on the specificity of such diverse preparations of SL in transformed cells 
is complicated by the inappropriate use of controls – a number of studies have excluded 
any normal cell controls in their studies (Shao et al., 2012, Ribeiro et al., 2015, Li et al., 
2016a) while other studies lack the use of appropriate primary or non-transformed cells 
which correspond with the tissue of origin for the cancer type used. Instead they opt for 
non-adherent cell lines such as peripheral blood mononuclear cells (PBMCs) in 
comparasion to pancreatic cancer cell lines (Fu et al., 2008) or Chang and co-workers, 
who used a HeLa contaminated cell line (Gao et al., 2011). 
To my knowledge, only one published study investigated the anti-cancer potential of SL, 
where a cervical cancer (HeLa) xenograft model was used and mice were treated with a 
crude LSL mixture at concentrations of 5, 50 and 500mg/kg bodyweight. In this study, a 
crude SL mixture dose dependently decreased tumour weights and sizes after 12 days of 
intragastrical administration. Samples of tumours from mice treated with a dose of 
50mg/kg LSL were shown to have a higher level of apoptosis compared to vehicle-only 
treated controls. However, the exact mechanisms of action in this aforementioned study 
are unclear (Li et al., 2016). 
Limitations of SL description in the literature and study design issues  
A wide range of bioactivities for SL have been documented, however the purity and 
composition of SL used in bioassays is highly variable, with most studies not disclosing 
the molecular species or their relative abundances within the mixtures (Fu et al., 2008, 
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Hardin et al., 2007, Chen et al., 2006b). Although LSL normally make up the highest 
proportion of crude preparations of SL (characteristically 70 – 85% (Manzke, 1999)), 
with varying amounts of ASL and other derivatives in the remaining mixture, this can 
change due to slight alterations in pH (Baccile et al., 2012) or temperature in the 
production process (Daverey and Pakshirajan, 2009, Amaral et al., 2010). 
A major problem with the majority of SL related cancer studies available in the literature 
is the difficulty in comparing and contrasting the data due to the use of poorly 
characterised crude preparations. This also poses an issue with reproducibility of studies 
due to the difficulty of reproducing batches of similar composition which will also causes 
problems for the clinical translation studies (Harvey, 2008). 
Another major issue of SL related cancer studies that populate the literature is the lack of 
follow through to in vivo model testing. With exception of our published study (Callaghan 
et al., 2016), only one other study has investigated the anti-cancer effects of SL in vivo. 
describing a xenograft model of cervical cancer and intragastrical injection of a crude SL 
mixture (Li et al., 2016a).  
We proposed that due to the biosafety of SL, they could be administered orally. Therefore, 
we employed the FAP - Apcmin+/- mouse model, which allowed the oral administration of 
a purified SL, giving direct access of the ingested SL to the growing of polyposis tumours 
along the intestinal tract. 
 
 
1.4 Colorectal cancer 
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In the western hemisphere, Colorectal cancer (CRC) in both men and women is the fourth 
most common cancer diagnosed each year (~298,000 cases) (Center et al., 2009) and is 
the second most common cancer-related cause of death in the UK (Torre et al., 2016). 
CRC onset can be attributed to both genetic and environmental factors. The most common 
developmental contributions include familial inheritance of CRC disorders such as 
familial adenomatous polyposis (FAP) and epigenetic alterations (Kondo and Issa, 2004) 
while environmental factors such age (Nakagawa et al., 2001), poor diet (Vargas and 
Thompson, 2012), smoking/alcohol intake (Giovannucci et al., 1995) and lack of exercise 
(Samad et al., 2005)  play a pivotal role in the development of CRC. 
CRC’s are defined as being highly heterogeneous at both the histopathological and 
molecular levels (Stigliano et al., 2014) and are classified as adenocarcinomas, squamous 
cell carcinomas, carcinoid, sarcomas or lymphomas. Clinical and histopathological 
analysis suggests that 90% of diagnosed CRC cases are adenocarcinomas arising from 
adenomatous polyps, originating in the intestinal lining, and are firstly benign before 
developing into carcinomas over a 60-80-year time period (Justin et al., 2015) (Neugut et 
al., 1998). 
Theories designed to explain CRC pathogenesis include Foulds’ hypotheses, stating that 
cancer is a multistep process developing over a long period of time (Foulds, 1965). 
Chronologically, this was followed by Nowells’ Clonal Evolution Model, which 
hypothesized that the development of tumours is characterized by a number of repeated 
mutations causing a multi-clonal population which have the ability to invade surrounding 
tissue and subsequent metastatic disease (Nowell, 1976). This was followed with 
Volgelstein’s theory detailing the adenoma-carcinoma sequence, giving the first real 
insight into the molecular pathways governing the pathogenesis of CRC (Fearon and 
Vogelstein, 1990). In this aforementioned model, specific genetic and epigenetic changes 
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were directly correlated to the initiation of neoplastic transformation of normal colonic 
epithelial to form benign adenomas before the development of a more malignant state 
(Fig 1.2).  This model posits that mutations of four key genes (APC, KRAS, DCC, p53) 
can influence histopathological changes associated with clinical progression of CRC. The 
Loeb model closely followed in 1991, postulating that tumour progression is initiated by 
genetic instability resulting in the formation of a large number of random mutations and 
production of clonal clusters with a mutant phenotype (Loeb, 1991).   
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Vogelstein’s group determined that CRC tumour development was initiated by 
destabilisation of the genome resulting in the inactivation of the tumour suppressor 
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Adenomatous polyposis coli (APC) gene – the first notable event in the CRC cascade 
which occurs in 60-80% of colorectal tumours (Powell et al., 1992). 
The APC gene is found on chromosome 5q21 and plays an important role in cell adhesion, 
transcription as well as signal transduction and is a key player in the development of both 
sporadic and inherited CRC (CA44688 and CA41183, 1991, Fodde, 2002). The germline 
or somatic APC mutations present in 90% CRC tumours are found between codons 1286-
1513 and result in early truncation of the protein (Cetta et al., 2007). In order to observe 
neoplastic transformations, both APC alleles must be inactivated. The APC protein plays 
an important role in the WNT signalling pathway which regulates β-catenin turnover in 
the cytoplasm. Any mutation, such as truncation of the APC protein, stimulates the over-
production of β -catenin which can result in neoplastic growth (Näthke, 2004).  
Although APC gene mutation initialises the start of the adenoma sequence, progression 
to carcinoma can only occur with the mutation of other genes. K-Ras mutations are found 
in 40% of CRC cases (Lievre et al., 2006). This oncogene plays an important role in cell 
proliferation.  When combined with APC mutations, CRC progression only relies on one 
allele of the K-Ras gene to be mutated for the development of more advanced polyps with 
carcinoma potential (Fig 1.2). 
The underlying origin of genetic mutations in CRC are believed to be caused by genomic 
instability (chromosomal instability (CIN)) which occurs in 85% of CRCs resulting in a 
loss or gain of chromosomal DNA or microsatellite instability (MSI) generating defective 
mismatch repair proteins (MMR) (Worthley and Leggett, 2010). 
 
1.4.1 Types of colorectal cancer 
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CRC cases are categorised into sporadic (73%) or familial /hereditary (27%). A majority 
of sporadic cases occur with no underlying genetic origins yet they still share major 
similar genetic alterations as the inherited CRC forms. 
Sporadic  
Sporadic CRC account for 75% of all CRC cases and they usually occur in adults with a 
median age between 70-75 years (Hawk et al., 2015).  In a majority of cases, CRC occurs 
without previous family history or a genetic predisposition. Sporadic CRC tumours 
predominantly develop at distal sites of the colon such as the recto-sigmoid region 
(Connell et al., 1994). In comparison to other cancers, CRC is relatively easily diagnosed 
and treated upon early diagnosis (Stewart and Wild, 2016). Similar to the inherited forms 
(see below), CRC are formed from benign precursor lesions known as polyps (Figure 
1.2). As postulated by Vogelstein, these polyps develop into cancerous lesions under the 
influence of mutational changes brought about by age, diet, environmental or genetic 
factors. 
Familial /hereditary colorectal cancer 
Familial or inherited CRCs are caused by specific genetic alterations that result in patients 
being more susceptible to the development of adenomatous polyps. The most common 
familial conditions include Hereditary Non-Polyposis Colorectal Cancer (HNPCC) (5% 
of cases), MUT-associated polyposis (MAP) (1% of cases), Hamartomatous conditions 
and Familial Adenomatous Polyposis (FAP) (1% of cases)  
 
Hereditary Non-Polyposis Colorectal Cancer (HNPCC) 
HNPCC, also known as Lynch syndrome, was first described in 1985 by Henry T. Lynch 
(Lynch and Lynch, 1985) and is an autosomal dominant disorder with incomplete 
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penetrance (Steinke et al., 2013). HNPCC is caused by mutations in the mismatch repair 
(MMR) genes MLH1, MSH2, MSH6 and PMS2 (Dunlop et al., 1997). HNPCC patients 
usually inherit one defective copy of the gene from their parents; however, it is not until 
the second copy of the gene is mutated that the syndrome occurs (Knudsons two-hit 
hypothesis (Knudson, 1996)). Mutations in both MMR genes such as MSH1 (Fishel et 
al., 1993) results in the malignant progression of adenomas in the colon. HNPCC accounts 
for 5% of all CRC cases and patients have an 80% risk of a CRC diagnosis in their lifetime 
(Stigliano et al., 2014). Patients with HNPCC can develop one or more adenoma tumours 
along the colorectal tract. These cancerous tumours are distinguishable from a sporadic 
tumour by simple molecular testing (investigating MMR and MSI gene alterations) 
(Herman et al., 1998). HNPCC patients present with CRC at around 45 years of age and 
have a high probability (approximately 30%) of developing another tumour within 10 
years (Vasen et al., 2007). The histopathological presentation of HNPCC cancers are 
normally recognised as presenting as mucinous tumours which are poorly differentiated 
and favour growth on the right anatomical side of the colon (Steinke et al., 2013). 
MUTYH-associated polyposis (MAP) 
MAP, first reported in 2002, is an autosomal recessive disorder caused by biallelic 
mutations in the MUTYH gene and occurs in 1% of CRC cases (Sampson and Jones, 
2009). The MUTYH gene plays an important role in base excision repair system which 
protects genomic DNA from oxidative related damage (Barzilai and Yamamoto, 2004). 
MAP patients do not have any germline APC mutations; instead they harbour germline 
mutations in the MUTYH gene which results in the growth of 10-100 polyps, which are 
primarily located in the proximal colon. These polyps begin developing in affected 
individuals at around 50 years old and have a 43-100% chance of progressing to 
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adenocarcinomas (Fleming et al., 2012). MAP patients usually present with clinical 
symptoms that are similar to other familial disorders such as FAP and HNPCC. 
Hamartomatous conditions 
Hamartomatous polyposis syndromes account for 1% of CRC cases. Hamartomatous 
polyps are focal malformations which are similar to a neoplasm but occur due to a 
development abnormality of the attached organ.  The term is used to cover a unique group 
of inherited CFC forms which develop hamartomatous polyp’s rather than the 
conventional epithelial polyps. This class of tumours includes Juvenile Polyposis (JPS), 
Peutz-Jeghers syndrome (PJS), Cowden syndrome (CS). Less common hamartomatous 
conditions include Bannayan-Riley-Ruvalcba syndrome and Cronkhite-Canda syndrome 
(Zbuk and Eng, 2007).  Like the other CRC familial disorders, hamartomatous conditions 
can arise due to underlying genetic alterations involving SMAD-4 (JPS), LKB1 (PJS) and 
PTEN (Cowden syndrome) (Wirtzfeld et al., 2001). 
Familial Adenomatous Polyposis (FAP) 
FAP is the second most common inherited colorectal cancer syndrome and occurs in 
approximately 1/10,000 people (Ruys et al., 2010). FAP is an autosomal dominant 
disorder with typical clinical presentation occurring in adolescence that includes the 
development of hundreds to thousands of large adenomatous polyps, coupled with severe 
colonic and rectal bleeding as well as severe anaemia. Although initially asymptomatic, 
these polyps invariably develop into colorectal cancer by the age of 50 (Bisgaard et al., 
1994) without medical intervention. However, due to the new age of medical surveillance 
in patients at risk of polyp development, only 1% of cases progress to colorectal cancer 
(Bonnington and Rutter, 2016). Although polyps are predominantly found in the colon of 
FAP patients, primary tumours can also be found in the small intestine with secondary 
tumours located in the liver, brain and thyroid (McConnell, 1976). 
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The majority of patients diagnosed with FAP have a family history of colorectal cancer 
however 20-30% of cases are diagnosed with no previous clinical or genetic familial 
association (Giardiello et al., 2014). Medical surveillance occurs in patients with a family 
history of FAP from as young as ten years old and includes colonoscopy, polyp removal 
and prophylactic colectomy to dramatically reduce development and mortality rates 
associated with colorectal cancer secondary to FAP (Syngal, 2015). Although medical 
intervention in FAP cases is required to prevent disease progression, the specialist 
consultations and clinical/surgical interventions that are required results in a significant 
financial burden to the NHS. This emphasises the need for a cheap and easily produced 
pharmacotherapeutic agent to prevent or reduce the number of polyps which form in FAP 
patients.  
Investigations of cancers with familial associations, have given insight into the 
mechanisms governing the development of sporadic colorectal cancer allowing the 
development of biomarkers and therapeutic targets. The most widely used methods for 
developing and testing therapeutic agents and their interaction with CRC progression 
involves the use of in vitro cultures (Cayrefourcq et al., 2015), human biopsies and tumour 
xeno-transplants (Tentler et al., 2012). Although tumour xeno-transplants are invaluable 
methods for scientific discovery, the major criticisms of their use are their inability to 
fully mimic progression of CRC as they do not grow within the natural hosts organ 
environment and often do not metastasise as they are most often implanted 
subcutaneously (McIntyre et al., 2015).  
 
 
1.4.2 Experimental models of CRC 
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In order to determine a consistent response to potential therapeutics, is important to use a 
large panel of tumour-derived human cell lines from the same location (e.g. lung, 
pancreas or colon) which comprise different stages of the tumour development. However, 
the use of cell lines alone does not mimic the natural progression and development of 
colorectal cancer tumours as they lack key features of the natural micro-environment 
including cell-matrix interactions, stromal involvement or chemical/genetic influences. 
This emphasises the need for in vitro studies to be corroborated with an appropriate 
animal model (Richmond and Su, 2008).  The ability to choose an appropriate animal 
model to characterise the effect of a chemotherapeutic, one must fully understand the 
pathogenesis of the disease.  
 
 
 
 
 
 
 
 
 
 
 
1.5 Animal models of CRC Syndromes 
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Over the past 80 years, many models of colorectal cancer have been developed using 
different methods which include diet/chemical/mutagen induced (Liu et al., 2012, Chong, 
2014), sporadic (Meyskens et al., 2008), xenograft (subcutaneously and orthotopic) 
(Hoffman, 2015). The main aim of an in vivo animal model of CRC is to mimic the 
molecular aetiology, pathology and clinical presentation in humans as close as possible.  
However due to the diverse causes of CRC, it is impossible for a sole model to encapsulate 
every aspect of the disease. Therefore, it is important, for translational purposes, if the 
following characteristics are present: tumour development limited to the large intestine, 
histologically and molecular progression similar to the human disease and should have 
similar cellular interactions (ie not immune compromised). 
Several animal models which falls within a majority of the criteria above and are widely 
used can be grouped in three categories: spontaneous intestinal cancer models, exogenous 
promotors of CRC or genetic manipulation and mutagen-induced germline mutations. 
Models of spontaneously occurring CRC 
Intestinal cancer models in canines and sheep recapitulate human pathophysiology of 
CRC as tumours also occur in the large intestine, with pedunculated adenomas appearing 
in the distal colon/rectum and sessile tumours occurring in the proximal colon (Simpson, 
1972). However, the use of both dogs and sheep has severe limitations including the high 
cost, specialised animal handling needs and the low prevalence of disease presentation 
(Church et al., 1987). Rodent models of spontaneous CRC development are preferred due 
to their low cost and ease of reproducibility. A spontaneous form of CRC has been 
reported in a very small number of C57BL mice, though this is extremely rare. Here a 
small number of adenomas formed along the small intestine spontaneously in a mouse 
without the use of genetic alteration or xenografting. However due to the rare occurrence 
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of spontaneous CRC development in mice it is not a viable option to meet the demands 
of medical research (Rowlatt et al., 1969). 
Exogenous promotion of CRC 
Mice or rats which are fed a diet that is high in fat (>20%), low in calcium (<0.05%) and 
low in Vitamin D (<100 lU/kg) that mimics a “western world diet” and leads to pre-
cancerous changes associated with CRC. After 12 weeks on a Western diet, mice present 
with hyper-plastic crypts and two years’ post-treatment show histological evidence of 
crypt dysplasia, polypoid lesions and an atypical nuclear epithelial phenotype (Newmark 
et al., 1990) which are also seen in CRC patients (Roncucci et al., 1991, Kiesslich et al., 
2004, Sánchez-Tilló et al., 2011).Unfortunately, rodents are also subjected to a diet defect 
in calcium (1/10th of the dietary requirement) therefore concluding they may also undergo 
other physiological changes not relevant to CRC.  
Chemical: The administration of carcinogenic agents to rodents have proved a common 
method of cancer induction. Both 1,2-dimethylhydrazine (DMH) and azoxymethane 
(AOM) (Wood et al.) are two commonly used agents, which when injected 
intraperitoneally or subcutaneously over six weeks induce CRC in rats. Rodents treated 
with these alkylating agents develop tumours in the colon after one year (DuBois et al., 
1996). A majority of the tumours collected have β-catenin, K-Ras mutations and 
microsatellite instability (De Robertis et al., 2011) which is also commonly seen in both 
sporadic and HNPCC patients  (Bissahoyo et al., 2005, van Zeeland, 1996).  
A second combination of carcinogens known as N-methyl-N-nitro-N-nitrosoguanidine 
(MNNG) and N-methyl-N-nitrosourea (NMU) that can induce sporadic CRC in rodents 
when injected into the rectum for 5 weeks (Narisawa et al., 1974) . NMU-induced CRC 
is a relatively fast acting model (15 weeks vs 52 weeks AOM) which induces tumours 
that are genetically (K-ras mutations) and histopathological (aberrant crypt foci) similar 
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to humans (Bara et al., 2003). However, it must be injected intrarectally as oral 
administration (Maekawa et al., 1988) can cause neoplasms to also develop in the prostate 
(Boileau et al., 2003), kidney (Sharma et al., 1994), lung (Schoental and Magee, 1962), 
breast (Chander et al., 1994) and thymus (Newcomb et al., 1988). 
Genetically modified mice 
The use of genetically modified mice is useful to study the underlying genetic alterations 
which must occur for CRC development. These models can be designed to specifically 
target and control the type and location of the tumour growth by controlling the regulation 
of specific genes using transgenic mice (Madison et al., 2002, Saam and Gordon, 1999). 
This method of CRC induction has been previously used to study the initial stages of 
adenoma development by employing the Cre-loxP system. This introduces two loxP sites 
into the APC gene at introns 13 and 14 and introduced into embryonic stem cells. This 
resulted in the formation of a pair of homologous recombinant embryonic stem cells 
clones which allowed the development of a transgenic mice model via blastocyst 
injection. These chimeras can be breed to form a transgenic mouse colony which develop 
adenomas in the small intestine (Shibata et al., 1997). These models prove beneficial in 
studying the link between genes and tumour development however, the development of 
the model is time consuming and requires experienced personnel. 
Mutagen-induced murine models 
The use of mutagen-induced models of CRC have become the favourite and most used 
model for pre-clinical research due to their molecular (alterations in APC gene) and 
pathogenic (multiple neoplasm development) similarity to human CRC cases. The i.p. 
injection of ethylnitrosourea (ENU) in C57/BL mice resulted in the development of the 
Apcmin+/ mouse model by inducing a germline mutation in the APC gene (Moser et al., 
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1995). These mice develop mutations in the APC gene resulting in the growth of 
numerous polyps along the intestinal tract (McCart et al., 2008).  
Injection of ENU into rats also resulted in the development of the F344- Pirc (polyposis 
in rat colon) model, with 100% of affected animals developing intestinal polyps and 
progression to adenocarcinoma. Unlike the mouse model, Pirc rats develop equal 
numbers of polyps in the colon and small intestine (Amos-Landgraf et al., 2007), although 
it is not readily available for purchase by cancer researchers.  
Although there are a wide range of animal models available to study the dietary, genetic 
and environmental changes that lead to CRC, the mutation-induced Apcmin+/-  model have 
proved to be most useful as it has a relativity fast experimental turnover (<150 days), 
reproducible, cheap and mimic neoplastic development seen in familial CRC conditions 
– FAP and HNPCC. They both have their benefits however the Apcmin+/- mice are readily 
available to buy and does not require the use of hazard carcinogenic compounds results 
in a shorter experimental time frame, making it ideal to test potential chemotherapeutic 
compounds (Johnson and Fleet, 2013). 
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1.5.1 Apcmin+/- mouse model of FAP 
Although there are over 300 unique mutations in the human Apc gene that cause FAP, 
they all result in truncation of the APC protein and this mutation is an early event (pre-
adenoma stage) in the pathogenesis of both familial and sporadic cancers (De la Chapelle, 
2004). Adenomatous polyps are primary precursor lesions for the development of 
colorectal cancer in humans, thus making them attractive targets for chemotherapeutic 
agents. 
The Apcmin+/- mouse model of FAP was first genetically engineered in the 1990’s by 
Moser (Moser et al., 1995) and provides an excellent in vivo system of the human disease 
and its development.  It has become one of the most widely used models to investigate 
the effects of genetics (cMyc and ERK signaling) (Ignatenko et al., 2006) , diet (high fat 
foods) (Baltgalvis et al., 2009) and therapeutic drugs (Piroxicam and NSAIDs)(Jacoby et 
al., 1996) on tumorigenesis in the gastrointestinal tract. Moser et al, first produced the 
Apcmin+/- mouse model by inducing the germline mutation with the use of ENU. This is a 
compound which can induce forward germline mutation in each locus by an occurrence 
of 1:700 resulting in gain or loss of function mutations. They detected this mutation in 
C57BL/6J (B6) male mice injected with ENU and mated them with AKR/J female mice 
and the female off-spring (F1) were subsequently mated again with a wild-type C57Bl/6J 
B6 male (F2 generation). A number of the off-spring (~25%) from these mice developed 
adult-onset anaemia with haematocrit levels <45%. It was noted that these mice did not 
have a long life span and at the point of death, haematocrit levels were 10-20%, with 
lethality being a consequence of severe anaemia. Later studies have shown that anaemia 
is evident from as early as 60 days (12 weeks) of age (Gould et al., 2003) and may be 
used as an early indicator of disease progression. It was also noted, upon autopsy, that 
Apcmin+/- mice develop splenomegaly (Wood et al., 2008) and lymph node (Puppa et al., 
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2011) enlargement near the end of their lifespan.  The passing of bloody stools from 140 
days+ was also observed in Apcmin+/- mice and at the peak of their life-span, protruding 
tumours were viable form their anus. On post mortem, numerous tumours were found 
along the small intestine – ranging between 1-8mm in size (Moser et al., 1995). 
Apc model alternatives 
Following the development of the Apcmin+/-  mouse model, researchers produced 
genetically modified versions of the APC model replicating the different genotype-
phenotype changes seen in human CRC such as polyps that were specific to the colon 
only compared to the Apcmin+/- mice which developed them in the small intestine only 
(Corpet and Pierre, 2003). These genetically modified models are created to include 
mutations in other regions of the APC gene. For example, coupling a truncation mutation 
at the 850 amino acid region of the APC gene (APC850) with Msh2 mutations results in 
mice bearing 160+ polyps in the small intestine and 5+ polyps in the colon compared to 
the 40+ in the small intestine seen in the Apcmin+/- mouse model (Karim and Huso, 2013). 
Use of the different types of Apc models allow researchers to manipulate polyp onset 
(Apc580 develop polyps within 4 weeks) and polyp origin (Apc1638N polyps found 
primarily in the colon) (Fodde et al., 1994). Although there are different variations of the 
Apcmin+/- mouse model, as mentioned above, the Apcmin+/- is still the most widely used as 
it is commercially available to purchase and well characterised. The location of the 
tumours in Apcmin+/- mice along the intestinal tract opens it up to orally administered drugs 
which, in theory, allows the drug direct access to the developing tumour on the epithelial 
surface.  
SL haven been shown to be safe, non-toxic and orally tolerated in mice (Ikea et al., 1986) 
therefore making them a potential candidate for oral administration in the treatment of 
CRC.  
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1.5.2 Limitations of the Apcmin+/- mouse model 
Although the Apcmin+/- mouse model makes an excellent candidate for the testing of 
potential drugs against the development of familial CRC, it does not come without its 
limitations. In patients with FAP, polyps tend to be isolated to the colon however in the 
mouse model, they grow along the intestinal track, with few to none located in the colon. 
Another notable difference between the animal and human form of FAP is the severity of 
tumours. In both mice and humans, numerous polyps develop however in the Apcmin+/- 
mouse model, these adenomas are benign and rarely advance any further. In comparison, 
adenomas that develop in FAP patients have the potential and often to progress into 
invasive carcinoma (Young et al., 2013)  
 
 
 
 
 
 
 
 
1.6 Project hypothesis and overview 
In this thesis, we hypothesized that purified sophorolipids selectively inhibit colorectal 
cancer cell growth in vitro and inhibit pre-cancerous tumour development in the Apcmin+/- 
mouse model of CRC. In order to minimize batch to batch variation and the proportions 
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of specific congeners, SL was obtained from a tightly-controlled batch fermentation 
method in order to produce a stock of highly pure and well characterized LSL and ASL, 
that were used for all in vitro and in vivo studies.  
• To characterise the cytotoxic effects of SL in vitro, LSL (chapter three) and ASL 
(chapter four) were tested at a range of concentrations on 5 different CRC cell 
lines representing different stages in the development of CRC. Both congeners 
were also tested to examine their toxic effect on normal human adherent epithelial 
and fibroblast cell lines. 
• To test the ability of SL to mediate tumour growth, purified LSL or ASL was 
administered orally to Apcmin+/- mice for 70 days (chapter three and four). In 
chapter five we describe the results of experiments which investigate a possible 
mechanism of action of ASL on disease progression in vivo.  
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Chapter 2 
 
General Materials and Methods 
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2.1 Sophorolipid production and purification 
The SLs used in this study were produced, purified and characterised by our collaborators 
(Bio base plant, Ghent, Belgium (LSL) and UPMC, Paris, France (ASL)). The isolation 
and purification methods are briefly described below. All SL compounds used in this 
thesis were derived from a single production batch. 
Lactonic SL 
A lactonesterase overexpressing strain of Starmerella bombicola (oe sble; (Roelants et 
al., 2016)) was used for the production of 96% pure lactonic diacetylated SL. HPLC- 
ELSD and LC-MS analysis was performed by collaborators at the Bio base plant, Ghent, 
Belgium and was carried out as described by (Roelants et al., 2016).  This was carried out 
by cultivating Starmerella bombicola (oe sble) in a production medium consisting of 
glucose monohydrate, yeast extract, sodium citrate tribasic dihydrate, NH4Cl, KH2PO4, 
K2HPO4, NaCl and CaCl2.2H20. Rapessed oil was added 48h later as a carbon source. 
Fermentation was carried out in 3 litre culture vessels at a temperature of 30oC and a pH 
of 3.5. Fermentation was carried out for 97h before the product was removed and purified.  
Purification was carried out by precipitation of the ASL at 80oC. The remaining product 
was filtrated using an Amicon 8200 (200 mL) stirred cell system with regenerated 
cellulose membranes (5, 10, and 30 kDa, filtration area 28.7 cm2; Millipore). The yeast 
cells were removed by centrifugation (15 min at 6000 rpm) and the cell-free fermentation 
medium (100 mL) was subjected to ultra- filtration. Nitrogen gas at a maximum pressure 
of 50 psi was applied over the filter cell. Samples were analysed using HPLC-ELSD 
analysis for SL content (Roelants et al., 2016). 
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Purified LSL was stored in a dehumidified chamber at room temperature and solubilised 
in 0.1% DMSO/PBS (in vitro) or 0.1% ethanol/ 10% sucrose (in vivo) for the duration of 
the experiments. 
Acidic SL 
The crude precursor used to prepare the acidic SL was purchased from Soliance (Pomacle, 
France; Batch # 11103A) as a lactone/acidic (~ 80/20) mixture. In order to open the 
lactonic form and remove the acetylated groups a classical hydrolysis step was performed 
in 5 M NaOH for 10 minutes. The solution was allowed to cool to RT and pH was adjusted 
to ~4.1. Extraction of ASL was performed as previously described (Baccile et al., 2013). 
In brief, following extraction, the water was removed using isopropanol under a vacuum. 
To extract ASL, a CH2Cl2/MeOH (60/40) mixture was used which prevented the 
remaining salt content from being extracted. After removal of the solvent via evaporation, 
the residual fatty acids were washed away using acetone (into which ASL are insoluble). 
This process lasted one day and it was repeated twice. The resulting white powder was 
allowed to dry at 55°C under vacuum for 5 days. The compound was analyzed using 1H 
NMR and HPLC-ELSD to determine the identity and composition of the compound. The 
most abundant compound (75.0%) within the purified ASL is the acidic C18:1 with the 
remainder of the sample composed of a terminal C18:1 and C18:2 congeners (~10% 
each), while all other congeners are limited to less than 2%. (Baccile et al., 2012, Baccile 
et al., 2016).  
Purified LSL was stored in a dehumidified chamber at room temperature and solubilised 
in PBS (in vitro and in vivo) for the duration of the experiments. 
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2.2 Cell culture 
2.2.1 Cell lines 
A total of five CRC cancer cell lines were chosen to determine SL bioactivity as they 
cover a wide range of cell types and stages of cancer development observed in the clinic 
(Table 2.1). The cell lines were maintained in DMEM (HT29, HT115, HCT116, LS180 
or MEM (CaCo2, CCD0841-CoN, MRC5) media or supplemented with 10% foetal 
bovine serum (Gibco Invitrogen; Paisley, UK). All cultures were maintained at 37°C and 
at 5% CO2. All cell lines were maintained in a T175 flask (Thermos scientific, Paisley 
UK) and sub-cultured when reached 80% confluency. All cell lines used for experiments 
were passaged no more than 15 times and were at least 90% viable which was determined 
by treating the cells with 1% trypan blue solution (Invitrogen; Paisley, UK) and counting 
the number stained (dead) or unstained cells (alive).  Viability was calculated by using 
the following equation:  No. of Viable Cells Counted / Total Cells Counted (viable and 
dead) x 100 = % viable cells. 
 
 
 
 
 
 
 
Table 2.1:  Cell lines used in this thesis and their genetic characteristics 
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HT29 ATCC® HTB-38, 
Human 
Colorectal 
adenocarcinoma 
(Fogh and Trempe, 
1975) 
Apc mutant, 
p53 mutant  
(Ying et 
al,2006) 
HT115 ECACC-cultures 
85061104, Human 
Colorectal 
carcinoma (Fogh 
and Trempe, 1975) 
Apc wt, p53 
wt (Ying et 
al,2006) 
HCT116 ATCC® CCL-247, 
Human 
Colorectal 
carcinoma (Brattain 
et al., 1981) 
Apc wt, p53 
wt (Ying et 
al,2006) 
Caco-2 ATCC® HTB-37, 
Human 
Colorectal 
adenocarcinoma 
(Fogh and Trempe, 
1975) 
Apc mutant, 
p53 mutant 
(Ying et 
al,2006) 
LS180 ATCC® CL-187, 
Human 
Colorectal 
adenocarcinoma 
(Tom et al., 1976) 
Apc wt, p53 
mutant (Ying 
et al,2006) 
CCD-841-CoN ATCC® CRL-1790, 
Human 
normal colonic 
epithelium 
(Thompson et al., 
1985) 
 
MRC5 ATCC® CCL-171, 
Human 
Foetal lung 
fibroblasts (Holliday 
and Tarrant, 1972) 
 
 
2.2.2 MTT assay 
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A total of 5x103cells per well were seeded (96 well plate; Nunc Thermos scientific, UK) 
and allowed to attach overnight forming a monolayer. Media was then replaced with 
serum free DMEM (Gibco, Invitrogen; Paisley: UK) media for a further 24h. A range of 
final concentrations of LSL or ASL (from 0.001μg/ml – 100μg/ml) were added to the 
wells and the cells incubated for another 24h. Subsequently, 10μl of a 25mg/ml solution 
of MTT (3-(4, 5-dimethylthiazol-2-yl) -2, 5- diphenyltetrazolium bromide; Sigma-
Aldrich Company Ltd, Dorset, UK) was added to each well and the plate was further 
incubated for 1h at 37°C. The remaining liquid was removed and the formazan crystals 
were solubilized with 100μl of DMSO (Sigma-Aldrich Company Ltd, Dorset, UK) and 
the absorbance at 570nm was read on a spectrophotometer plate-reader (BMG-
LABTECH, Omega, Aylesbury, Bucks UK). Dosages and control groups consisted of 
triplicate repeats and each experiment was carried out six times, with a single 
representative data set (mean ± SEM) presented in the results. 
2.2.3 Visualization of morphological changes induced by SL  
A total of 5x103 cells per well were seeded (96 well plate: Nunc Thermos scientific, UK) 
and allowed to attach overnight forming a monolayer. Media was then replaced with 
serum free DMEM (Gibco Invitrogen; Paisley, UK) media for a further 24h.  A final 
concentration of 0, 40 or 70μg/ml of LSL or ASL was added to the cells and the cultures 
incubated for another 24h. The cells were subsequently imaged with a Zeiss microscope 
(Axio Scope 1, Zeiss, Germany).  The operator was blinded to the experimental groups 
and three random fields were selected and captured at 20x objective magnification. 
Images were assessed for morphological changes by comparing each cell line to the 
vehicle control and looking for changes in cell shape, confluency or other morphological 
changes. Experiments were plated in triplicate and repeated three times, with a single 
representative data set shown as mean ± SEM. 
 42 
 
2.2.4 Quantification of detached cells 
A total of 5x103 cells per well were seeded (96 well plate: Nunc Thermos scientific, UK) 
and allowed to attach overnight forming a monolayer. Media was then replaced with 
serum free DMEM (Gibco Invitrogen; Paisley, UK) media for a further 24h. 
Concentrations of 0, 50 or 100μg/ml of LSL or ASL were added to the cultures and 
incubated for another 24h. Supernatant (10μl) was removed from each well, placed into 
a 1ml microcentrifuge tube (Thermo-fisher scientific: Leicestershire: UK). Cells were 
stained with Syto 9 (5µM) (Invitrogen Company Ltd: Paisley: UK) and propidium iodide 
(5µM) (Invitrogen Company Ltd, Paisley, UK) by adding it directly into the 
microcentrifuge tube  and incubated at room temperature for 30 minutes. The cells were 
centrifuged at 300x g for 5 minutes and the supernatant was removed. Cells were washed 
using ice-cold phosphate buffered saline (pH 7.4, Oxoid Company Limited: 
Leicestershire: UK) and spun onto a microscope (Thermo-fisher scientific: 
Leicestershire: UK) slide using a cytocentrifuge (Shandon, Thermo-fisher scientific: 
Leicestershire: UK) for five minutes at 1200g. Slides were subsequently imaged with a 
Zeiss florescence microscope (Axio Scope 1, Zeiss, Germany) at a range of objective 
magnifications. The operator was blinded to the experimental groups and 3 random fields 
were selected (40X objective magnification), with a between 1 - 250 cells counted per 
field of view. Following staining with Syto9 and PI, fluorescent staining was present in 
nucleus, with live cells appearing green while dead cells fluoresced red (Altman et al., 
1993). Experiments were plated in triplicate and repeated three times, data set shown as 
mean ± SEM. 
 
 2.2.5 Cell viability analysis: acridine orange/ethidium bromide staining  
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To determine the number of necrotic or apoptotic cells resulting from addition of LSL or 
ASL to cultures, the cells were stained in situ with 10mg/ml acridine orange (Sigma-
Aldrich Company Ltd, Dorset, UK) and 1mg/ml ethidium bromide (Sigma-Aldrich 
Company Ltd, Dorset, UK) and morphological changes were assessed by fluorescence 
microscopy (Ribble et al., 2005). For assessment of apoptosis, a total of 3x105 cells were 
seeded onto a 10mm coverslip (Agar Scientific; Stansted: Essex, UK), incubated 
overnight and allowed to form a confluent monolayer. Following serum starvation for 
24h, either LSL, ASL (at 20μg/ml or 70μg/ml, concentrations chosen based on the results 
from the MTT assay) or 5μM of etoposide (positive control for induction of apoptosis 
(Barry et al., 1993) (Sigma-Aldrich Company Ltd: Dorset: UK) was added to the wells 
and the cells incubated for a further 24h. To determine the number of live cells remaining 
on the coverslip, the samples were washed three times with ice-cold phosphate buffered 
saline (pH7.4, Oxoid: Leicestershire: UK), followed by incubation at room temperature 
in the dark, with a solution of 10μl of 1:1 acridine orange/ethidium bromide for 5 minutes 
and then the cells were washed 3x with ice-cold PBS and subsequently imaged with a 
Zeiss florescence microscope (Axio Scope 1, Zeiss, Germany) at a range of objective 
magnifications. The operator was blinded to the experimental groups and 3 random fields 
were selected and images were captured using a 40X objective). A total of 300 attached 
cells per coverslip were counted and identified by their morphological features as being 
either necrotic (red/orange nuclei), apoptotic (green condensed or fragmented nuclei) or 
live (green non-condensed ovoid or rounded nuclei). Experiments were plated in triplicate 
and repeated three times, data set shown as mean ± SEM. 
  
 
2.2.6 Migration assay- Boyden chamber 
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A migration assay was carried out in a modified Boyden chamber, based on a previously 
described protocol (Chen, 2005). The individual cell lines, CCD-841-CoN, HT29 or 
HT115 CRC cells (104 cells/100μl medium), were placed in the upper compartment of a 
96-well FluoroBlok transwell inserts (Analab; Lisburn, Northern Ireland) which 
contained 8μm pore size polyethylene terephthalate filters (Analab; Lisburn, Northern 
Ireland) and the cells were allowed to attach overnight. A final concentration of 0, 10 or 
50μg/ml of LSL or ASL in serum free media was added to the upper chamber, while 
DMEM supplemented with 10% FBS was added (as a chemoattractant) to the bottom 
chamber and cells were left to migrate overnight in an incubator at 37°C and at 5% CO2. 
After the incubation, all media in the upper chamber was removed and all cells that failed 
to migrate was removed using a sterile cotton swab. Cells that had migrated through to 
the lower surface of the filter insert were stained with a 0.1% solution of crystal violet 
(Sigma-Aldrich Company Ltd: Dorset: UK) made up in 25% methanol (Sigma-Aldrich 
Company Ltd: Dorset: UK). A total of three random areas were chosen and a minimum 
of 1 cell and a maximum of 300 cells stained with crystal violet was counted under a light 
microscope at 40x (Zeiss microscope; Axio Scope 1, Zeiss, Germany). Migration rates 
was expressed as total percentage of the control.  Experiments were plated in triplicate 
and repeated three times, data set shown as mean ± SEM. 
 
 
 
 
2.2.7 Invasion assay 
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This assay is an adaption to the migration assay using a Boyden chamber as previously 
detailed (Albini et al., 1987). The upper filter insert compartment of a 96-well FluoroBlok 
transwell boyden chamber (Analab; Lisburn, Northern Ireland) containing 8μm 
polyethylene terephthalate pore inserts (Analab; Lisburn, Northern Ireland) were 
removed and coated with 10μg ECM (Sigma-Aldrich Company Ltd, Dorset,-Aldrich; 
UK) at room temperature for 1hr. CCD-841-CoN, HT29 or HT115 CRC cells 
(102 cells/100μl medium) were placed on top and treated with 0, 10 or 50μg/ml of LSL 
or ASL in serum free media. 
DMEM supplemented with 10% FBS was used as a chemoattractant in the bottom 
chamber and cells were left to migrate through the ECM and through the insert following  
overnight incubation at 37°C and with 5% CO2. After the overnight incubation, all media 
in the upper chamber was removed and cells that failed to migrate were removed using a 
sterile cotton swab. Cells that had migrated through to the lower surface of the filter insert 
were stained with a 0.1% solution of crystal violet (Sigma-Aldrich Company Ltd: Dorset: 
UK) made up in 25% methanol (Sigma-Aldrich Company Ltd: Dorset: UK). A total of 
three random areas were chosen and a minimum of 1 cell and a maximum of 300 cells 
stained with crystal violet were counted with a light microscope using a 40x objective 
(Zeiss microscope; Axio Scope 1, Zeiss, Germany). Migration rates was expressed as 
total percentage of the control.  Experiments were plated in triplicate and repeated three 
times, data set shown as mean ± SEM. 
 
 
2.2.8 Scratch assay 
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For the wound healing scratch assay (Todaro et al., 1965, Rodriguez et al., 2005), 1.6x105 
CCD-841-CoN, HT29 and HT115 cells were plated in each well of a 6 well plate (Nunc 
Thermos scientific, UK) and allowed to attach overnight. A “wound” was made in the 
confluent monolayer by scratching a line in the centre of the well using a sterile toothpick. 
Cells were rinsed very gently with PBS three times and serum free media supplemented 
with vehicle-control or 10µg/ml ASL was added to the cultures before incubation for 
another 72 hours. Images were captured at 10x objective magnification at various time 
points using a Nikon microscope (Nikon ELWD TI SCP, Japan) and stored as .tif files 
for offline analysis. The area of the gap not occupied by cells was measured using ImageJ 
software (Schneider et al., 2012).  After 72h, measures were taken from the area not 
occupied by cells. Experiments were plated in triplicate and repeated three times. 
 
 
 
 
 
 
 
 
 
 
2.3 Animal model 
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All animal procedures were approved by the animal care and ethics committee (Ulster 
University) and national (UK Home Office) ethical guidelines. 
 The Apcmin+/- male and wild type female mice were housed together for breeding 
purposes and subjected to a 12/12 light cycle. Food and water were available ad 
libitum and animals were weighed on a weekly basis to evaluate consumption. Mice were 
monitored on a daily basis by recording grooming habits, behaviour, activity levels and 
general well-being (for details see Appendix 1). Once treatment with SL commenced, a  
loss of 10% or more of body weight and/or any obvious signs distress resulted in 
immediately euthanization by an overdose of inhaled CO2. 
2.3.1 Genotyping 
Ear punch biopsies were obtained from the 21-day old progeny of Apcmin+/-/wt crosses for 
the purpose of genotyping, using primers specific for the APC mutation . Genomic DNA 
was isolated from samples of ear tissue by first solubilizing them in 75µl of an alkaline 
lysis reagent (25mM NaOH, 0.2MmM disodium EDTA; (Sigma-Aldrich Company Ltd, 
Dorset, UK) in a 0.2ml tube (Thermo-Fisher scientific: Leicestershire: UK)  at 95°C for 
40 minutes, allowing them to cool and neutralizing the digested sample with 75µl of Tris-
HCl (40mM; (Sigma-Aldrich Company Ltd, Dorset, UK). The digested samples were 
mixed with PCR master mix (Qiagen Company Ltd, Manchester, UK), taq polymerase 
(Qiagen Company Ltd; Manchester: UK), nuclease free water (Qiagen Company Ltd; 
Manchester: UK),  and Apcmin+ specific primers (forward: TCT CGT TCT GAG AAA 
GAC AGA AGC T/reverse: TGA TAC TTC TTC CAA AGC TTT GGC TAT;100μm 
each; Invitrogen Company Ltd, Paisley, UK). Samples were placed in a thermocycler 
(Techne TC-5000 Gradient Thermocycler, Hanwell, London UK) and a PCR reaction 
performed under the following conditions: 94°C, 2min; (94°C, 1min; 60°C, 1min; 72°C, 
1min) for 30 cycles followed by a final extension step at 72°C for 2 minutes. The PCR 
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products were subjected to HindIII digestion (Invitrogen, Paisley, UK) for 1h at 37°C 
followed by a 20 minute denaturing step at 65°C. Digested PCR samples were 
electrophoresed on a 4% agarose/TBE-buffered gel (Sigma-Aldrich, Dorset, UK) for 40 
minutes. The presence of a single band at 111bp indicated a wt mouse, while an additional 
band at 123bp indicated a heterozygous Apcmin+/- mouse (Fig. 2.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.2 Sophorolipid dosing 
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Mice were treated orally via a voluntary drinking routine (by dispensing solutions through 
a sterile p20 pipette tip) every other day with either vehicle-only control (LSL; 0.1% 
ethanol/ 10% sucrose) (ASL; 10% sucrose in saline) or a solution containing 50mg/kg 
body weight of LSL suspended in vehicle. Mice were observed for 20 minutes following 
feeding treatment to ensure all solution was ingested.  
2.3.3 Tolerance study 
To test the ability of wt and Apcmin+/- mice to tolerate the oral administration of SL, a pilot 
study was undertaken in C57 wt mice of which 2 mice/group were fed a solution of either 
LSL or ASL (0.5, 5 or 50mg/kg) for 5 weeks. This determined that there were no adverse 
effects to as body weight or general well-being observed. During the experiment, body 
weights, food and water consumption were measured weekly. After 5 weeks of treatment, 
the mice were euthanized by an overdose of CO2 inhalation. Subsequently, major organs 
(liver, stomach, kidneys, lungs, heart, spleen and pancreas) were isolated, weighed and 
changes in gross morphology such as shape and colour were recorded.2.3.4 Efficacy 
study 
At five weeks of age, wt and Apcmin+/- males and females (separated by gender), were 
placed into experimental groups (10 per group). Both wt and Apcmin+/- mice were fed 
vehicle or 50mg/kg LSL or ASL for 10 weeks. During the experiment body weights, food 
and water consumption was measured every other day. At the mid-point of the SL 
treatment protocol (35 days), blood was extracted from the tail vein from the mice for 
haematocrit analysis. This was carried out by first dipping the mouse’s tail in warm water 
(40ºC) to expose the veins. Blood was collected from the vein using a 23G needle and 
collected in EDTA tubes (Aquilant Scientific, Down, NI). After 70 days of treatment, 
mice were euthanized with an overdose of non-recovery anaesthesia (Ketamine (100 
mg/kg BW) (Ketavet; Pfizer, Berlin, Germany) and xylazine (16 mg/kg BW) (Rompun; 
 51 
 
Bayer, Leverkusen, Germany) and blood was immediately collected by cardiac puncture, 
placed into EDTA tubes (Aquilant Scientific, Down, NI) and the haematocrit determined 
(Cole-parmer, Trickenham,UK) within 60 minutes of extraction.  
2.3.5 Tissue collection and assessment 
Following euthanasia, samples of intestinal tract, colon, spleen, heart, liver, kidneys and 
lungs were carefully removed, weighed and then fixed in 10% buffered formal saline 
(pH7.4, Oxoid: Leicestershire: UK). The intestinal tracts were laid out (Fig 2.2) and 
divided into the duodenum, jejunum and ileum according to the description of  (Casteleyn 
et al., 2010) and inspected for the appearance of Peyer’s Patches  along the outside of the 
intestinal tract. After identification of the specific intestinal regions, the samples were cut 
longitudinally, the number of polyps was recorded and their diameters measured with 
callipers (Fig 2.2). Individual specimens were then cut into ~2cm strips and placed in 
cassettes containing 10% BFS, prior to standard tissue processing and wax embedding.  
2.3.6 Tissue processing and wax embedding 
Cassettes were subsequently placed into 10% neutral buffered-formalin (Sigma-Aldrich; 
Dorset, UK) for 1hr and placed into the Leica TP 1020 tissue processor (Leica; Milton 
Keynes, UK). The tissue was processed according to the following automated machine 
program: 70% ethanol (2h), 80% ethanol (2h), 90% ethanol (2h) 100% ethanol (1h), 
100% ethanol (1h) 100% ethanol (1h), xylene (1h 30min), xylene (1h 30min), paraffin 
wax (4hr), paraffin wax (2hr). Following the wax infiltration, the tissue was embedded 
by pouring melted wax into a medium surgipath embedding mould (Leica; Milton 
Keynes, UK) and critically orientating the tissue.  
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2.3.6 H&E staining 
To assess qualitative histopathological changes in the intestines and spleen, the paraffin 
–embedded tissues were cut using a microtome (Shandon; Cheshire, UK) into 5μm 
sections. The sections were then placed on glass slides, cleared with xylene, dehydrated 
in descending grades of ethanol, stained with Mayer’s haematoxylin and eosin stain 
(Sigma-Aldrich, Dorset, UK) and examined with a Zeiss light microscope (Axio Scope 
1, Zeiss, Germany) at a range of objective magnifications. 
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2.4 Statistical analysis 
Statistical analyses of in vitro data was performed using either one-way ANOVA or 
student’s t- test using the GraphPad Prism programme (GraphPad software, San Diego, 
USA). All comparisons between in vivo groups were assessed using a students’ t-test. A 
value of p <0.05 was defined as being statistically significant. Significance is signified as 
follows in all Figures: * p<0.01, ** p<0.001 ***p<0.0001. 
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Chapter 3    
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Lactonic Sophorolipids increase tumour burden in Apc
min+/- 
mice.  
 
 
 
 
 
 
 
 
 
 
 
 
The majority of data obtained from this chapter is included in a publication in PLoS one 
(Callaghan et al., 2016). This manuscript is included as Appendix 3.
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3.1 Introduction 
SL produced by the non-pathogenic yeast, Candida bombicola has received an increase in 
research interest due to their reported biological functions. This has prompted the 
exploration and possible manipulation of these biodegradable SL for their potential clinical 
and pharmacological applications.  
SL are created via fermentation of yeast producing a compound made up of LSL or ASL 
mixtures. LSL and ASL differ in chemical structure and thus may have differing potential 
applications. For instance, LSL have shown to be the preferred SL compared to ASL and 
other derivative congeners as it excels as an antibacterial, anti-viral and anti-inflammatory 
agent. LSL concentrations as low as 0.01% w/v, impart lower surface tension to solutions 
and are proving useful in detergent formulations (Cox et al., 2013). LSL detergents have 
been shown to be more effective at stain removal at lower washing temperatures making 
them more economical and environmental friendly in comparison to other commercially 
available detergents (Marchant and Banat, 2012).   
LSL have an established reputation of being strongly anti-microbial, with a pronounced 
effect against gram-positive bacteria in vitro (Shah et al., 2007) and in sepsis models in vivo 
(Bluth et al., 2006).  They have also shown demonstrated anti-fungal activity against plant 
pathogens such as Phytophthora sp. and Pythium sp. (Schofield et al., 2012) as well as 
having spermicidal activity. However more recent in vitro studies indicate that LSL may 
have potential as anti-cancer agents.  
The in vitro activities of SL has been reviewed, with LSL enriched preparations showing 
potent cytotoxicity against human liver (HT402), lung (A549) and leukemic (HL60 & 
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K562) cells (Chen et al., 2006a). Cruder preparations of SL are reported to show dose-
dependent, anti-proliferative and pro- apoptotic activity against pancreatic cancer (H7402, 
HPAC) (Fu et al., 2008) and esophageal cancer (KYSE450, KYSE109) cell lines (Shao et 
al., 2012). 
Conclusions on the specificity of such diverse SL preparations (i.e. many are poorly 
characterized and contain unspecified mixtures of LSL and ASL) to transformed cells 
growth is complicated by the inappropriate use of normal cell controls to properly assess 
their specific toxicity. One such study used non-adherent peripheral blood mononuclear 
cells (PBMCs) (Fu et al., 2008) to test the compounds toxicity in comparison to pancreatic 
cancer cells. This is not an appropriate control as it is a non-adherent cell line and does not 
originate from the same organ as the cancer being tested. 
The purity and composition of SL preparations used in these bioassays is highly variable, 
with most studies not disclosing the molecular species or their relative abundances within 
the “purified” mixtures (Fu et al., 2008, Chen et al., 2006b). Acetylated LSL predominate 
in most SL mixtures (characteristically 70 – 85%) (Hu and Ju, 2001), therefore, due to the 
high percentage of LSL, studies claim these formulations as being in “purified” forms.  
Despite a number of studies showing that SL preparations have anti-proliferative effects on 
tumour cell lines in vitro, there are few in vivo studies in tumour models. To our knowledge, 
the only other study reported the effects of SL mixture in a cervical cancer tumour xenograft 
model. Here Li et al, demonstrated that intragastrically SL administered for 12 days resulted 
in a dose dependent (5, 50 and 500mg/kg) decrease in tumour weights in BALB/c nude mice 
injected with HeLa cells (Li et al., 2016a). 
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In order to minimize batch to batch variation and reduce specific congeners (2.5% ASL and 
<1% free fatty acids as a proportion of dry weight) we used stock samples from our 
collaborators who used a tightly-controlled batch fermentation method of 96% pure and 
well characterized LSL that was used in all our in vitro and in vivo studies. 
In test the potential toxicity of purified LSL in vitro, we examined its’ effect on 4-5 CRC 
cells lines which cover the different severities of CRC seen in humans. Two normal adherent 
and well known cell lines – a colonic epithelial coupled with a lung fibroblast cell line was 
also treated with various concentrations of LSL was used to examine the ability of SL to 
differentiate between normal and cancerous cells in vitro.  
 To further quantify the effects in vivo- LSL was orally administered to the Apcmin+/- mice, 
a gold standard CRC model use to test chemotherapeutic agents.  Prior the commencement 
of the study, a “pilot” study was carried out to ensure that both C57 and Apcmin+/- mice could 
tolerate the oral administration of the LSL at doses of up to 50mg/kg. 
 
 
 
 
 
 
 60 
 
3.2 Hypothesis: 
Purified forms of LSL specifically inhibit colorectal tumour cell growth in vitro and polyp 
growth in a FAP model in vivo. 
Aims and objectives: 
1) Obtain a purified and well characterized LSL stock produced by Starmerella 
bombicola. 
2) Assess the cytotoxic properties of a purified LSL sample on four unrelated colorectal 
cancer cell lines: HT29, HT115, HCT116, Caco-2 and in addition to two non-
transformed lines: normal human colonic epithelium CCD-841 CoN and lung 
fibroblast MRC5 in vitro. 
3) Determine the ability of orally administered LSL to inhibit polypgrowth in Apcmin+/- 
mice, a well-established model of FAP. 
 
 
 
 
 
 
 
 61 
 
3.3 Results 
Production and purification of LSL 
The production of the C18:1 lactonic diacetylated SL (Fig 3.1) used for our in vitro and in 
vivo studies was produced by collaborators (Roelants et al., 2016).  A S. bombicola oe sble 
strain  was employed and a bioreactor experiment similar to one previously described 
(Roelants et al., 2016) was carried out. However, instead of rapeseed oil, oleic acid was 
used as the hydrophobic carbon source. This resulted in a very uniform SL product (Fig 3.2) 
containing 99%  SL  (97.3  %  C18:1  SL  [Mw  =  688],  1.3  %  C18:2  SL  and  0.4  %  
C18:0  SL).  
The final purity of the sample was >99.5% SL and the composition in terms of SL was 
determined to be 96% diacetylated C18:1 LSL (Mw = 688; Fig. 3.2, 3.8 % diacetylated C18:1 
ASL (Mw = 706; Fig. 3.2) and minor impurities consisting of 0.04% free fatty acids/oil, 
0.001% glucose, 0.004% glycerol and total nitrogen of 0.14%. This batch sample was stored 
at room temperature and solubilized in 0.1% DMSO/PBS (in vitro) or 0.1% ethanol/ 10% 
sucrose (in vivo) for use in all the experiments described in this chapter. 
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LSL reduces cell viability in CRC cells 
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LSL concentrations above 20μg/ml resulted in reduced viability of both colonic epithelial 
(CCD-841-CoN) and lung fibroblast (MRC5) cell lines (Fig. 3.3a; p<0.0001), in addition to 
Caco2, HCT116 and LS180 colorectal tumour cell lines (Fig 3.3b; p < 0.05).  HT29 cells 
show a trend towards an increase in viability at doses between 20 - 40µg/ml; however, this 
is not statistically significant (p ˃ 0.05). In both HT29 and HT115 colorectal cancer cell 
lines a significant decrease in viability was observed at doses exceeding 70µg/ml (Fig. 3.3b; 
p < 0.001).  
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LSL induces morphological changes and loss of adherence in vitro 
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Microscopic examination of confluent cultures of CCD- 841-CoN cells revealed a bimodal 
morphology following exposure to vehicle, whereas at doses of 40 and 70 µg/ml LSL there 
were large areas devoid of cells, with remaining adherent cells displaying a shrunken and 
rounded phenotype (Fig. 3.4). In vehicle-treated cultures, all the cancer cell lines (HT29, 
HT115, HCT116 and Caco2 cells) display densely packed, cobblestone-like monolayer 
morphology. HT29 and HY115 cells had no obvious change in phenotype at a dose of 
40µg/ml LSL. At a dose of 40 µg/ml, LSL resulted in the detachment of HCT116 and Caco2 
cells (Fig. 3.4). In HT29, HT115, HCT116 and Caco2 cells that were exposed to 70µg/ml 
LSL, the confluent monolayer was disturbed and there were clear signs of cell rounding and 
cell-free areas indicative of detachment (Fig. 3.4).  
Following treatment with the middle and maximum doses - 0, 50 and 100µg/ml LSL, 
detached cells were isolated from the supernatant of wells to determine if they were alive 
or dead, using propidium iodide and Syto 9 staining (Fig 3.5). At doses of 50 and 
100µg/ml, all cells found in the normal CCD-841-CoN supernatant were stained red, 
positive for cell death (Fig 3.5a p<0.001). In the cancer cell lines, 4% of cells found in the 
supernatant stained green – a positive for being alive while 96% of the detached cells were 
dead (Fig 3.5b-e p <0.01). At 100µg/ml, all detached colorectal cancer cells were dead 
(p<0.001)
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LSL induces cell death in vitro 
Cells treated with LSL were assessed via ethidium bromide staining and morphological 
analysis to determine if they were alive, apoptotic or necrotic as outlined in Chapter 2.2.5. 
LSL treatment resulted in a higher proportion of cells undergoing necrosis compared to 
apoptosis in both normal colonic as well as the four colorectal cancer cell lines we 
examined (Fig. 3.6). In CCD-841-CoN cultures a dose of 20μg/ml LSL resulted in ~70% 
cell death (Fig. 3.6f), the majority of which showed morphological features consistent with 
necrosis (Fig. 3.6p). Both HCT116 (Fig. 3.6i p<0.001) and Caco2 (Fig. 3.6j p<0.001) were 
susceptible to cell death at a dose of 20μg/ml LSL, while HT29 (Fig. 3.6g) and HT115 
(Fig. 3.6h) were relatively resistant. In CCD-841-CoN cells exposed to 70µg/ml LSL, the 
few attached cells available for quantification (Fig. 3.6k) were either necrotic or apoptotic 
whereas in HT29 (Fig. 3.6l), HT115 (Fig. 3.6m), HCT116 (Fig. 3.6n) and Caco2 (Fig. 
3.6o) all showed a significant increase in both necrotic (p < 0.0001) as well as apoptotic (p 
< 0.001) cells when compared with vehicle only (Fig. 3.6a-e). Etoposide was used as a 
positive cell death inducer control (Fig 3.6p-t). Etoposide induced primarily apoptosis in 
all cell lines with the exception of Caco2 where higher levels of necrosis was observed. 
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High concentrations of LSL reduce cell migration and invasion                                                                                                                                                                                                                                                                                                                                              
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To determine the effects of LSL on cell migration and invasion, the Boyden chamber assay 
was used as described in chapter 2.2.6.  CCD-841-CoN treated with the vehicle-only control 
solutions were set to a 100% migration rate to compare with the LSL treatments. In media 
supplemented with 10µg/ml LSL cell migration was reduced to 32% of control values (p 
<0.0001 Fig 3.7a). The addition of 50µg/ml of LSL further decreased migration to 11% of 
control values (p <0.0001 Fig 3.7a). Concentrations of 10µg/ml did not significantly alter the 
migration of either HT29 or HT115 cultures. However, at 50µg/ml the migration of HT29 
and HT115 decreased to 60% (p <0.001 Fig 3.7a) and 73% (p <0.001 Fig 3.7a) respectively 
of control values for these cell lines. 
To determine the ability of LSL to influence the invasive properties of cancer cells, CCD-
841-CoN, HT29 or HT115 cells were plated on a layer of Matrigel™ in the upper part of a 
Boyden chamber. The normal CCD-841-CoN cell line failed to invade through the Matrigel. 
At 10µg/ml there was no significant difference in invasion percentages in the HT29 or HT115 
cells compared to vehicle control. At 50µg/ml LSL, the percentage of invasion in HT29 and 
HT115 cells was reduced to 30% (p <0.001 Fig 3.7b) and 50% (p <0.0001 Fig 3.7) of control 
values respectively. 
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wt and Apcmin+/- mice tolerate the oral administration of LSL 
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In order to determine the palatability and assess any potential contra-indication for oral 
administration of LSL, a small number (3 per LSL concentration in a dose escalation 
protocol) of wt and Apcmin+/- mice were fed a vehicle consisting of either 0.1mM DMSO in 
10% sucrose water or 0.5, 5 or 50mg/kg LSL dissolved in 0.1 DMSO /10% sucrose water for 
5 weeks.  
The weights (Fig 3.8a) of the mice and their water (Fig 3.8b) and food consumption (Fig 
3.8c) was measured each week. Both wt and Apcmin+/- mice gained weight at the same rate 
which was not affected by LSL administration. On average, both vehicle and LSL treated wt 
and Apcmin+/- consumed 12.5 grams of food and 13.4 grams of water per week.  
Mice were also monitored for any change to normal behavioral habits such as grooming, 
nesting and reaction to humans during the study. There was no change in behavioral activity 
noted across the different treatment groups or LSL dosing concentrations (Appendix 1). 
On completion of the tolerance study, major organs (liver, stomach, kidneys, lungs, heart, 
spleen and pancreas) were removed weighed and a gross inspection was carried out (Fig 
3.9b).  There were no significant differences in organ weights of the vehicle treated compared 
to LSL treated mice. There were no statistically significant differences in weight gain, food 
or water consumption, behavioral activity or organ weights in either wt or Apcmin+/-  mice at 
any of the concentrations of LSL (0.5, 5, 50mg/kg) tested (see Appendix 1). 
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Oral administration of LSL to Apc
min+/- 
mice exacerbates polyp 
development 
Genotyping of mice was undertaken following genomic DNA extraction, PCR and 
subsequent restriction enzyme digestion and electrophoresis; this methodology yielded a 
single 111bp band for the wt allele or dual 111/123 bp alleles (Fig. 3.10a) that are consistent 
with a heterozygous Apc
min+/- 
mouse. On the basis of genotyping, mice were randomly 
assigned to either LSL or vehicle-only dosing groups, irrespective of gender. The weights 
of both wt and Apc
min+/- 
mice fed with either vehicle-only control or LSL solutions were not 
significantly different (25.2g vs 24.9g; NS p < 0.1) and there were no differences in water 
(98.2ml vs 99ml; NS, p > 0.05) or food (180.7g vs 178g; NS p > 0.05) consumption over 
the duration of the experiment.  
After two weeks of treatment, bloody mucus and small polyps (0.3mm +/- 2) were observed 
around the anus of the LSL treated mice (n=6/10 mice). By the end of the LSL treatments 
the anal polyps were 1-2mm in size and there were obvious signs of bleeding from the 
intestinal tract (3.10b). 
Following euthanasia and removal and inspection of the intestinal tract, this revealed an 
exacerbation in the growth of polyps in LSL treated Apc
min+/-  
mice compared to the 
vehicle-control mice (Fig 3.11). The gross morphological appearance of unfixed flat 
mounted ilea from wt mice (Fig. 3.11 top) treated with vehicle-only (left) or 50 mg/kg 
LSL (right) was characterized by a flattened, uniformly smooth mucous epithelium. In 
vehicle-only treated Apc
min+/- 
mice (Fig. 3.11;), there was clear evidence of occult 
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bleeding throughout the ileal segment and numerous polyps (modal diameter 2mm; Fig. 
3.11) compared to wt mice. Following treatment with 50mg/kg LSL for 70 days, there is 
clear evidence of recent bleeding as well as a greater number (vehicle-only = 55.5 ± 3.3 vs 
50mg/kg LSL = 70.5 ± 7.8; Fig. 5c; p < 0.05) of larger diameter (modal size 4mm; Fig. 
3.11; p < 0.001) polyps throughout the ilea compared to the vehicle only treated 
Apc
min+/-  
mice (p < 0.001).  
The number of polyps along each segment of the intestinal tract (duodenum, jejunum, 
ileum, colon and rectum) was analyzed (Fig 5e). No polyps were found in any segment of 
the intestinal tract in wt mice treated with either vehicle or LSL.  There were no significant 
changes to the number of polyps found growing along the duodenum (8 ±2 vs 9±4 p >0.05 
ns), colon (2±3 vs 4±4 p >0.05 ns) or rectum (0±0 vs 0±0 p >0.05 ns) in Apcmin+/- mice fed  
vehicle or 50mg/kg LSL.  There was a significant increase in the number of polyps in the 
jejunum ( 12±4 vs 21±4 p >0.0001) and ileum (20±8 vs 42±9 p >0.0001) in Apcmin+/- mice 
fed  vehicle or 50mg/kg LSL. 
Histological features of sections from wt mouse ilea treated with vehicle or 50mg/kg LSL 
are characterized by evenly spaced, narrow villi with mucoid glands at their base (Fig. 
3.12; top). Sections through Apc
min+/- 
polyps (Fig. 3.12b; bottom) treated with vehicle- 
only (left) or 50mg/kg LSL (right) reveals a severely disturbed villous architecture
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LSL treatment specifically increases splenic weight and red pulp proportion and 
decreases Payer’s patch numbers in Apc
min+/- 
mice 
Feeding wt mice with either vehicle-only or 50mg/kg LSL, also did not affect the wet 
weights of excised spleen (Fig. 3.13a,b; NS, p > 0.05). However, spleens from Apc
min+/- 
mice were both larger (Fig. 3.13a) and heavier (Fig. 3.13b; p < 0.0001) than those from wt 
mice. Administration of 50mg/kg LSL for 70 days to Apc
min+/- 
mice also resulted in a 
statistically significant increase in splenic size (Fig. 3.13a) and weight (Fig. 3.13b; p < 0.05). 
Examination of histological sections from wt mouse spleen (Fig. 3.13c; top) revealed 
conspicuous intensely basophilic areas of white pulp, separated by less dense regions of red 
pulp in the areas responsible for removal of old or damaged erythrocytes. In Apc
min+/- 
mice 
the proportion of red pulp was increased compared to wt (c.f. Fig. 3.13c top and middle; p 
< 0.05). Following treatment with 50mg/kg LSL there was a further increase in red pulp 
size as compared to vehicle-only controls (c.f. Fig. 3.13c middle and bottom p < 0.05).  
Apc
min+/-  
mice had a lower number of Peyer’s patches (PP) along the intestinal tract (Fig. 
3.14). There were no significant difference between wt vehicle and LSL (11 vs 10; ns, p > 
0.05). Apcmin+/- had reduced PP numbers compared to vehicle (4.4 vs 11 **p <0.002). LSL 
dosing significantly decreased PP numbers compared to  vehicle (1.4 vs 4.4 * p <0.01) (Fig 
3.14b).  
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LSL significantly decreases haematocrit levels in Apcmin+/- mice. 
The haematocrit levels of both wt and Apc
min+/- 
mice were determined at both the mid-point 
of LSL dosing (day 35) (Fig 3.15a) as well as at time of euthanasia (day 70) (Fig 3.15b). At 
35 days there were no significant changes in haematocrit levels between wt and Apc
min+/-  
mice (49.0 ± 0.5 vs 50.0 ± 1.0; NS, p > 0.05). There were also no significant differences 
observed between vehicle-only or LSL treatment groups (47.5 ± 1.2 vs 48.0 ± 1.2; NS, p > 
0.05). Haematocrit values were significantly higher in wt than Apc
min+/- 
mice (49.5 ± 0.9 
vs 38.1± 1.2; p <0.001). Additionally, the feeding of Apc
min+/- 
mice with 50 mg/kg LSL 
for 70 days caused a significant decrease in haematocrit compared to the vehicle-only control 
(38.1± 1.2 vs 28.2 ± 1.8; p<0.05). 
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3.5 Discussion 
In order to decrease dependency on petrochemical derived surfactants, biosurfactants are 
increasingly finding use in a variety of applications ranging from industrial and household 
cleaning reagents through to skin-care products and foodstuffs (Levin and Miller, 2011). The 
organism with the highest productivity yield of biosurfactants is the pathogenic species 
Pseudomonas aeruginosa, which has made their large scale industrial and health-care use 
problematic (Lang and Wullbrandt, 1999). Modified strains of the yeast Starmerella 
bombicola are a potential commercially viable alternative, as it is non-pathogenic and a high 
yielding producer of homogenous SL In addition to their current commercial uses, SL 
preparations have previously been reported to have anti-cancer activity based on their ability 
to reduce the viability of pancreatic (Fu et al., 2008), lung , liver (Chen et al., 2006a) and 
esophageal cancer cells (Shao et al., 2012) in-vitro. However, these aforementioned studies 
are difficult to compare, as inter-study variation is significant and the purity as well as 
homogeneity (proportion of SL species) is often unreported. Since both purity of SL as well 
as homogeneity (Cavalero and Cooper, 2003) can affect the outcome of biological responses 
to these molecules, we produced a large batch of pure (99% SL) and homogeneous LSL 
preparation (96% C18:1) which was used for all subsequent use in in vitro and in vivo 
experiments. SL are normally formed as a complex mixture with related species differing by 
the degree of sophorose acetylation as well as fatty acid length and saturation (Otzen, 2016). 
This species diversity, coupled with the various congeners found in crude SL preparations 
makes separation and purification difficult, demanding and expensive; however, it is vital 
when considering potential pharma-therapeutic uses  (Rodrigues et al., 2006). In the past 
number of years, purification of SL species have been achieved by the use of thin layer 
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chromatography, HPLC and column chromatography (Develter and Lauryssen, 2010). The 
majority of studies investigating the anti-cancer potential of SL separate and purify samples 
with the use of HPLC, MS or NMR (Fu et al., 2008, Chen et al., 2006b) producing data 
showing the exact composition of the SL to be tested, but the information on purity and 
composition is often omitted. One notable study (Ribeiro et al., 2015) which used pure and 
well characterized SL (92% 18:1 LSL) examined their effects on breast carcinoma cells and 
found a dose-dependent cytotoxic effect. Here we report on a 96% 18:1 LSL preparation that 
was used throughout both our in vitro and in vivo experiments. 
We addressed whether a pure preparation of LSL from Starmerella bombicola has a 
differential and/or dose-dependent effect on transformed adherent cells in comparison to 
“normal” adherent cells; a highly desirable property for potential cancer chemotherapeutics. 
We assessed five well characterized colorectal cancer cell lines (HT29, HT115, HCT115, 
LS180 and CaCo2) in addition to adherent, non-transformed colonic epithelium (CCD-
841-CoN) and lung fibroblasts (MRC5). The 96% 18:1 LSL preparation used in our 
experiments had a differential effect on induction of cell death in these cell types; more 
specifically, they have a more potent effect against “normal” cells at lower doses (10µg/ml). 
Only a small number of studies have been carried out looking at the anti-cancer activities of 
SL isolated from Starmerella bombicola, such as that described in the breast cancer line 
MDA-MB-231 (92% C18:1 LSL). The majority of studies have been carried out using SL 
produced by Wickerhamiella domercqiae, which was recently identified as C. bombicola 
after genome sequencing (Li et al., 2016b). These cytotoxicity studies (Chen et al., 2006a), 
also demonstrate a similar potent effect of SL from doses ranging from 40µg/ml – 2mg/ml 
(compared our study: 3—60µg/ml). The wide range of dose efficacy may be partially 
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explained by the differences in SL species and uncharacterized mixtures. The repeatability 
and high level of consistency in the data from our in vitro and in vivo studies is consistent 
with our conclusions on the biological activity of our LSL sample, although we cannot 
exclude the possibility that the 3.8% ASL found within our SL mixture may have some co-
incident biological activity (see Chapter 4).  
In one previous study, LSL mixtures demonstrated no effect on circulating (non-adherent) 
blood monocytes, although their comparison with adherent pancreatic tumour cells is 
spurious (Fu et al., 2008). Other non-transformed cell lines examined in the literature 
include the uncharacterized, and not readily available HL7702 and the ‘Chang’ liver cells, 
believed to derived from normal liver, but later found to be HeLa contaminated (Masters, 
2002). 
We determined that colorectal cells treated with 40 – 70µg/ml LSL begin to die after 24hr 
in vitro. The predominant type of cell death observed, following ethidium bromide/acridine 
orange staining, was morphologically consistent with necrosis. This morphological 
necrosis occurred at doses of 70µg/ml in the cancer cell lines and 20µg/ml in the normal 
cell lines. Necrosis is a type of unregulated programmed cell death (Ouyang et al., 2012), 
characterized by the disruption of the lipid membrane resulting in the leakage of 
intracellular proteins, reduction in ATP and cell lysis thus provoking an immune response 
(Kumar et al., 2012). SL induced necrosis has been demonstrated in other cell lines, as 
quantified by LDH release: such as HPAC (Fu et al., 2008) and the HL-60 leukemic cell 
line (Isoda et al., 1997). The induction of necrosis in various cell lines (including those 
described in this study) likely occurs via the intercalation of BS into the lipid bilayer as 
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previously documented (Isoda et al., 1997). Koley et al., (2010) explained that, at a cell-
line specific minimal concentration, surfactants integrate into the cell lipid membrane, 
resulting in carbon chain structural rearrangement. High doses of SL induce tension at the 
interfacial region of the bilayer, resulting in phospholipid dehydration which affects lipid 
stability, cellular adhesion and function (Koley and Bard, 2010, Fracchia et al., 2012). This 
disruption of the lipid bilayer, has also been described as the mechanism of action from  
SL-induced cell death in human sperm (Shah et al., 2005).  
We also tested the migration inhibitory potential of LSL on CRC cell lines in vitro. Doses 
of 10 and 50µgml were chosen based on the previous cell viability and cell death assay as 
a concentration which could have a potent effect without resulting in a change in viability 
or morphology across the cell lines. At both 10 and 50µg/ml, there was a significant 
decrease in migratory activity of CCD-841-CoN cells. However, in HT29 and HT115 cells, 
a reduction in migration only occurred at the higher 50µg/ml dose. Studies carried out by 
Ribeiro and co-workers have shown that LSL decrease migration in the scratch assay, a 
measure of migration, in breast cancer MDA-MB-231 cells at a dose of 5mg (Ribeiro et 
al., 2015). 
Cancer cells are renowned for possessing the ability to invade through an extracellular 
matrix; a key hallmark for the progression to metastasis (Hanahan and Weinberg, 2011). 
Therefore, we tested the ability of LSL to inhibit invasion through Matrigel (Nicosia and 
Ottinetti, 1990) of HT29 and HT115 cell lines. Similar to the results from our migration 
study, only the higher 50µg/ml concentration of LSL resulted in a decrease in the 
percentage of cells that invaded through the Matrigel. LSL demonstrated more effective 
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inhibition of invasion against HT29 cells compared to HT115, however this may be 
attributable to the metastatic carcinoma phenotype associated with the HT115 cell line 
(Jonas et al., 1996) (Parr et al., 2000). 
The in vitro data presented in this chapter clearly demonstrates the ability of LSL to reduce 
the viability of normal and cancer cells and disrupt the migration and invasion of cancer 
cells at high concentrations. However, this study would have benefited from the addition 
of extra intraexperimental controls. This includes the addition of a well characterised 
chemotherapeutic such as etoposide or doxorubicin to compare the efficacy of LSL in 
reducing cell viability and seeing how that compares to the gold standard chemotherapeutic 
drugs. It would be suggested that this would be included in future repeats of the 
experiments.  
Studies investigating the therapeutic potential of SL in in vivo models are limited, with the 
exception of  models describing their potential for reduction of sepsis. SL mixtures reduce 
mortality in rats with experimentally induced sepsis induced via caecal puncture. However, 
in comparison to the crude SL mixtures, LSL caused an unexpected increase in the 
mortality rate in rats with septicaemia at the same dose (5mg/kg) (Hardin et al., 2007, Bluth 
et al., 2006). 
The Apc
min+/- 
mouse is a widely used animal model for investigating the correlations 
between food, genetics and chemotherapeutic intervention in the development of intestinal 
adenomatous neoplasms (polyps). These mice have a life span of <150 days due to 
secondary consequences of the disease (extensive bleeding of colonic polyps accompanied 
by anemia), this is one of the reasons it makes an ideal and quick model to study the effects 
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of compounds (Yekkala and Baudino, 2007). Oral administration was chosen as the ideal 
route of administration, in contrast to a traumatic abdominal injury, as it allows the LSL to 
have direct access to the gut epithelium and polyps to exert their biological effect.   
SL have been reported to be well tolerated and non-toxic in mice at doses below 15g/kg 
(Ikeda et al., 1986). To confirm this prior to embarking on a full-scale study, we tested if 
the oral administration of 0.5, 5 and 50mg/kg LSL would be well tolerated by wt (C57Bl/6j) 
and Apcmin
+/-  
mice. The behavior, weight development, food and water intake were not 
significantly different between treatment groups and there was no difference in the weights 
or gross morphology of the major organs after 5 weeks of treatments. On the basis of this 
pilot study we treated, we treated wt C57 and Apcmin+/- mice with 50mg/kg of LSL for a 
total of 70 days.    
Our pilot data, in addition to the long-term administration study of LSL clearly demonstrates 
that oral administration has no detrimental effect on behavior, weight, or food/water 
consumption at doses of 0.5, 5 and 50mg/kg.  Considering the ability of SL mixtures to 
reduce cancer cell viability, it is surprising that there is only one other in vivo study 
investigating the use of SL in a pre-clinical model of cancer  (Li et al., 2016a). In the 
aforementioned study, BALB/c nude mice were subcutaneously injected with HeLa cells 
and either 5, 50 or 500mg/kg of SL mixtures were administered by intragastric gavage for 
12 days. Tumour analysis revealed that treatments with either 5, 50 or 500mg/kg SL 
inhibited tumour growth by 29%, 41% and 52% respectively (Li et al., 2016a).  
Our studies indicated that LSL has a potent effect on survival, migration and invasion of on 
CRC and normal cell lines at a range of concentrations starting from 20µg/ml and was well 
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tolerated via oral administration in vivo. We, therefore hypothesized that long-term 
treatments (70 days) would slow the progression of colorectal polyps in the Apc
min+/- 
mouse 
model. Our results conclusively show that orally administered purified LSL do not decrease 
polyp development in this model. In contrast, LSL causes an exacerbation of growth of 
adenomatous polyps in the intestinal pre-cancerous Apc
min+/- 
mouse model. After 7 weeks 
of treatment, small polyps were also visible growing from the anus and by 10 weeks, the 
anal polyps had a 3-fold increase in size and there were obvious signs of bleeding. 
The number of polyps along each segment of the intestinal tract was individually counted 
and compared. Interestingly the number of polyps quantified in each segment of the vehicle 
treated Apc
min+/-  
mice were in line with other published studies (Song et al., 2000). It was 
noted that LSL administration resulted in a significant increase in the number of polyps 
found in the jejunum and ileum of LSL treated Apc
min+/- 
 mice. The biggest difference 
between the different segments of the small intestine is the pH levels. As it moves away 
from the gastric acid levels in the stomach the pH begins to rise. The duodenum has a pH 
of 4-6, while the jejunum and ileum has a pH 6-7. LSL has a neutral to basic pH by nature, 
therefore it could be hypothesized that an acidic environment can alter the biological activity 
of LSL. This could be tested further in the future by changing the pH of the LSL solution 
and testing its biological activity on cells using an MTT assay or running it through an 
HLPC-MS to look for any changes, 
LSL treatment also increased the size (volume) of intestinal polyps, a method that is 
currently used as an indicator of polyp burden in the Apc
min+/-
 mouse model
 (
Goodlad et al., 
2006). The severity of the polyp burden is readily apparent by visual inspection of the 
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unopened intestinal tract of Apc
min+/- 
mice fed LSL compared to the vehicle control (see Fig 
3.10a), with the large numbers and increased sizes of polyps resulting in the disfiguration 
and expansion of the intestinal lining. It is highly likely, that continuation of the feeding of 
LSL in this experiment, would have hindered their ability to consume and process food, 
further reducing the life span of these mice (Weindruch et al., 1986).  
Other markers of disease progression in Apc
min+/- 
mice have been reported, with an enlarged 
spleen and reduced hematocrit as a result of colorectal bleeding (Yekkala and Baudino, 
2007, You et al., 2006). Our study showed that LSL administration resulted in a significant 
increase in splenic size. Histological analysis also revealed that LSL treatment resulted in a 
further increase in red pulp regions in the Apc
min+/- 
 mice and a reduction in the number of 
Peyer’s patches present in the intestinal tract lining. The reduction in hematocrit levels is a 
late stage indicator of disease progression (Moser et al., 1995).  as there was change in levels 
following 35 days of LSL dosing in this experiment.  The reduced hematocrit, a sign of 
anemia may explain the increase in spleen size due to the role it has in clearing out dead and 
defective erythrocytes (Crosby, 1959; Cesta, 2006). The increasing splenic size has also 
been documented by Petrioianu et al., when benzo(a)pyrene, an immunomodulatory drug 
was administered in mice (Petroianu, 2007). It is believed that this may be a consequence 
of increased lymphatic damage associated with a decrease in Peyer’s Patch numbers along 
the intestinal tract (You et al., 2006).   
In conclusion, LSL induce cell death in 5 CRC cell lines in addition to 2 normal cell lines 
and while oral dosing is well tolerated, our studies indicate that a dose of 50mg/kg increases 
polyp progression and reduces hematocrit in the pre-clinical Apc
min+/- 
mouse model. This 
chapter would benefit from the addition of a control agent to compare the effects of the LSL 
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with. As polyps that grow along the intestinal tract in FAP patients are benign – they are 
often not treated with chemotherapeutics unless they become malignant. Currently in the 
clinic Celebrex, a cyclooxygenase-2 inhibitor, has been approved to help decrease polyp 
burden in patients that are in the high-risk category for developing CRC (Steinbach et al., 
2000).  It has also been shown to reduce the polyp burden significantly in the Apc
min+/- 
mouse model (Jacoby et al., 2000). Therefore, in future studies, Celebrex could be used as 
a control to compare against the efficacy of SL. 
This study would also benefit from extra experiments in the future. This chapter would 
benefit from a time course study. This chapter looks only at the effects on cell viability after 
LSL application for 24hrs.  Future studies could examine if the SL still has an effect after 
48 and 72hrs. It would also be interesting to see how     quick SL affected cell viability and 
induced cell death. This could be carried out by stopping the experiment in increasing 
increments until viability is altered.  It would be first carried out on a large scale using a 
MTT and stopping the assay every 15 minutes which would give an approximate time scale. 
This could then be applied to the cell death assay.
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Chapter 4 
 
Purified acidic sophorolipids selectively inhibit colorectal 
tumoucell growth in vitro and restore haematocrit levels in 
Apcmin+/- mice 
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4.1 Introduction 
Compounds that are non-toxic, orally tolerated and specifically target epithelial 
neoplastic cells (Kelloff et al., 1994) in the intestinal tract could have great potential in 
delaying progression of intestinal neoplasms; in particular, those that are associated with 
progression to colorectal cancer (D'Incalci et al., 2005) such as Familial Adenomatous 
Polyposis (FAP) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC)/Lynch 
syndrome. Currently, the gold standard for treatment of FAP/HNPCC is surgery, followed 
by adjuvant chemotherapy (O'Connell et al., 2010). Adjuvant chemotherapy does not 
discriminate between normal and transformed tissue, which leads to a variety of 
potentially serious complications including cardiotoxicity, immune dilapidation and 
neurotoxicity (Morgan and Rubin, 1998, Mazevet et al., 2013). 
The Apcmin+/- mouse is a widely used model of FAP as it recapitulates key pathological 
features of the human disease (Hinoi et al., 2007) and provides a useful tool to investigate 
the effects of genetics, diet and therapeutic drugs on tumorigenesis in the gastrointestinal 
tract. Similar to human FAP, it was first noted that Apcmin+/- mice develop adult-onset 
anaemia with haematocrit levels <45%, the passage of bloody stools and have a reduced 
life span, with post mortem analysis revealing the growth of numerous tumours along the 
small intestine (Moser et al., 1995). The Apcmin+/-  mouse model has also been widely 
used to test the effects of chemotherapeutics on tumour growth and development such as 
NSAIDs (Aspirin) (Jacoby et al., 2000). In addition, the Apcmin+/-  mouse model has also 
be used to develop a further understanding of clinically used chemotherapeutic drugs such 
as 5-fluorouracil (Tucker et al., 2002), which is widely used in the treatment of CRC. The 
cytotoxity of chemotherapeutic drugs such as 5-fluorouracil are similar in mouse models 
as well as human trials; the side effects including weight-loss, hair-loss, 
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myelosuppression and cardiovascular toxicity (Steger et al., 2012, Popovic et al., 1981). 
Although this specific range of side effects are unique to 5-fluorouracil, off target effects 
of clinically used chemotherapeutic agents, such as doxorubicin (Avilés et al., 1993) , 
bleomycin (Cohen et al., 1973) and cyclophosphamide are well recognised. It has been 
suggested that use of naturally derived compounds as alternatives to synthetic drugs may 
help reduce this bystander tissue toxicity. A number of naturally derived compounds are 
already in widespread use in cancer treatment such as Taxol, first derived from the bark 
of the yew tree (Stierle et al., 1993), although demand for this single species 
chemotherapeutic agent has necessitated synthetic production in the laboratory (Flam, 
1994). This has also has been seen in other drugs such as vinblastine, morphine and 
digoxin, to name a few (Fabricant et al.,2001).  It has been hypothesised that drugs  
dervived from naturally occurring sources and contain highly purified levels of the 
naturally occurring biologically active agent may reduce toxicity and side effects  
(Beutler, 2009) i.e. 94% ASL, as used in this chapter. 
 Similar to the crude preparations of natural compounds (such as Yew bark described 
above), naturally occurring SL mixtures contain a variety of amphiphilic species, 
composed of a hydrophobic fatty acid (C16- C18) tail and a hydrophilic carbohydrate 
sophorose head, and made up mostly of ASL or LSL. The anti-cancer properties of SL 
have received a lot of attention in recent years, as they show cytotoxic effects in human 
pancreatic (HPAC) (Fu et al., 2008), liver (H7402), lung (A549) (Chen et al., 2006a), 
brain (LN229,HNCG-2) (Dhar et al., 2011), esophageal (KYSE109, KYSE450) (Shao et 
al., 2012), breast (Ribeiro et al., 2015), cervivcal (HeLa) (Li et al., 2016) and leukemic 
(HL60,K562) (Chen et al., 2006b) cell lines in vitro  and a potential tumour shrinking 
capability in an in vivo model of cervical cancer (Li et al., 2016). We have previously 
shown that a highly purified preparation of LSL results in the exacerbation of tumour 
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growth in the intestinal tract of Apcmin+/- mice and secondary consequences including 
splenomegaly and reduced haematocrit levels (Callaghan et al., 2016). 
To date, very few in vivo bioactivity studies have been reported for SL mixtures, although 
toxicology experiments have shown SL is well tolerated in mice, non-irritant when 
topically applied to the skin and eyes of rabbits and non-toxic when administered orally 
to either mice (Callaghan et al., 2016) or rats (Ikea et al., 1986). SL mixtures have also 
been observed to reduce inflammation and increase life-span in a model of severe 
abdominal sepsis in rats (Hardin et al., 2007) as well as decreasing IgE levels in a murine 
asthma model (Bluth et al., 2008). Although SL shows promising anti-cancer activity in 
vitro, the gross composition and percentage of congeners within the SL mixture used in 
studies are not disclosed in a majority of investigations, although claims of LSL enriched 
preparations are common due to the preponderance of LSL in comparison to ASL’s within 
naturally occurring SL mixtures (Marchant and Banat, 2012, Van Bogaert et al., 2011).  
The process of synthesis produces complex molecular mixtures of SL, differing in their 
quantities, acetylation and saturation levels, which prove tedious to separate and purify 
(Asmer et al., 1988). In comparison to other SL congeners, ASL have reduced production 
costs as they require less yeast in the culture medium (20g/l for ASL vs 50g/l for LSL) 
(Casas and García-Ochoa, 1999) and are the first congener to be produced in the 
bioreactor when there are less favourable conditions present (i.e. less energy required for 
production) (Ducreux et al., 1997). The proportion of ASL within enriched preparations 
can be improved when the media is supplemented with polyunsaturated fatty acids and 
this can be further increased via simple hydrolysis of the SL mixtures which increases the 
number of open ring structures (Van Bogaert et al., 2007). 
ASL have enhanced solubility when compared to other SL congeners (Baccile et al., 
2017), which may prove useful for their use as pharmaceuticals, as they can be dissolved 
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in saline instead of potentially toxic solvents such as DMSO. Both solubility as well as 
enhanced foaming attributes of ASL contribute to their preferred use in the food, cosmetic 
and the bioremediation industries (Lang et al., 2000).    
In order to clarify whether ASL has colon tumour cell-specific cytotoxicity, we used a 
well characterized homogeneous a 94% ASL composed of mostly of C18:1 and 
compared its anti-cancer activity with that of LSL (see Chapter 3) both in vitro and in-
vivo. 
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4.2 Hypothesis: 
A highly purified and well characterised preparation of ASL (94% pure diacetylated) 
selectively inhibits colorectal tumour growth in vitro and delays disease progression in 
the Apcmin+/- mouse model. 
 
Aims and objectives: 
1) To determine the proportion and composition of congeners in a purified ASL stock 
produced by Starmerella bombicola for use in in vitro and in vivo experiments. 
2) To assess the cytotoxic properties of the ASL sample on four unrelated colorectal 
cancer cell lines, which mimic the different stages of cancer in the clinic, in addition 
to two representative normal lines: normal human colonic epithelium CCD-841 
CoN and lung fibroblast MRC5 in vitro. 
3) Determine the ability of orally administered ASL to inhibit tumour growth in 
Apc
min+/- 
mice, a well-established model of colorectal neoplasia. 
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4.4 Results: 
Production and purification of ASL 
A purified form of diacetylated ASL was produced by our collaborators for use in the in 
vitro and in vivo studies described in chapter 2.1 of the materials and methods section. In 
brief, a crude SL precursor was purchased as a typical LSL/ASL (~ 80/20) mixture 
(Sopholiance S, Batch N°11103A) and the ASL (Fig 4.1) were purified from this mixture 
as described previously (Baccile et al., 2013). 
HPLC-ELSD data confirmed that the sample is composed of 94% diacetylated ASL. 
Figure 4.2 shows the exact composition of the ASL batch and the percentage of each 
congener present. On the basis of the HPLC-ELSD integrated area values: the most 
abundant compound (75.0%) is composed, as expected, by the acidic C18:1s. The 
terminal C18:1t and C18:2t congeners represent 10% each, while all other congeners are 
limited to less than 2%. This batch sample was stored at room temperature and 
solubilized in PBS (in-vitro) or 10% sucrose (in-vivo) for use in all the experiments 
described in this chapter. 
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ASL has a selective effect on colorectal cancer cell viability. 
At concentrations ranging from 0.01-100µg/ml ASL did not affect the viability of either 
non-transformed colonic epithelial (CCD-841-CoN) or lung fibroblast (MRC5) cell lines 
(Fig. 4.3a) after 24h in comparison to vehicle-only control treated cultures. However, 
ASL concentrations above 20μg/ml resulted in a significantly reduced viability of both 
HT29 and LS180 cell lines (p <0.001); whereas at concentrations over 40μg/ml a 
significant reduction in cell viability of HT115, Caco2 and HCT116 tumour cell lines was 
noted (p <0.001). 
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ASL induces cell rounding in CRC cells 
Vehicle treated CCD-841-CoN cells grow as a confluent monolayer with a bipolar 
morphology following treatment with 40 or 70μg/ml ASL (Fig. 4.4), with no significant 
morphological features of cells in the monolayer noted being related to dose. 
The CRC cell lines HT29, HT115, HCT116 and Caco2 that were treated with vehicle-
only control solution display a densely packed, cobblestone-like monolayer morphology 
(Fig 4.4). At a dose of 40μg/ml ASL , disruption in the monolayer and detachment of 
CRC cells was observed. Partially detached and rounded HT29, HT115 and Caco2 cells 
were conspicuous within the cultures treated with 40μg/ml ASL.  The HT29, HT115, 
HCT116 and Caco2 cells exposed to 70μg/ml ASL, demonstrated extensive monolayer 
disruption with distinctive cell free areas within the cultures (Fig 4.4). 
To determine if the detachment of cells observed in tumour cell cultures treated with 0, 
50 and 100μg/ml ASL resulted in cell death, cells were isolated from the supernatant of 
wells, stained with syto9 and propidium iodide and the numbers of live/dead cells counted 
(Fig 4.5). In the CCD-841-CoN cultures following treatment with 50 and 100μg/ml ASL 
there were small numbers of detached cells observed (NS; p <0.1). In contrast, at 50μg/ml, 
there were significant increases in the numbers of dead, detached HT29 (Fig 4.5b p 
<0.0001), HT115, HCT116 and Caco2 cells (Fig 4.5c-e respectively; p <0.001). While at 
a dose of 100μg/ml ASL, 100% of all counted CRC cells in the supernatant were dead 
(Fig. 4.5b-e; p <0.0001). 
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ASL induces cell death in vitro. 
Treatment of CCD-841-CoN cells with 20µg/ml of ASL did not result in a significant 
increase in the numbers of either apoptotic or necrotic cells (Fig. 4.6p; NS, p > 0.05); 
however a dose of 70µg/ml resulted in ~10% cell death within the cultures that was 
identified morphologically as apoptosis (p < 0.05).  
We observed a dose-dependent increase (starting with doses as low as 20µg/ml) in cell 
death in all four human colorectal cancer cell lines following ASL treatment (4.6q-t). At 
a dose of 20µg/ml, there were equivalent numbers of apoptotic and necrotic cells in HT29, 
HT115 and HCT116; however, there was a higher number of apoptotic cells in Caco2 
cells (p < 0.01). 
Exposure of cultures to 70µg/ml ASL, resulted in a markedly reduced number of 
adherent CRC cells available for quantification (Fig. 4.6l-o). HT29 and HT115 
cultures showed a significant increase in the numbers of apoptotic and necrotic cells (p 
< 0.001, p < 0.01 respectively) while HCT116 cells were predominantly necrotic (p 
<0.0001) and Caco2 cells had a higher number of apoptotic cells (p <0.001) compared 
to vehicle control only. 
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ASL reduces motility and anchorage-independent growth of tumour cells. 
To determine the effects of ASL on cell migration and invasion, the scratch (Fig 4.7a&b) 
and Boyden chamber assays (Fig 4.7c&d) respectively, were used. A dose of 10 µg/ml 
ASL had no significant effect on CCD-841-CoN cell migration, with 90% of the total 
scratch area being covered after 72h (Fig. 4.7a; top panel). In contrast, 10µg/ml of ASL 
resulted in a highly significant decrease in the proportion of the total scratch area covered 
after 72h in HT29 (10%; p < 0.0001) and HT115 cells (22%; p < 0.0001),  
To test the migration potential, cells were plated in the upper portion of a Boyden chamber 
and the number of cells migrating in response to FCS were counted after 24h (Fig 4.7c). 
CCD-841-CoN cultures treated with the vehicle control were set at 100% migration to 
compare the effect of ASL treatment. Media supplemented with either 10 or 50µg/ml 
ASL did not significantly affect the migration of CCD-841-CoN cells (NS; p > 0.05). The 
addition of 10µg/ml ASL to cultures resulted in a reduction in migration of HT29 (33%) 
and HT115 (29%) compared to control values (p <0.001). The addition of 50µg/ml ASL 
reduced migration of HT29 and HT115 to 8.3% and 10.4% of control values respectively 
(p <0.0001).  
To determine the ability of ASL to influence the invasive properties of cancer cells, CCD-
841-CoN, HT29 or HT115 cells were plated on a layer of Matrigel in the upper 
compartment of a Boyden chamber (Fig 4.7d). The normal CCD-841-CoN cell line failed 
to invade through the Matrigel. At a dose of 10µg/ml ASL, 46% of HT29 (p< <0.0001) 
and 41.1% of HT115 (p <0.001) cells migrated through the Matrigel matrix. At 50µg/ml 
ASL, the percentage of invasion in HT29 and HT115 was reduced to 16.6% (p <0.001) 
and 22.1% (p <0.0001) of control values respectively. 
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wt and Apcmin+/- mice tolerate the oral administration of ASL 
In order to determine palatability and potential toxicity, a pilot study was performed (n 
= 2/group) with both wt and Apcmin+/- mice which were fed either a vehicle-only control 
solution consisting of 10% sucrose water (vehicle-only) or vehicle containing either 0.5, 
5 or 50mg/kg ASL) for a period of 5 weeks. The weights of the mice (Fig 4.8a) in 
addition to their water (Fig 4.8b) and food consumption (Fig 4.8c) was measured each 
week. Both wt and Apcmin+/- mice gained weight at a similar rate, which was unaffected 
by the dosage of ASL administered (Fig. 4.8a). On average, both vehicle and ASL 
treated wt and Apcmin+/- consumed 11.25 ± 2.5 grams of food (Fig. 4.8b) and 14.1 ±3.2 
grams of water (Fig. 4.8c) a week.  
Mice were also monitored for any change to normal behavioural habits such as 
grooming, nesting and reaction to humans during the study. There was no change in 
behaviour between any of the treatment groups (Appendix 1.1). 
On completion of this oral feeding tolerance study, the major organs (liver, stomach, 
kidneys, lungs, heart, spleen and pancreas) were removed, weighed and a gross 
inspection of morphology was carried out (Fig 4.9).  There were no significant 
differences in organ weights or gross organ morphology observed between the vehicle 
treated compared to ASL (0.5, 5, 50mg/kg bodyweight) treated mice.  
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ASL does not affect the size or number of tumours in Apcmin+/- mice. 
The weights of wt and Apcmin+/- littermate mice fed with either vehicle-only control or 
ASL solutions were not significantly different (endpoint: 25.2 ± 0.9g vs 22.9 ± 1.8g; NS, 
p >0.05) and there were no differences in water or food consumption over the duration of 
the experiment. The gross morphological appearances of unfixed, flat-mounted ilea from 
wt mice (Fig. 4.10a top) treated with either vehicle or 50 mg/kg ASL was characterised 
by a flattened, uniformly smooth mucous epithelium with prominent patent blood vessels. 
In vehicle-only treated Apcmin+/- mice (Fig. 4.10a; bottom left), there is clear evidence of 
polyp associated bleeding (arrow heads) within the ileal segment. Following treatment 
with 50 mg/kg ASL for 70 days, there was little evidence of bleeding from intestinal 
polyps (Fig. 4.10a; bottom right) in comparison to vehicle treated animals (4.10a; bottom 
left). The number of intestinal polyps in Apcmin+/- mice was not significantly different 
following treatment with 50 mg/kg ASL for 70 days (vehicle = 48 ± 2 vs ASL = 45 ± 4; 
Fig. 4.10b; p < 0.1). ASL treatments also had no effect on the modal size distribution of 
the polyps in comparison to vehicle-only (vehicle- 4mm vs ASL 4mm; Fig 4.10c; NS, p 
> 0.05).   
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ASL reduces splenic weight and the proportion of red pulp in Apcmin+/- mice   
The spleens from vehicle-control fed Apcmin+/- mice (0.58 ± 0.2g) were significantly 
heavier than their wt littermates (0.15g ± 0.5g; Fig. 4.11a&b; p <0.0001). A dose of 
50mg/mg ASL had no effect on splenic weight in wt mice after 70 days of treatment. 
However, administration of 50 mg/kg ASL for 70 days to Apcmin+/- mice resulted in a 
statistically significant decrease in splenic weight (Apcmin+/- = 0.58 ± 0.2 g vs ASL 
Apcmin+/- 0.40 ± 0.4g; Fig 4.11b; p < 0.001).  
Histological examination of sections from wt mouse spleen (Fig. 4.11c; left panel) 
revealed conspicuous intensely basophilic areas of white pulp; these are separated by less 
dense regions of red pulp, the areas that are responsible for removal of old or damaged 
erythrocytes. In vehicle treated Apcmin+/- mice there is conspicuous clumping of the red 
pulp and the proportion of this tissue is significantly increased when compared to wt ( 
middle vs left panel; Fig. 4.11c). Following treatment with 50 mg/kg ASL there was a 
significant reduction in red pulp size as compared with vehicle-only controls (Fig. 4.11c 
right vs middle panel; Fig. 4.11d).  
Haematocrit levels were not significantly different after 35 days of ASL treatment 
between wt and Apcmin+/- mice (41.2% ± 0.8 vs 40.0% ± 1.1; p <0.1). However, after 70 
days of ASL administration, haematocrit levels were significantly higher in wt than 
Apcmin+/- mice and feeding Apcmin+/- mice with 50 mg/kg ASL resulted in a significant 
increase in haematocrit compared to the vehicle-only control (Fig. 4.12; vehicle = 36.0% 
± 1.9 vs ASL = 42% ± 1.2; p < 0.05).  
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4.4 Discussion  
The ability of chemotherapeutic agents to distinguish between normal tissue and 
cancerous cells is a highly desirable trait, as it may mitigate against the common side 
effects associated with this toxic therapeutic (McQuade et al., 2014) such as hair loss and 
immunosuppression (Burish, 1988). 
Here we investigated the effects of a 94% pure preparation of ASL on two normal cell 
lines (CCD-841 and MRC5) and 5 CRC cell lines (HT29, HT115, Caco2, HCT116 and 
LS180) in vitro. Colonic epithelial (CCD-841-CoN) and lung fibroblasts (MRC5) treated 
with ASL showed no evidence of toxicity as evidenced by maintenance of their viability 
at doses ranging between 0.01 – 100µg/ml. However, at doses of 20µg/ml and above, 
ASL potently reduced cell viability in all the CRC cells examined. Although the cytotoxic 
potency of SL mixtures has been reported against cancer cell lines previously (Chen et 
al., 2006a, Fu et al., 2008, Shao et al., 2012, Ribeiro et al., 2015), this is the first time an 
anti-cancer effect has been reported from a purified and well characterised ASL on a 
range of cell lines from the same tissue of origin (i.e. colorectal cancer cells). 
Interestingly, ASL exhibit a differential effect in normal compared to CRC cells in vitro, 
with a dose-dependent cytotoxic response only observed in the five CRC cell lines across 
the range of doses examined. A differential effect has been reported in previous studies 
with SL mixtures of uncertain purity (Fu et al., 2008) where SL were cytotoxic to both 
pancreatic and liver cancer cell lines but with no demonstrated toxicity to a normal cell 
line. However, in the aforementioned study non-adherent, circulating blood monocytes 
(PBMC) were used as a control for adherent transformed cells making conclusions from 
this study difficult to interpret. Therefore, we believe this to be the first directly 
comparable description of the specificity of a pure preparation of ASL that uses a normal 
adherent cell line from the same tissue of origin as the transformed CRC cells.  
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It has been hypothesised that SL have the ability to intercalate into the cytoskeleton of 
cells resulting in membrane disruption. Changes in cell morphology consistent with 
disruption of membrane cytoskeletal protein distribution have previously been shown to 
occur with SL doses as low as 30µg/ml in pancreatic H7402 and lung cancer A549 cell 
lines (Chen et al., 2006a). Our study demonstrates that single congener ASL at low 
concentrations (40g/ml) induce cell rounding, cytoplasmic condensation and cell 
detachment (Fig 4.4) in all the CRC cancer cell lines tested, with the adenocarcinoma cell 
lines HT29 and Caco2 being most susceptible. At doses of 70 - 100µg/ml, ASL causes a 
significant increase in the numbers of detached cells with all cells in the supernatant from 
treated cultures showing morphological features consistent with apoptosis or necrosis 
(Fig 4.5). Although the difference between live and dead cells, are easily seen, it is harder 
to distinguish between apoptosis and necrosis in this assay. To be able to better compare 
the data, future studies would benefit from the addition of both an apoptosis (Apoptolidin 
(Chong et al., 2016)) and necrosis (Chrysophanol (Lu et al., 2010)) inducer.  Future 
studies could also use a flow cytometer to analysis apoptosis or necrosis after SL 
treatments. This may prove a better non-bias approach to quantification of cell death 
mechanisms (Liu et al., 2015).     
BS used at the doses described in our study, induce a reduction of tension at the interfacial 
region of the bilayer resulting in phospholipid dehydration which affects lipid stability 
and ultimately results in cell death (Fracchia et al., 2012, Shah et al., 2005). To assess cell 
death mechanisms caused by ASL, ethidium bromide/acridine orange staining was 
carried out allowing the morphological identification of the type of cell death.  We have 
conclusively demonstrated that ASL induces both apoptosis and necrosis in these cancer 
cell lines in a dose-dependent manner. The ability of ASL to induce either apoptosis or 
necrosis may be cell line specific as high proportion of apoptotic cells have been reported 
following the addition of diacetylated LSL to liver (H7402) and lung cancer (H7402) cell 
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cultures, while necrosis is primarily observed in a pancreatic carcinoma cell line (HPAC) 
treated with SL mixtures, LSL or methyl ester derivative SL (Shao et al., 2012).  
An important characteristic of malignant growth is the ability of tumour cells to leave 
their restricted compartment and gain access to blood vessels to initiate the first phase of 
metastasis (Hanahan and Weinberg, 2011). The movement of cells across tissues 
therefore plays an important role in this progression thus highlighting the need for an 
agent that can counteract the migratory and intravasative properties of CRC cells 
(Dianzani et al., 2014). It has been postulated that the amphiphilic properties of SL permit 
their incorporation into the mammalian cellular membrane disrupting cellular functions 
such as proliferation and migration (Fracchia et al., 2015). We assessed the ability of ASL 
to inhibit migration of the CRC cell lines HT29 and HT115. At a low doses (10µg/ml) of 
ASL there was no effect on normal colonic epithelial cells (CCD-841-CoN) and scratch 
coverage after 72 hrs. However, when the same dose of ASL (10µg/ml) was applied to 
HT29 and HT115 cultures the total percentage area of scratch covered was reduced. An 
inhibition of migration induced by SL (as measured in the scratch assay) has only been 
documented in one other study (Ribeiro et al., 2015) where 5µg/ml of a 93% pure, 
diacetylated LSL resulted in significantly reduced migration of MDA-MB-231 breast 
cancer cells.  
The use of both migration and invasion assays incorporating the Boyden chamber are 
widely used to test candidate chemotherapeutics with the HT29 and HT115 cell lines 
commonly employed to test anti-invasive properties of potential chemotherapeutics in 
vitro (Li and Zhu, 1999). Currently the only studies investigating the potential anti-
metastatic properties of BS are limited to the inhibitory effects on in vitro invasion 
mediated by the surfactant produced by Baccillus subtilis in the breast cancer cell lines 
MCF and MDA-MB-231 (Park et al., 2013). Addition of 10µM (equivalent to approx. 
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660µg/ml  of LSL in this study) of biosurfactant had the ability to reduce the migration 
of MCF-7 and MDA-MB-231 through an extracellular matrix by 68% and 84% 
respectively. The uncharacterized surfactants used in this study also reduced the colony 
forming ability of both cell lines by 70% and 61%. To investigate the migration inhibitory 
properties of ASL, HT29 and HT115 cells were plated on a porous membrane and allowed 
to migrate through a septum in the chamber below. ASL had no effect on the migration 
of normal colonic CCD-841-CoN cells, however, migration was significantly decreased 
in HT29 and HT115 cultures (by 65% and 72% with 10µg/ml and 86% and 81% with 
concentrations of 50µg/ml ASL). A modification of this method involving placing a layer 
of matrigel on the porous membrane can measure the ability of cancer cells to invade 
through a matrix in response to a stimulus (Krishnamachary et al., 2003). This in vitro 
model mimics the action of cancer cells invading through and metastasising through the 
body, a key step in the hallmarks of cancer (Pietras and Östman, 2010). ASL dose 
dependently reduced the invasion of  HT29 and HT115 through an extracellular matrix 
with doses as low as 10µg/ml. This is the first time that inhibitory properties of ASL on 
tumour cell invasion have been reported.  In addition, differential effects of BS congeners 
is a common phenomenon, previously observed when comparing the antibacterial effects 
of rhamnolipids, which can be produced as mono or di-rhamnolipids (Martin et al., 2016). 
For instance, di-rhamolipids produce a more potent antibacterial effect against 
Burkholderia thailandensis biofilm formations (De Rienzo and Martin, 2016). Similarly, 
mono-rhamnolipid congeners show enhanced anti-cancer potential against  HL-60, BV-
173, SKW-3 and JMSU-1 cells in vitro in comparison to the di-rhamnolipids (Christova 
et al., 2013) .  
The anti-tumour activities of SL preparations are unclear, as in a study by Li and co-
workers, an intragastrically administered SL mixture, of an undisclosed composition, was 
shown to reduce the size of tumours in a murine HeLa xenograft model (Li et al., 2016) 
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whereas  a purified form of LSL exaggerated the growth of neoplasm along the intestinal 
tract and increased intestinal blood loss in the Apcmin+/- mouse (Chapter 3 and Callaghan 
et al., 2016). 
Apcmin+/-  mice develop intestinal adenomatous neoplasms (polyps) and animals typically 
present with enlarged spleens and reduced haematocrit by 4 months of age (Yekkala and 
Baudino, 2007). This is an acute model with a life span of <150 days, where the primary 
cause of death is not directly attributable to the development of numerous polyps but 
rather as a result of extensive intestinal bleeding and anaemia (Hinoi et al., 2007). 
When administered orally, topically or via i.v. injection SL mixtures are well tolerated 
(Ikeda et al., 1986). Similarly, in our study, both wt and Apcmin+/- mice tolerated the oral 
administration of relatively pure single congener ASL (this Chapter)  with no measurable 
gross anatomical or behavioural differences noted. Post mortem analysis also revealed no  
effects in systematic organ measures after ASL treatment. However, oral feeding of ASL 
to Apcmin+/-  for 70 days resulted in a reduction of spleen size and significantly increase in 
haematocrit, consistent with decreased intestinal bleeding and improvement in the 
associated anaemia characteristic of this model (Moser et al., 1990). This is a potentially 
significant finding, as rectal bleeding and anaemia are reported in over 30% of CRC 
patients and it is a contributing factor in reduced life-span in both humans (Ronnekleiv-
Kelly and Kennedy, 2011) as well as Apcmin+/- mice . In humans, laser ablation encourages 
coagulation of tumours demonstrating significant blood loss and this technique has shown 
to be effective after 2 - 5 treatments with a success rate of 80% (Kimmey, 2004). However 
recurrent bleeding episodes result in surgical intervention in 2 - 15% of patients (Rao et 
al., 2005). The oral administration of a well-tolerated non-toxic, pro-thrombotic agent to 
reduce intestinal blood loss in patients with haemorrhagic colo-rectal tumours may be a 
useful addition to the therapeutic treatment of these conditions. As mentioned in chapter 
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three, this chapter would also benefit from the addition of controls such as Celebrex, a 
cyclooxygenase-2 inhibitor which can reduce the size of polyps in this model. This would 
help complement the data making conclusions on the ASL more scientifically conclusive.  
As seen in the data, the 96% pure C18:1 ASL had no effect on polyp number. Future 
studies could look at other ASL congeners or a mixture of C18:1-3 ASL congeners to see 
if it would improve the biological activity in vivo.In conclusion, the purified ASL mixture 
we report in this study differentially effects non-transformed in comparison to colorectal 
cancer cell lines, resulting in a significant and dose-dependent decrease in their viability, 
migration and anchorage-independent growth characteristics. While ASL does not change 
either the size or number of intestinal polyps in Apcmin+/- mice, both spleen size and 
tumour-associated bleeding was apparent. This warrants further investigation of this 
orally available BS as a chemotherapeutic for delaying disease progression in pre-
cancerous colorectal neoplasms. 
Overall, when comparing the effects of LSL in chapter three and the ASL in this chapter 
– it is easy to see that ASL provides a more desirable biological effect. Unlike LSL – ASL 
demonstrates the ability to differentiate between normal and cancerous cell lines, 
inflicting a response only to the latter. The mechanisms behind how this phenomenon 
occurs is yet unknown. It can be hypothesised that ASL is fast acting compared to LSL 
and targets fast cancer proliferating cells. This could be address using time scale tests and 
comparing how fast ASL vs LSL affects the cells. The difference in biologically activity 
could also be associated with the ability of SL to enter the cell. These questions can be 
explored using mechanistic in vitro studies. 
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Chapter 5 
Investigation of the mechanism of SL-induced death in HT29 
CRC cells  
 
 
 
 
 
5.1 Introduction 
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Biosurfactants in general and SL mixtures in particular, have been well documented to 
inhibit tumour cell growth in vitro, however the mechanisms of action underlying this 
effect is still unclear. The first insight into the inhibitory properties of SL mixtures was 
observed following the treatment of H7402 liver cancer cells, which resulted in an 
increase in the percentage of cells arresting in the G1 and S1 phases (Chen et al., 2006a).  
This group also reported an influx of Ca2+ released into the supernatant and an increase 
in caspase-3 levels after SL treatment in vitro. They hypothesised that SL treatment in 
cancer cells causes an increase of intracellular Ca2+ which results in the arrest of cells in 
the G1 and S1 phase of the cell cycle, inducing apoptosis via the capsase-3 pathway (Chen 
et al., 2006a).  
It was initially postulated that the mechanism of action of BS induction of cell death is 
via triggering a non-specific, detergent-like effect that causes the formation of holes in 
the cell membrane (Heerklotz et al., 1997). This concept was developed in studies 
showing the ability of BS to cause destabilisation of lipid-rich clusters in the bilayer of 
the cell membrane, leading to a disruption in lamellar structure and leakage of 
cytoplasmic material (Heerklotz, 2001, Heerklotz and Seelig, 2007). This membrane 
disrupting activity has previously been shown for preparations of both non-ionic 
surfactants (Groot and Rabone, 2001) and BS produced by Bacillus subtilis, and is 
believed to be mediated by their surfactant properties (Rodrigues et al., 2006). 
Due to their lipid structure, it has been hypothesised that BS can be inserted into the outer 
lipid layer of a cell causing an increase in lateral pressure and disruption to the cell 
membrane (Heerklotz, 2001). This mechanism of action has been established with 
surfactan (a lipopolysaccharide), using a vesicle membrane to model the characteristics 
of a human cell membrane which allows the analysis of membrane incorporation, 
membrane leakage and cell lysis using fluorescent dyes (Heerklotz and Seelig, 2007). The 
 
 
129 
 
model has also been used to investigate the BS Trehalose, which was shown to 
incorporate into cell membranes confirming that BS can self-insert into the phospholipid 
bilayer causing dehydration of the phospholipids, thus disrupting protein conformations 
and affecting cell transport and energy production (Ortiz et al., 2009, Heerklotz, 2008).  
The biological action of surfactant is dependent on its concentration and saturation, with 
low concentrations (<100µg/ml), penetrating easily into the membrane and having no 
deleterious effects on the membrane integrity but affecting cell adhesion and migration. 
At concentrations between 100 - 1000µg/ml, surfactants such as triton x-100 cause pore 
formation on the cell surface and at concentrations above 1mg/ml), surfactants cause 
complete permeabilization of the cell (Carrillo et al., 2003).  
Mechanistic studies revealed that non-ionic surfactants disrupt the natural distribution of 
lipid rafts in the cell membrane resulting in changes in cell shape, structure, composition 
and size (Heerklotz, 2002). This phenomenon is accompanied by disruption in the natural 
signalling pathway of the cell causing changes to viability, as well as adhesion (Huang et 
al., 2006) and the activation of cell death (Bang et al., 2005). An ex vivo study employing 
isolated neural stem cells from the subventrical zone (SVZ) of mice demonstrated that di-
rhamolipids (a type of glucolipid) have a dose-dependent effect on cell viability 
(Stipcevic et al., 2013). The authors hypothesized that rhamolipids induce this response 
by interfering with the lipid raft domain, disrupting cell-signalling pathways (Stipcevic et 
al., 2013). 
Lipid rafts are micro-domains present in the cell membrane bilayer which are 
heterogeneous molecular complexes made up of tightly packed lipids (cholesterol and 
sphingolipids) and can include proteins. They play a vital role in physiological processes 
such as polarization, signalling (Simons and Toomre, 2000), trafficking, adhesion, sorting 
and regulation of cell death mechanisms (Simons and Ikonen, 1997, Brown and London, 
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1998). Little is known about the effects cell transformation has on lipid rafts, however it 
is thought that they undergo structural changes resulting in fluctuations in protein 
expression and alterations to raft linkage to the cytoskeleton rendering the rafts unstable 
(Staubach and Hanisch, 2011).  
Lipid rafts can be visualised microscopically using the cholera toxin subunit B (CTxB)   
(Harder et al., 1998) which can be fluorescently tagged. In culture, lipid rafts can be seen 
as a fluorescent coating surrounding the outer layer of the cell membrane. Under cellular 
stress – such a drug therapy or the development of pathological diseases, an increase in 
the intensity of CTxB is observed (Allen et al., 2007). In the initial stages, small clusters 
are evident at the polar cap of the cells. Prolonged stress can result in the visible formation 
of several clusters. These clusters have been linked to the activation of receptors and it is 
hypothesised that a majority of cell signalling occurs in these clusters in the lipid rafts 
(Simons and Ehehalt, 2002). These clusters have been seen in HT9 cells in response to 
cisplatin (Lacour et al., 2004) and immune cells in reaction to IgE production causing 
allergies (Sheets et al., 1999). 
Studies have also shown that disruption to lipid rafts can result in changes to tight 
junctions which result in a decrease in cell migration and invasion rates in cancer cells 
(Murai, 2011). It has also been shown that lipid raft changes cause alterations to the 
mitochondrial membrane potential of cells (MMP) (Gajate and Mollinedo, 2014) and can 
result in an increase of reactive oxygen species (ROS) (Turrens, 2003), resulting in cell 
death (Simon et al., 2000). Currently, research aimed at the targeting of lipid raft domains 
in cancer cells has attracted great interest (Mollinedo and Gajate, 2010) with several 
potential chemotherapeutic agents targeting multiple myeloma, leukaemia (Gajate and 
Mollinedo, 2007) and prostate cancer (Zhuang et al., 2005) respectively, being trialled. It 
is also believed that the targeting of lipid rafts may help decrease the phenomenon of 
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multidrug resistance that is currently observed with conventional chemotherapeutics 
(Hendrich and Michalak, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2 Hypothesis  
The treatment of HT29 CRC cells with SL results in the redistribution of lipid rafts, which 
disrupts the tight junction distribution and increases intracellular ROS production. 
 
Aims and Objectives: 
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1) Determine the differential effect of SL on lipid raft disruption between “normal” 
colonic (CCD-841-CoN) and CRC HT29 cell cultures in vitro. 
2) To determine if ASL and LSL interrupt ZO-1 distribution in CCD-841-CoN and 
HT29 cells. 
3) Determine if SL treatment results in a change to Mitochondrial Membrane 
Potential levels and Reactive Oxygen Species production in CCD-841-CoN and 
HT29 cells.  
 
 
 
 
 
 
 
 
 
5.3 Materials and methods 
Lipid rafts 
A total of 3x104 of CCD-41-CoN or HT29 cells were seeded onto a 10mm coverslip (Agar 
Scientific; Stansted: Essex, UK), incubated overnight in a 24 well plate to attach. Media 
was replaced with serum free media and further incubated for 24h. Vehicle-only solutions 
(ASL: PBS or LSL: 0.01% DMSO in PBS), ASL or LSL (at 10 or 50µg/ml final 
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concentration) were added to the cell lines for 24h. Cells were then washed with ice cold 
PBS and incubated with 200µl of fluorescent CT-B conjugate (1µg/ml; Invitrogen; 
Paisley, UK) for 20 minutes at 4ºC in the dark. After aspiration of the liquid, the cells 
were washed three times with ice cold PBS and subsequently fixed in 10% neutral 
buffered formalin (Sigma-Aldrich; Dorset, UK) for 15 minutes at 4ºC in the dark.  
Coverslips were mounted on to a slide using histamount and visualised immediately by 
florescence microscopy (Axio Scope 1, Zeiss, Germany) using a 488nm filter at 40x 
objective magnification.  
ZO-1 expression 
A total of 3x104 of CCD-41-CoN or HT29 cells were seeded onto a 10mm coverslip (Agar 
Scientific; Stansted: Essex, UK), incubated overnight in a 24 well plate to attach. Cell 
growth media (see above) was replaced with serum free media and the cells further 
incubated for 24h. Vehicle-only solutions (ASL: PBS or LSL: 0.01% DMSO in PBS), 
ASL or LSL (at 10 or 50µg/ml final concentration) were added to the cell lines for 24h. 
The cells were subsequently washed with ice cold PBS and fixed with neutral buffered 
formalin (Sigma-Aldrich; Dorset, UK) for 20 minutes at room temperature. A ZO-1 
antibody (Invitrogen; Paisley, UK) was added overnight using a 1:1000 dilution in 5% 
BSA (Sigma-Aldrich; Dorset, UK) at 4ºc. Cells were washed with ice cold PBS several 
times. Cells were stained with Hoechst (Invitrogen; Paisley, UK) for 10 minutes in the 
dark and washed with ice-cold PBS. Coverslips were mounted on to a slide using 
histamount and visualised immediately by florescence microscopy (Axio Scope 1, Zeiss, 
Germany) using a 594nm (ZO-1) and 461nm (Hoechst) filter at 40x magnification.  
Measuring Mitochondrial Membrane Potential: 
MMP quantification was carried out as previously described (Mortiboys et al.,2008). A 
total of 1x103 of CCD-41-CoN or HT29 cells were seeded into a 96 well plate (Nunc 
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Thermos scientific, UK) and incubated overnight to attach. Media was replaced with 
serum free media and further incubated for 24h. Cells were treated with either Vehicle-
only solutions (ASL: PBS or LSL: 0.01% DMSO in PBS), ASL or LSL (at 10 or 50µg/ml 
final concentration) were added to the cell lines for 24h. Cells were incubated with 1µM 
dihexyloxacarbocyanine iodide (DiOC6) (Sigma-Aldrich; Dorset, UK) for one hour at 
room temperature and washed with ice cold PBS. Cells were detached from the plate 
using 0.25% trypsin (Gibco Invitrogen; Paisley, UK) and re-suspended in 100µg/ml of 
PBS. Fluorescence intensity was read in FLUOstar Omega plate reader (BMG lab tech; 
Aylesbury, UK) using filter 488nm. 
In order to compare results between cell lines and experiments, intensity was normalised 
to cell number. This was carried out by plating out 1x103 of CCD-41-CoN or HT29 cells 
in a parallel plate. Cells were treated with either vehicle-only solutions (ASL: PBS or 
LSL: 0.01% DMSO in PBS), ASL or LSL (at 10 or 50µg/ml final concentration) were 
added to the cell lines for 24h. Cells were incubated with 1µm ethidium homodimer 
fluorescent dye (Sigma-Aldrich; Dorset, UK) for one hour at room temperature and 
washed with ice cold PBS. Cells were detached from the plate using 0.25% trypsin (Gibco 
Invitrogen; Paisley, UK) and re-suspended in 100µg/ml of PBS. Fluorescence intensity 
was read in FLUOstar Omega plate reader (BMG lab tech; Aylesbury, UK) using filter 
544nm (Mortiboys et al.,2008). 
Cellular Reactive Oxygen Species Detection Assay: 
A total of 1x103 of CCD-41-CoN or HT29 cells were seeded into a 96 well plate (Nunc 
Thermos scientific, UK) and incubated overnight to attach. Media was replaced with 
serum free media and further incubated for 24h. Cells were treated with either. Vehicle-
only solutions (ASL: PBS or LSL: 0.01% DMSO in PBS), ASL or LSL (at 10, 20, 40, 
60, or 80µg/ml final concentration) were added to the cell lines for 24h or H2O2 (0.1mM; 
 
 
135 
 
Sigma-Aldrich Company Ltd, Dorset, UK) for 24h. Cells were incubated with 10µM H2-
DCFDA (Sigma-Aldrich; Dorset, UK) for one hour at room temperature and washed with 
ice cold PBS. Cells were trypsinized from the plate using 0.25% trypsin (Gibco 
Invitrogen; Paisley, UK)) and re-suspended in 100µg/ml of PBS. Fluorescent intensity 
was read in FLUOstar Omega plate reader (BMG lab tech; Aylesbury, UK) using filter 
488nm. 
In order to compare results between cell lines and experiments, intensity was normalised 
to cell number. This was carried out by plating out 1x103 of CCD-41-CoN or HT29 cells 
in a parallel plate. Cells were treated with either vehicle-only solutions (ASL: PBS or 
LSL: 0.01% DMSO in PBS), ASL or LSL (at 10 or 50µg/ml final concentration) were 
added to the cell lines for 24h. Cells were incubated with 1µm ethidium homodimer 
fluorescent dye (Sigma-Aldrich; Dorset, UK) for one hour at room temperature and 
washed with ice cold PBS. Cells were detached from the plate using 0.25% trypsin (Gibco 
Invitrogen; Paisley, UK) and re-suspended in 100µg/ml of PBS. Fluorescence intensity 
was read in FLUOstar Omega plate reader (BMG lab tech; Aylesbury, UK) using filter 
544nm (Mortiboys et al.,2008). 
 
 
5.4 Results 
Treatment with SL results in a disruption of lipid raft structures in vitro 
To explore the possible mechanisms for the cell death inducing effects of SL (as shown 
in Chapter 3 &4), we examined the effects of SL on lipid raft structure in HT29 CRC 
cells in vitro. We examined the cell membranes of HT29 cells, via fluorescent imaging, 
exposed to 10 and 50µg/ml of ASL and LSL as these concentrations were shown (in 
 
 
136 
 
Chapters 3 & 4) to have an effect on both CCD-841-CoN and HT29 cells without causing 
changes to cell structure. Visualisation of lipid rafts was then performed by probing 
treated cultures with cholera toxin subunit B (CT-B) a well described marker of lipid rafts 
in (Fig 5.1) and subsequently examining the cultures with fluorescence microscopy. The 
normal distribution of lipid rafts in colonic epithelial cells CCD-841-CoN (Fig. 5.1a&e) 
and HT29 (Fig. 5.1b&d) CRC cells reveals a normal distribution of lipid rafts around the 
outer compartment of the membrane with no specific areas containing fluorescently 
stained clusters visible.  
Treatment of CCD-841-CoN cells with either 10µg/ml or 50µg/ml of ASL (Fig 5.1e, i) 
did not result in any conspicuous changes in the structure or distribution of the lipid raft 
membranes. However, a dose of 10µg/ml of ASL resulted in a change in the distribution 
of lipid raft in HT29 CRC cells via the formation of clusters evident by an increase in 
fluorescence intensity (Fig 5.1f) which further increased when treated with a dose of 
50µg/ml ASL (Fig 5.1j white arrows). 
In comparison, LSL caused significant visible changes to the disruption of lipid rafts in 
CCD-841-CoN cells from 10µg/ml (Fig 5.1g). Cells presented with high CT-B positivity 
showing activated raft clusters disrupted throughout.  However, examination of the 
normal CCD-841-CoN cells after 50µg/ml LSL treatments were difficult due to a large 
proportion of areas devoid of cells (Fig 5.1h). 10µg/ml of ASL demonstrated no 
significant changes to lipid raft morphology or disruption in HT29 cells compared to the 
vehicle control (Fig 5.1h). At 50µg/ml LSL there was a change in lipid raft disruption 
observed in HT29 cells with a small number of cells showing signs of raft clustering (Fig 
5.1). 
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SL disrupts gap junctional morphology in HT29 CRC cells 
To examine the effects that SL have on tight junction permeability, HT29 cells were 
treated with SL and later ZO-1 expression was examined by immunofluorescence staining 
(Fig 5.2a, top panel). After treatment with ASL at either 10µg/ml (Fig 5a, middle panel) 
or 50µg/ml (Fig 5a, bottle panel), a depletion of intracellular ZO-1 staining was observed 
within the HT29 monolayer (Fig 5b).  
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Treatments of HT29 monolayer cultures with 10µg/ml LSL (Fig 5c middle panel) caused 
no obvious change in the intensity or distribution of ZO-1 expression when compared to 
the vehicle control (top panel). At a concentration of 50µg/ml (bottom panel), intracellular 
depletion of ZO-1 was observed.  
 
Quantification of the florescent intensity observed in the HT29 cells was obtained by 
analysing the photomicrographs on image J (Fig 5b, d). The treatment of HT29 with 
10µg/ml of ASL resulted in a 32% decrease in ZO-1 expression (p <0.01) which 
decreased to 49% after 50µg/ml ASL treatment. Under the same conditions, LSL did not 
influence the ZO-1 intensity after 10µg/ml (p >0.05) however a significant decrease in 
intensity was observed with the 50µg/ml treatment (p<0.05). 
 
 
 
  
 
 
 
 
 
 
 
 
 
140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SL dose-dependently reduce MMP expression in HT29 cells 
Mitochondria plays a vital role in the cell physiology and is a key indicator in the health 
status of the cell.  CCD-841-CoN or HT29 cells were treated with various concentrations 
of ASL or LSL. MMP production was quantitated by measuring the fluorescent intensity 
emitted by the cells labelled with DiOC6, a dye which is used to detect MMP in cells. 
The fluorescence values were corrected for cell number.The treatment of CCD-841-CoN 
cells with ASL resulted in a significant decrease in the fluorescent intensity at 
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concentrations exceeding 60µg/ml (Fig 5.3a p <0.05). At doses of 40 - 80µg/ml 
(p<0.001), ASL induced a dose-dependent decrease in  the fluorescent intensity of HT29 
CRC cells (Fig 5.3b p<0.001). LSL caused a reduction in the fluorescent intensity at 
concentrations as low as 10µg/ml (Fig 5.3c p<0.05) and dose-dependent decreases in 
fluorescent intensity were observed up to 80µg/ml (p<0.001). Significant reductions in 
the fluorescent intensity of HT29 cells were observed following exposure to LSL 
concentrations of 60µg/ml and above (Fig 5.3d p<0.001).  
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SL dose-dependently increase ROS expression in HT29 cells 
The treatment of CCD-841-CoN cells with ASL caused a significant increase in in the 
fluorescent intensity at concentrations of 80µg/ml (Fig 5.4a p <0.05), a relatively high 
concentration compared to the 40µg/ml ASL concentration needed to induce a significant 
increase in the fluorescent intensity seen in HT29 CRC cells (Fig 5.4b p<0.05). The levels 
of ROS produced by CCD-41-CON cells subjected to ASL was less than the ROS 
produced by H2O2, a control known to elevate ROS expression in vitro. 
ASL further increased the fluorescent intensity ofHT29 cells (p<0.0001) above 
concentrations of 40µg/ml in a dose dependent manner. However, LSL treatments 
induced an elevation in the fluorescent intensity  observed in CCD-841-CoN cells at 
10µg/ml (Fig 5.4c p <0.05) with further increases in the fluorescent intensity observed up 
to 80µg/ml. This was higher than the amount of ROS expression with the control H2O2. 
In the HT29 cell line, an elevation in the fluorescent intensity was only evident from doses 
of 60µg/ml LSL (Fig 5.4d p <0.05) upwards. The fluorescence values were corrected for 
cell number.  
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5.5 Discussion 
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Local and metastatic recurrence of CRC commonly occurs, even when tumours are 
completely excised during surgical treatment. Following surgical resection, the current 
gold standard drug regimen used in the treatment of CRC in the UK, is a cocktail of 
chemotherapeutic agents made up of folinic acid, fluorouracil and oxalipatin (FOLFOX) 
(Mohelnikova-Duchonova et al., 2014). This combination of drugs is given by i.v. 
injection and primarily acts on residual CRC cells by blocking DNA replication. 
Although FOLFOX is the first-line protocol, only 40-50% (Longley et al., 2003) of those 
prescribed this regimen, respond to the treatment due to intrinsic or acquired drug 
resistance in the remaining patients (Chen et al., 2013). However, like other 
chemotherapeutic regimes, FOLFOX does not distinguish between normal or cancerous 
cells resulting in such side effects as hair loss (Taïeb et al., 2005), a reduced immune 
response and neurotoxicity.  As the current gold standard chemotherapeutics have 
restricted efficacy and severe side-effects, new approaches for treatment of CRC 
progression are warranted which target cancer cells whilst proving non-toxic to normal 
tissue cells. In chapter four, we have shown the ability of ASL to differentiate between 
normal or colon cancer cells, potentially paving the way to an alternative therapy giving 
a more natural anti-cancer therapy option any perhaps reducing the risk of resistance.  
Although the cytotoxicity of SL mixtures has been widely reported against pancreatic (Fu 
et al., 2008), lung (Chen et al., 2006b), esophageal (Shao et al., 2012) and breast cancer 
(Ribeiro et al., 2015) cell lines in vitro, the mechanism of how they inflict their toxicity 
is not clearly understood as only changes in viability was measured. Here we investigated 
the potential pathway of which purified ASL and LSL inflict a response in the normal 
colon CCD-841-CoN and CRC cell line HT29, which is commonly used to test the 
chemotherapeutic potential of compounds in vitro (Zweibaum et al., 2011, Baricault et 
al., 1995).  
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It has been proposed that the lipid structure of BS allows the molecules to interfere and 
integrate with the lipid bilayer. One of the major components of the lipid membrane in 
mammalian cells are the clusters of lipid rafts which play an essential role in cell 
signalling (Simons and Toomre, 2000). Previous studies have shown that lipid raft 
disruption by pharmacological agents such as lovastatin aids in inhibiting the growth of 
MCF7 breast cancer cells in vitro (Owens et al., 2013).  The HT29 cell line is a robust 
adenocarcinoma colonic cancer line often used, on its own, in pilot experiments to test 
the effects of candidate therapeutics against CRC. This cell line was one of the first CRC 
cell lines isolated and expresses many of the characteristics of mature intestinal cells 
(Martinez et al., 2015). To date, a majority of studies carried out investigating the in vitro 
effects of drugs on lipid raft disruption in CRC, have been carried out solely on HT29 
cells (Simons et al., 2011, Lacour et al., 2004). Therefore, in order to compare the results 
obtained in this chapter against previously published studies, we tested the ability of 
purified ASL and LSL to disrupt the membrane lipid rafts of HT29 cells.   
 ASL induced a dose dependent disruption and changes of the lipid raft component of the 
membrane visible by an increase in fluorescent signal intensity in the HT29 cancer cells. 
Both ASL and LSL caused alterations to lipid raft expression, when quantified using 
fluorescent intensity. Previous studies have shown that an increase in fluorescent intensity 
located in specific regions of the lipid raft, similar to those present after SL treatment, has 
been associated to receptor clusters in response to a stimulus (Simons and Ikonen, 1997). 
Similar cluster formations, to those observed in ASL treatments, has also been reported 
in HT29 cells treated with Cisplatin, an anti-cancer drug which showed that these clusters 
formed in the HT29 cells treated with Cisplatin stained positive for lipid rafts and also 
stained positive for the death receptor CD95 (RAS) hypothesising that activation  of the 
lipid raft cluster was caused by the activation of the RAS receptor and resulting in 
apoptosis of the cell (Lacour et al., 2004) and has also been reported HaCaTs subjected 
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to ultraviolet B light irradiation (Wu and Wu, 2012). This mechanism could potentially 
explain the apoptosis and necrosis observed in chapter three and four when cancer cells 
were treated with SL. 
It has been proposed that these lipid clusters are receptor patches within the lipid domains 
which accumulate and migrate towards a single cellular pole forming a cap. This causes 
the reorganisation of the cytoskeleton, a process that is highly dependent on energy 
expenditure and consequently allows alterations to signal transduction in cancer cells 
(Graziadei et al., 1990).  
Lipid rafts play a role in the regulation of tight junctional structure in vitro (Laing et al., 
2005, Head et al., 2014) which was shown by Lambert and coworkers using cholesterol 
depleting agents which disrupt the cholesterol-rich domains within the lipid membrane 
(lipid rafts) resulting in an increase in tight junction permeability by interfering with tight 
junction protein expression (Lambert et al., 2008). We observed a dose dependent 
decrease in ZO-1 expression, a key component of tight junction regulation, in HT29 cells 
treated with SL. ASL demonstrated a superior effect, causing a dose dependent disruption 
to the tight junction complexes in HT29 via downregulation of ZO-1. LSL treatment 
resulted in the downregulation of ZO-1 in CCD-841-CoN at relevantly low doses 
however HT29 cultures at concentrations but failed to have any effect on HT29 until 
higher doses. Studies carried out in CRC Caco-2 cell in vitro have shown that lipid rafts 
play an important role in stabilising tight junctions via mediation of WNT signalling 
(Lambert et al., 2008).  Change to lipid raft configuration ultimately leads to the loss of 
tight junction integrity (Owens et al., 2013, Lambert et al., 2008) similar to the results 
observed in this chapter. Future experiments could delve deeper and look at the 
expression of Z0-1 at a protein level using western blot analysis.  This data would also be 
strengthened with the addition of more cancer cell lines and the normal cell lines. The 
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addition of a drug which can inhibit ZO-1 expression such as cisplatin (Baribeau et al., 
2014). 
In this chapter, experiments were designed to investigate the effects of SL on the MMP 
and ROS expression. Over the years it has been widely accepted that there is a strong 
correlation between MMP regulation and ROS production. Many manuscripts have been 
published to test this theory including studies by Bonora et al., (2012).  Mitochondria 
have been linked to being the main source of ROS in the cell.  ROS generated by  
mitochondrial stress play an important role in the release of cytochrome c and other 
cellular death proteins which in turn activates the cell death cascade (Ott et al., 2007). 
ROS are expressed at low concentrations in cells under normal conditions as it plays a 
role in intracellular signalling however when elevated, ROS is a key inducer of cellular 
death (Simon et al., 2000). The ability of SL to increase the expression of ROS in culture 
has been previously reported in MDA-MB-231, an adenocarcinoma cell line, when 
treated with 12µM of purified LSL (92%) (Ribeiro et al., 2015) which is the equivalent 
to approximately 140µg/ml of our SL. In this chapter we observed a significant increase 
in ROS production in HT29 treated with ASL at concentrations starting at 40µg/ml and 
only affected while elevated ROS expression was observed in  CCD-841-CoN cells from 
80µg/ml. Alterations to the expression of ROS after SL treatment has also been observed 
in MCF- breast cancer cell lines treated with 30µM of surfactant - Surfactan (Cao et al., 
2010).   
The data obtained in this chapter demonstrating that SL administration may influence the 
expression of MMP and ROS may help to explain why a change to cell viability and 
increase in cell death that was seen in the in vitro components of chapter three and four. 
As mentioned above, the MMP and ROS relationship has been shown to result in the 
activation of cell death mechanisms. It has also been reported that mitochondrial induced 
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ROS regulation can stimulate the production of proinflammatory cytokines especially in 
malignancies and other diverse pathological conditions (Li et al., 2013). It has also been 
reported that several transcription factors (TF) present in the nucleus are also present in 
the mitochondria. These include p53, nuclear factor kappa B, STATs and HIF-1 (Zhang 
et al., 2007, Handy et al., 2012). These   TFs have also been shown to be effected by ROS 
production also.  
The primary data obtained in this chapter opens up a new avenue of prospective future 
mechanistic studies which could look deeper into the relationship between SL mediated 
regulation of MMP expression, ROS production and how they can regulate the TFs 
mentioned above. This could give a better insight on how SL target a cancerous cell and 
regulate cell death.  
It has been previously documented that lipid-based compounds such as Haloperidol, an 
antipsychotic drug which works by altering receptor clusters, (Otzen, 2016, Alves et al., 
2011) specifically G-coupled receptors present in the lipid raft compartment of the lipid 
membrane of SH-SY5Y neuroblastoma cells (Sánchez‐Wandelmer et al., 2009). We 
hypothesise that SL work in a similar manner to lipid-based compounds due to their 
ability to redistribute lipid raft structures inducing raft clusters in the membrane. At low 
concentrations, SL had the ability to disrupt tight junctional complexes, which play an 
important role in the regulation of cell adhesion and migration (Tokes et al., 2013). 
Changes to tight junctions within lipid rafts result in alteration of cell migration (Murai, 
2011) and inhibition of the invasive properties of cancer cells (Owens et al., 2013). The 
disruption of lipid raft formation and structure is known to influence the release of ROS 
and is linked to the induction of apoptosis and necrosis (Higuchi et al., 1998). Therefore, 
the results reported in these studies and also seen in this chapter, may explain how, at low 
concentrations, SL demonstrated the ability to influenced the migration and invasion of 
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CRC cells and at higher concentrations, mediate apoptotic and necrotic death in CRC as 
outlined in chapter three and four.   
Other anti-cancer drugs incorporating lipid structures such as edelfosine, an 
alkylphospholipid analog, has been shown to specifically target the cell membrane of 
cancer cells via lipid raft disruption (Gajate and Mollinedo, 2007) resulting in the 
inhibition of migration in an non-adherent Jurkat lymphoma cell line as well as the 
adherent MDA-MB-435  breast cancer cell line (Potier et al., 2011). Similar to the results 
observed using ASL, edelfosine has the ability to differentiate between normal and cancer 
cells, by sparing normal cells from toxicity and apoptosis (Gajate and Mollinedo, 2014).   
In conclusion, we showed that SL treatment results in lipid raft redistribution via cluster 
formation and caused the downregulation of ZO-1 expression in HT29 CRC cells. This 
cell membrane disruption may underlie the changes in ROS and MMP expression 
observed in the CRC cell lines induced to undergo an increased level of apoptotic and 
necrotic cell death in response to LSL and ASL (Chapter 3 & 4 respectively). However, 
a deeper mechanistic study would need to be carried out, with the inclusion of the other 
cell lines used in this thesis, to gain a better insight into how the purified SL regulate the 
death of cancer cells. 
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Chapter 6 
General Discussion  
 
 
 
 
 
 
 
 
6.1 Discussion 
The treatment of CRC is challenged by lack of recommended screening compliance, late 
diagnosis of sporadic CRC, cytotoxicity of chemotherapy agents, drug resistance and 
CRC relapse.  A method to combat the increasing desire for chemotherapeutic agents with 
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less cytotoxic side effects has involved the testing of naturally occurring agents derived 
from plants, marine, aquatic or microbiological origins (Newman and Shapiro, 2008).  
Since the 1940’s, over 60% of new pharmacological agents can be traced back to a natural 
origin (Demain and Vaishnav, 2011). This has increased to over 74% since 2002 (Cragg 
and Newman, 2005) and include Taxol (plant derived used to treat ovarian and breast 
cancer) (Weaver, 2014). A number of naturally derived compounds such as 
Salinosporamide A (isolated from Salinispora tropica for the treatment of multiple 
myeloma) (Harrison et al., 2016) and Rebeccamycin (isolated from Streptomyces sp. for 
the treatment of lung, breast, liver and kidney cancer) (Eckel and Schmid, 2014) are 
currently undergoing clinical trial testing in humans (Harvey, 2008). 
Due to the success of chemotherapeutics derived from naturally occurring compounds 
used in the treatment of cancer and metastatic disease, there is an increasing demand for 
the search of naturally-occurring novel compounds for use in the treatment of CRC. 
This aim of this thesis was to test the anti-cancer potential of purified SL congeners by 
evaluating their ability to reduce CRC cell viability, induce cell death and inhibit the 
migration and invasion properties of cancer cells in vitro. This thesis also aimed to 
determine a therapeutic window for SL congeners in cancer cell lines without inducing 
toxicity to normal colonic cells in vitro. This thesis also aimed to address the lack of in 
vivo anti-cancer assessment of purified SL by using the Apcmin+/- mice to assess the 
potential benefit of LSL or ASL treatment in a murine model of CRC progression. Finally, 
this thesis explores the possible mechanisms of for their chemotherapeutic effect on CRC 
cell lines.  
The literature is currently populated with several studies which explore the anti-cancer 
properties of BS in vitro, including SL, however the range of responses observed may be 
explained by the differing compositions and purities of the mixtures tested.  
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The differences observed during our in vitro and in vivo studies for assessing SL activity 
(as described in Chapter one) identified a number of issues, which we believe to be 
generic in the current approach to studies on SL using bioassays:  
1. Studies are carried out using crude mixtures which are neither purified nor well 
characterised. 
2. Studies are carried out on a variety of different cancer cell lines, that are unrelated: 
in one study a liver (HepG2), lung (A549) and breast (MCF-7) cancer cell line 
were examined (Rashad et al., 2014). To assess specificity, is important to include 
a sufficient number of similar cancer types from the same tissue of origin and their 
efficacy across different stages (adenocarcinoma vs carcinoma, neoplasm vs 
metastatic). This was the approach in our studies, where 5 of the cell lines 
represented the range of CRC pathophysiology (Wilding and Bodmer, 2014).  
3. Several manuscripts examining the effects of SL omit normal cell controls and 
often data sets are not included in the manuscripts. Any normal cell lines that are 
used are of different origin and non-adherent thus bearing no similarities to the 
cancer cell lines tested. 
4. The anti-cancer mode of action in vitro is rarely investigated. 
5. Anti-cancer studies are rarely carried into a relevant tumour model for in vivo 
testing of the compound. There is only one other report of an in vivo model, where 
the effects of a crude SL mixture with an unknown composition was examined in 
a cervical cancer (HeLa) xenograft model (Li et al., 2016). 
 
The use of purified preparations of SL instead of crude mixtures: 
To address the issues described above, we use a highly purified preparation of LSL and 
ASL and tested them on a range of CRC cell lines, which best incorporated the different 
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stages of the cancer development and coupled it with a normal colonic epithelial cell line 
and a lung fibroblast cell line. We next administrated the purified LSL and ASL, orally, 
to the Apcmin+/- mouse, a pre-cancerous tumour model frequently used in CRC studies 
(chapters three and four). Finally, we investigated a potential method of how SL exerts 
their biological activity against CRC (chapter five). 
SL congeners (composed of a hydrophobic fatty acid and a hydrophilic carbohydrate 
head) occur in varying amounts within crude mixtures and demonstrate differences in 
both carbon chain length and their degree of acetylation (Rau et al., 2001).  Due to time 
constraints, SL are generally produced as crude mixtures with low quantity retrieval in 
order to reduce production costs (Mukherjee et al., 2006). For SL to be considered for use 
as a therapeutic agent, the characterisation and purification of the product is essential. 
This is to ensure the exact composition of the compound is known and each component 
is safe for potential clinical use and to ensure the formulation is consistent from batch to 
batch (Raskin and Ripoll, 2004). It has previously been shown that ASL are the easiest 
SL congener to obtain and purify as it is the first to be produced in the bioreactor and 
further purification of the sample can be performed via a hydrolysis reaction of SL 
(Asmer et al., 1988, Van Bogaert et al., 2007).  
New advances in biotechnology have enabled a more cost effective method of purification 
of LSL. One methodology which was used to generate the batch samples for this thesis 
involved induction of overexpression of S. bombicola lactone esterase (SBLE) allowing 
the lactonization (esterification) of ASL to form a highly purified LSL product (Roelants 
et al., 2016). In this thesis, the aforementioned method was used to produce single batches 
of either diacetylated C18:1 LSL or ASL, which were shown to be 96% (chapter three) 
and 94% (chapter four) pure respectively. 
 
 
156 
 
The potential of SL in biomedical applications have been well established with a diversity 
of studies claiming anti-microbial (Sleiman et al., 2009), anti-inflammatory (Hardin et 
al., 2007, Mueller et al., 2006), anti-viral and spermicidal properties (Gross et al., 2004, 
Shah et al., 2005) in vitro, although few show their effectiveness in vivo (Bluth et al., 
2006, Li et al., 2016).  
The ability of crude SL preparations to reduce cell viability and/or induce cell death has 
been documented in pancreatic (Fu et al., 2008), liver, lung (Chen et al., 2006), 
oesophageal (Shao et al., 2012), leukemic (Joshi‐Navare et al., 2011) and breast (Ribeiro 
et al., 2015) cancer cell lines in vitro. Generally, mixtures with a high percentage of LSL, 
(specifically C18:1 structures), show the greatest potency when compared with ASL 
(Ribeiro et al., 2015). 
In chapter three, we demonstrate that LSL exert a cytotoxic effect in CRC cell lines, 
resulting in a reduction of CRC and normal cell viability at similar doses therefore 
concluding that there is no therapeutic window of which LSL can inflict a toxic effect on 
the CRC cells without any adverse effects on the normal cell lines. In contrast to other 
available studies, LSL is reported to show a wide therapeutic range with reductions in 
viability at concentrations as low as 15µg/ml+ in MDA-MB-231 breast, 30µg/ml+ in 
H7402 liver, 40µg/ml+ in A549 lung and as high as 500µg/ml and 2mg/ml in HPAC 
pancreatic cancer cell lines in vitro (Ribeiro et al., 2015, Chen et al., 2006, Fu et al., 2008). 
These studies have also reported the ability of LSL rich mixtures to differentiate between 
normal and cancer cell lines showing no toxicity to a non-adherent, circulatory monocyte 
cell line (PCBM) or an uncharacterised cell line (Chang) (Chen et al., 2006) later shown 
to be contaminated with HeLa cells (Gao et al., 2011). 
Our results established the ability of ASL to reduce the cell viability of CRC cells at 
concentrations of 20µg/ml. Under the same conditions, there were no change to the 
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viability of the normal control CCD-841-CoN cell lines.  This has only been reported in 
one other study, in a pancreatic cell line HPAC, where viability was reduced with doses 
of 500µg/ml and complete inhibition of viability observed at 2mg/ml (Fu et al., 2008).   
The anti-cancer potential of other BS compounds have also been reported. A preparation 
of a lipopeptide produced by B. circulans with undisclosed purity, reduced the viability 
of HT29 and HCT15 cell lines by 90% with doses of 300µg/ml in both cell lines after 24h 
and deemed the IC50 values at120µg/ml and 80µg/ml respectively. The study also deemed 
the IC50 of NIH/2T2, a mouse adherent fibroblast cell line, to be 500µg/ml, five times 
higher than the cancer cells. Interestingly, the study states that crude preparations of the 
compound had little to no anti-cancer potency which can be explained by the low 
concentrations of lipopeptide present in the mixture (Sivapathasekaran et al., 2010) while 
the biosurfactants surfactant isolated from Bacillus subtilis reduced the viability of LoVo 
colorectal cancer cell lines at doses of 50µg/ml to 80% cell death after 24h (Kim et al., 
2007). 
To date, the majority of SL studies investigate cytotoxicity and viability of cancer cells  
in vitro. An exception to this a report by Chen (Chen et al., 2006) in liver cancer cells 
(H7402) where changes in cell morphology were observed (cells appearing rounded with 
condensed chromatin). This study demonstrated that doses of 40µg/ml of SL mixtures 
resulted in an influx of stationary G1 and S1 phase cells, an increase in intracellular Ca2+ 
and a rise in apoptotic positive cells (Chen et al., 2006). Our results have shown that LSL 
causes morphological changes which are observed in the normal CCD-841-CoN cell lines 
with cell rounding and detachment evident. In the CRC cell lines there are signs of cell 
detachment from 40µg/ml LSL. The detached cells counted in the supernatant tested 
positive for cell death while 70µg/ml resulted in obvious signs of cell rounding and large 
areas devoid of cells. ASL treatments resulted in no observable morphological changes 
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in the normal CCD-841-CoN cells. However, similar to LSL, ASL resulted in 
morphological changes in the CRC cells at both concentrations. Cell rounding has also 
been reported in a melanoma cell line (A 375), when treated with pseudofactin, a 
biosurfactants produced by Pseudomonas fluorescens BD5 from 7µM (equivalent to 
4.8mg/ml LSL used in this thesis) after 24h. At this concentration, pseudofactin also 
failed to induce morphological changes in Normal Human Dermal Fibroblast (NHDF) 
cells and Normal Human Epidermal Keratinocytes (NHEK) cells in vitro (Janek et al., 
2013). 
It is vital that potential chemotherapeutic agents must be able to do to more than just 
reduce the viability and induce cell death in cancer cells. Although these constitute an 
important part of cancer development, it is important that anti-cancer agents, such as SL, 
have the ability to influence the remaining hallmarks of cancer which include metastasis 
and invasion (Hanahan and Weinberg, 2011).  
Metastasis is defined as the movement of cells that originate from primary neoplasms to 
distal organs and proves to be one feared complication of CRC. Although there has been 
prodigious development in the diagnosis and treatment of the primary neoplasms in CRC, 
metastasis is still the major cause of deaths associated with this cancer and is caused by 
cells resistant to treatment (Fidler, 2003).  
Migration is an essential part of the metastasis cascade in cancer and plays a key role in 
the migration, invasion, intravasation and extravasation process of tumour cells.  The 
measurement of migration and invasion, the first major steps, can be easily measured in 
vitro using the scratch assay or a Boyden chamber (Roussos et al., 2011). The effects of 
SL on cancer cell migration was assessed in chapters three and four.  
The CRC cell lines HT29 and HT115 are derived from patients with adenocarcinoma and 
aggressive carcinoma tumours respectively and their use has risen in popularity to study 
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the CRC pathogenesis and the response to chemotherapeutics (Lengauer et al., 1997, 
Lacour et al., 2004, Coates et al., 2007). We employed these cell lines to investigate the 
effects of SL against metastatic properties in vitro and demonstrated LSL had a 
differential effect and resulted in the exacerbated the migration of HT29 and HT115 cells 
across the scratch compared to the vehicle alone, at 10µg/ml, a relatively low dose while 
at the same dose, LSL completely inhibited the migration of the normal CCD-841-CoN 
cells.   In comparison, the results obtained from chapter four demonstrated the ability of 
ASL to reduce the migration of HT29 and HT115 compared to the vehicle control, 
without inhibiting the migration of the normal CCD-841-CoN cells. A previous study 
evaluating the effects of a 92% C18.1 diacetylated pure LSL preparation against a breast 
cancer cell line MDA-MB-231, also tested their anti-migratory potential via the starch 
assay. LSL demonstrated the ability to reduce the migration of MDA-MB-231 cells by 
41.5% after 24hr (Ribeiro et al., 2015).  It may be concluded the biological effect of SL 
is dependent on the cancer/tissue type. 
Although the scratch assay is a good indicator of migration, the Boyden chamber proves 
more advantageous as it measures the movement of cells across a porous membrane in a 
response to a stimulus. The Boyden chamber can also be modified by adding a layer of 
extracellular matrix (ECM) allowing cancer cells to invade through the ECM before 
migrating through the porous membrane.  In chapter three, LSL resulted in 35% inhibition 
of migration at doses of 50µg/ml and above while in chapter four, ASL decreased the 
migration of cancer cells by almost half from only 10µg/ml. It can be concluded that ASL 
are more efficient at reducing the metastatic properties of CRC cell lines HT29 and 
HT115 and yet again proved to be non-toxic to the normal CCD-841-CoN colonic cells 
when compared to LSL. This first time the Boyden chamber has been used to assess the 
anti-metastatic properties of SL. 
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This thesis focusses on the evaluation of five colorectal cancer cell lines which differ by 
type (adenocarcinoma (HT29) vs carcinoma (HCT116)) and stage of cancer such non-
metastatic or metastatic. The data presented in the in vitro proportion of chapter three and 
four demonstrates a high potency of SL against CRC cells and strongly suggests that ASL 
has the ability to differentiate between cell lines inflicting a chemotherapeutic effect in 
the cancer cell lines alone compared to LSL. This is a highly sought after 
chemotherapeutic trait which has been a novel concept since being proposed by 
Blagosklonny and Pardee. They believe that chemotherapeutic drugs should target 
tumours via a nongenomic altering mechanism and kill cancer cells quickly (days)(Liu et 
al., 2015) rather than weeks or months which is the case for the chemotherapeutic 
currently used. This is highly possible as many in vitro studies demonstrated the ability 
of drugs to kill cancer cells with an hour while in chapter three and four, SL have been 
shown to reduce viability and induce cell death within 24h. This potential fact acting 
method of hitting tumours with an initial hard dose may reduce the side effects often 
associated with cancer drug treatments such as immunodeleption and due to these cell 
types such as bone marrow growing quicker than the tumour cells thus can be replaced 
with healthy cells after the initial hard dose (Liu et al., 2015).  
As aforementioned, the in vitro experiments carried out highlight a clear difference 
between the interactions of LSL and ASL when applied to both cancerous and normal 
colon cell lines. Although these congeners both belong to the same family known as SL, 
they both differ in their own ways. LSL is the later product to be retrieved from the batch 
ferminatator, has a basic pH and consists of a closed ring structure. In contrast, ASL is 
the first congener to be produced, is more acidic in nature and presents as an open ring 
structure. These stark differences, especially in relation to the structure have shown to 
play a role in the biological activity a compound. This phenomenon has also been noted 
in the testing of statins as anti-cancer agents in vitro. It was demonstrated that a closed 
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ring statin structure, such as mevastain, had a potent effect on a range of cancer cells lines 
while an open ring structure, such as pravastatin, had little to no effects on the cancer 
cells. 
One of the most significant results obtained from the in vitro component of this thesis 
was the discovery that ASL had the ability to differentiate between normal and cancer 
cell types. It is still unknown exactly how the ASL congener has the ability to differentiate 
between cancer and normal cells as seen in chapter four. One possible theory for this 
could be the ability of ASL to be fast acting killing cells that divide more rapidly – eg 
cancer cells (in culture: HT29 has a doubling time of 12hrs while normal CCD-841-Con 
is 36hrs). This theory could be carried out by comparing the time it takes cancer and 
normal cells to die when treated with various concentrations of LSL and ASL in vitro. 
Other drugs such as cyclophosphamide are well known to work by killing fast dividing 
cancer cells (Chan et al., 2012) such as leukaemia and small cell lung carcinoma (Reeder 
et al.,2009) . 
Due to lack of in vivo evaluations investigating the inhibitory influence of SL in an in 
vivo model of cancer we focused on the effects of purified LSL (chapter three) and ASL 
(chapter four) in a pre-cancerous model of CRC. We hypothesised that that oral 
administration of SL inhibited the development of neoplasms in the Apcmin+/- mouse 
model.  Mice were fed orally to allow direct access of the SL to the intestinal and colonic 
epithelial to exert a therapeutic effect.  
The treatment of Apcmin+/- mice dosed with 50mg/kg LSL resulted in an increase in the 
number and size of polyps found in the small intestine. These mice have a predisposition 
to splenomegaly and reduced haematocrit, resulting in anaemia (You et al., 2006). LSL 
treatments resulted in a further increase in spleen size and a reduction in haematocrit 
levels. This could further decrease in the lifespan of the Apcmin+/- mice (Holcomb et al., 
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2008). In contrast, although ASL did not cause a change in tumour number or size, there 
was a significant decrease in the spleen size and haematocrit levels. This proves a highly 
significant result as these mice tend to die as a consequence of the anaemia rather than 
neoplasm growth (Holcomb et al., 2008). The development of anaemia has been noted as 
a serious issue in FAP patients also (DeCosse et al., 1989) which is caused by 
gastrointestinal bleeding caused by epthelial eroision caused by polyp development 
(Adolph and Bernabe, 2008). A study carried out by (Hasty et al., 2014) demonstrated an 
increase in life span of Apcmin+/- mice treated IV with eRAPA, an anti-aging drug. They 
also correlate the increase in haematocrit levels (vehicle 17% vs 45% eRAPA) as a result 
of reduced blood loss, as a contributing factor to the increased life span seen after 
treatment (Hasty et al., 2014).Although the ability of ASL to help project the haematocrit 
and spleen can be seen as promising data, it would be further strengthened by the addition 
of a well-known chemotherapeutic agent such as cisplatin to compare against the efficacy 
of SL. 
The in vivo component of this thesis clearly investigates the biological activity of LSL 
and ASL in animal model of FAP. As mentioned previously, this is the most widely used 
model to investigate familial CRC syndromes. However, this model does not fully 
encapsulate all aspects of CRC developed as seen in FAP patients as it only produces 
benign tumours along the intestinal tract while humans develop both benign and 
malignant tumours in the colon. This is a major limitation of the study and in order to 
truly investigate the appropriateness of SL as a potential anti-cancer agent, an extra study 
would need to be carried out testing the biological activity in a malignant colon model in 
vivo. This will be discussed in more detail in the future experiments section of this thesis. 
After the publication of the first manuscript derived from the results of this thesis [Chapter 
3] (Callaghan et al., 2016) an article by Li et al, (Li et al., 2016) reported on the ability of 
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a crude SL preparation to reduce the tumour burden in a HeLa xenograft model using 
BALB/c nude mice and demonstrated a dose dependent decrease in tumour burden. This 
study, however, warrants caution for interpretation of experimental results as this amount 
of ethanol could result in long-term side-effects especially where dosing exceeds the 12-
day treatment period used in this paper. Consistent with this, another study using 80% 
ethanol administered intragastrically for 28 days was used to induce alcoholic liver in an 
animal model (Ji and Kaplowitz, 2003).  
Chapter 5 explores the possible mechanisms by which SL exert their biological actions.  
We hypothesised that SL disrupt membrane organisation via lipid raft integration within 
CRC cells resulting in a dose dependent downstream effect on cell adhesion and induction 
of cell death (as seen in chapters three and four) tight junction disruption, influence MMP 
and ROS production (chapter 5). 
It has been hypothesised that SL cause cell death via their strongly amphiphilic properties, 
which cause physical changes to the lipid bilayer. A study by Isoda et al, used SL mixture 
supplementation in a glioma cell line (HL60), which resulted in a decreased cell viability                                                                                                                                  
and inhibited protein kinase C activity (PKC) which plays a vital role in the modulation 
of membrane structure, transcription and cell proliferation regulation (Nishizuka, 1984). 
It has been reported that glycolipids isolated from Gigartina tenella induce changes to 
the lipid raft structures by inducing the aggregation of rafts at the membrane surface, a 
phenomenon which is microscopically visible via fluorescent dyes and is correlated to 
activation of receptors such as death receptor (FAS)s (Zhang et al., 2006). This clustering 
of raftsresulted in the disruption to the actin cytoskeleton structure in the JURKAT 
leukaemia cell line (Vali et al., 2005). In comparison to the primary cell cultures or non-
transformed cells, it has been hypothesised that cancer cell lines have varying levels of 
lipid rafts with different structures, compared to normal cells, thus rendering then unstable 
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(Patra, 2008). We have shown that both ASL and LSL have the ability to alter raft 
formation by increasing cluster formations on the surface of the cell membrane. This 
cluster formation have been shown to be caused by receptor activation (Simons and 
Toomre, 2000) in response to a stimulus such as chemotherapeutics and can result in 
disruption to raft integrity (Gajate et al., 2009). Lipid raft integrity is essential for maintain 
cell homeostasis because of their fundamental use as signalling platforms for the 
activation of receptors, kinases (George and Wu, 2012) and calcium channels (Berthier 
et al., 2004)  , which are all key players in the mediation of cell death in cells. This makes 
lipid rafts a potential anti-cancer drug target (Li et al., 2006).  
It has been shown that changes to lipid raft structure via receptor activation plays an 
important role in the disruption of cell adhesion via tight junction deregulation. An 
important player in this process is ZO-1, which is a member of the occludin protein 
family. ZO-1 is a key role as a scaffold protein which holds together fibril structures in 
the lipid bilayer to the cytoskeleton thus affecting cell adhesion (Itoh et al., 1997). As it 
is well known that BS can disrupt the adhesion of cells, we investigated if SL disrupts 
ZO-1 in cells which may give an insight into their mechanism of action.   
 We demonstrated the ability of ASL to influence ZO-1 expression at 10µg/ml ASL. 
Studies have shown that alterations to ZO-1 can induce changes in cell migration and 
disrupt CD44 expression in cells resulting in the reduction of adherence (Okada et al., 
1996, Harley et al., 2008) which may explain why we observed a reduction in cell 
migration in response to ASL treatment in chapter four.  
The increase of ROS production promotes cell death in cells (Wang and Yi, 2008). In 
chapter five, we also demonstrated the ability of SL to increase ROS production in HT29 
cells. The ability of SL to increase ROS production has also been shown in the breast 
cancer cell lines MDA-MB-231 when treated with 120µg/ml and 150µg/ml of C18:1 
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diacetylated LSL (Ribeiro et al., 2015). Similar results have been shown in other BS such 
as surfactan, which has been shown to induce cell death via elevation of ROS production 
in MCF-7 cells (Cao et al., 2010) in vitro. 
The increase of ROS production has also been correlated to the disruption of lipid rafts 
found in the cell membrane caused by pathological modification such as disease 
development (Alzheimer’s or Atherosclerosis (Ehehalt et al., 2003)) or drug 
administration (Edelfosine, a chemotherapeutic)  which can result in the signalling of cell 
death (Gniadecki et al., 2002) (Circu and Aw, 2010) by apoptosis and/or necrosis (Fiers 
et al., 1999), which is similar to the results we observed in chapter three and four.In 
addition to testing the anti-cancer properties SL, we also tested the bioactivity of 
Bolaform SL (BfSL) (Appendix 1.2) and glucolipids (Appendix 1.3). These differing 
classes of SL are produced in large quantities by strains of Starmerella bombicola 
deficient in acetyltransferase and lactonesterase enzymes. BfSL consists of two sophorose 
heads attached to either end of a lipid and often contain a small percentage of ASL. BfSL 
are naturally easier to solubilise, compared to other classes of surfactants, due to the 
carbohydrate head on each side of the fatty acid (Van Bogaert et al., 2016). BfSL mixtures 
may prove useful in the purification and transfection of DNA due to their ability to bind 
and compact DNA (Sohrabi et al., 2013), however any other biological activities are 
unknown.  Glucolipids are a derivative of SL which contain a glucose head replacing the 
sophorose head. This SL derivative has been first isolated by our collaborators at the 
Biobase plant in Belgium, therefore any biomedical applications are unexplored. 
Our results showed that both bolalipids and glucolipids resulted in a differential effect 
depending on concentration. Results show a non-linear fluctuation to viability across all 
CRC cell lines tested. This may be explained due to reduced purity in the samples we 
obtained. BfSL was 84% pure while the glucolipids 77%. This is a large difference 
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compared to the 96% and 94% LSL and ASL used in the previous studies. Any leftover 
reagents from the production process can prove detrimental and will contribute 
significantly to the bioactivity differences in the compounds obtained from different 
production batches.  
 
 
 
 
 
 
 
 
 
6.2 Conclusion: 
The overall aim of this thesis was to characterise the molecular congeners and standardize 
the in vitro and in vivo models of CRC used to assess biological activity of several 
different classes of SL produced by the commercially exploited yeast Starmerella 
bombicola. In addition, a partial characterization of the cellular /molecular mechanism of 
action of these SL was performed on selected CRC lines in vitro. Specifically, in this 
thesis it is shown that: 
1. It is possible to obtain a highly purified preparation of SL for preclinical testing. 
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2. This is the first report of the use of a purified ASL preparation in cancer related 
studies. 
3. SL congeners have a cytotoxic effect against 5 different well characterized CRC 
cell lines in vitro. 
4. Dose-dependent administration of ASL reveals differential effects on cell viability 
in normal versus cancer cells in vitro.  
5. LSL and ASL induce significant levels of apoptosis and necrosis in vitro. 
6. LSL exacerbates tumour growth, increases splenomegaly and decreases 
haematocrit levels in the Apcmin+/- model of neoplasia.  
7. ASL has no influence on tumour number or size in the Apcmin+/- model of 
neoplasia, however a systematic therapeutic effect was observed which reduced 
splenomegaly and increased haematocrit. 
8. SL increases lipid raft expression in CRC cells, a potential molecular-cell  based 
mechanistic explanation.  
9. LSL increases the lipid raft expression in HT29 CRCS at a higher dose than in 
normal CCD-841-CoN. ASL results in an increase in lipid rafts in CRC cells but 
not in non-transformed “normal” cells.  
6.3 Clinical significance:  
Overall the data collected for this thesis shows that purified ASL preparations have the 
potential to treat people diagnosed with FAP in the clinic. Although ASL administration 
demonstrated no ability to reduce the polyp burden, it did however, improve the 
haematocrit levels of the mice and reduce the observed splenomegaly. This could have a 
large impact on people living with FAP as an enlarged spleen and anaemia can result in 
abdominal pain, severe fatigue, increased chance of infection and can also reduce the 
quality of life. Currently there are no agents on the market that can help regulate these 
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secondary complications therefore the production of an ASL drug to target this would 
have a major impact in the clinic by improving the patients’ ability to live life and reduce 
the amount of hospital visits and stays. 
6.4 Study limitations:  
Although this thesis demonstrates a strong correlation between the ability of ASL to 
regulate the secondary effects associated with FAP in vivo, the study its self does not 
come without its limitations.  
The main selling point of the data collected, both in vitro and in vivo, is in the use of a 
purified SL compound. A single batch of both ASL and LSL was used throughout the 
study which was carried out over three years. The purity of the compound was only tested 
on a single occasion – after the production stage. To improve confidence of the compound 
purity, MS analysis could have been performed on a regular basis.  
The Apcmin+/- mouse model is an excellent model for testing drugs. As mentioned in the 
introduction, it is not a model of CRC and drugs tested in this model cannot be labelled 
as an anti-cancer agent. This issue can be addressed with more experiments and will be 
discussed in future experiments section 
6.5 Future experiments: 
The data collected for this thesis points towards the use of ASL as a candidate drug in the 
treatments of FAP. However, a plethora of future experiments could need to be carried 
out in order to fully understand how SL work. These include:  
Mechanistic analysis: 
An in-depth characterisation of the molecular pathways involved in ASL regulation  of 
CRC cells compared to normal cells. This can be carried out using genomic and proteomic 
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studies. Not only will this give a deeper understanding into how SL work but it may also 
give a better understanding on how ASL can differentiate between cancer and normal 
cells and LSL doesn’t.  
Synergistic studies: 
In addition, further studies could investigate the synergistic effects of SL in combination 
with current chemotherapeutic treatments for CRC such as 5 fluorouracil. Although the 
synergic effect of SL with current chemotherapeutics this has never been tested before, it 
is not a new concept. There have been a number of studies have been carried out on 
mutant p53 cancer types such as small cell lung carcinoma, testing the synergic effects of 
current chemotherapeutics with other compounds e.g.  cisplatin, an anti-cancer drug used 
to treat a wide range of cancers coupled with a chemical compound PRIMA-1MET. This 
combination of drugs reduced the amount of cisplatin needed. A reduction in the use of 
systemic chemotherapeutics has the potential to reduce side effects associated with their 
clinical use, such as hair loss, weight loss, sickness and a reduction in immune 
responsivity (Bonavida et al., 1999).  
SL combination studies: 
It would be interesting to see the biological effects of different ratios of purified ASL and 
LSL in combination against polyp growth. While our studies have shown the ASL 
provided a preferred biological effect compared to LSL, although LSL resulted in an 
increase in tumour number, it had visible effects on tumour growth while ASL had no 
effects on the growing polyps. It could be hypothesised that a small percentage (10 – 
20%) of LSL with the remaining being ASL may help target and reduce polyp number in 
vivo. 
 Alternative dosing routes, schedules and concentration in vivo: 
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In this study, mice were administered SL orally, once a day. The most convenient and 
popular mode of drug administration is oral ingestion as it has a higher patient compliance 
compared to injection and formulations are cheaper to produce (Krishnaiah, 2010). 
However one of the major issues with oral ingestion is solubility of compounds that are 
not readily soluble in aqueous solutions. Oral administration has been linked to slow drug 
absorption, reduced bioavailability and toxicity of the gastrointestinal tract (Vemula et 
al., 2010). The ability of ASL to dissolve easily in water is a desirable trait (Savjani et al., 
2012) compared to LSL which can only be dissolved in DMSO thus questioning its 
bioavailability and potential absorption which administrated orally.  Other possible routes 
of administration which could be tested in future experiments include intravenous 
injections. This method provides good absorption with the drug reaching circulation 
immediately, provides dependable and has shown to provide consistent reproducible 
effects, however it needs a highly trained person such as a health care professional to 
administer it in the clinic, proves more expensive and has a higher risk of toxicity. In vivo 
testing of IV administered compounds to rodents can cause damage to the tail over time 
thus limiting the number of dosing occasions.   
In this study Apcmin+/- mice were dosed with 50mg/kg once daily. Future studies could 
also look at dosing twice daily or increasing the concentration to 100mg/kg. Changes to 
the concentration and frequency would first need to be assessed using a pharmacokinetic 
study to analyse the drug metabolism, bioavailability and elimination in an organism. 
This can be carried out by dosing a mouse with SL orally, i.v. or i.p, and withdrawing 
blood at pre-determined time points (0, 5min, 15mins, 30mins, 1hr up to a 48hr 
timepoint.)  Blood, plasma or serum would be obtained and ran through a mass 
spectrometer to determine the quantity of drug in circulation. This will help determine a 
dose and appropriate dosing schedule that will reduce the chances of toxicity and side 
effects. 
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This thesis looks at the effects of SL against CRC cells in vitro however in vivo we test 
their effects against a model of FAP. Although, some would argue that the Apcmin+/- model 
is a model of CRC, it is in fact a benign pre-cancerous model and lacks many of the 
clinical characteristics of colon cancer. This is a major limitation to this thesis. In order 
to be able to label ASL as an anti-cancer agent future experiments would need to test SL 
in an CRC animal model. CRC animal models are severely limited and rarely used. Two 
models that can be used are:  
DMH/AOM model: 
The injection of 2-dimethylhydrazine(DMH) or azoxymethane (AOM) into Balb/c mice 
(Nyce et al., 1984) has proved a popular alternative choice for inducing colon 
carcinogenesis in rodents (Rosenberg et al., 2008). The injection of these inducer CRC 
drugs have shown to cause moderate to severe dysplasia along with Unfortunatly time 
and cost is a limiting factor with this model – induction can take anywhere from six to 
twelve months.  This increases the cost of animal husbandry and coupled with the cost of 
the AOM and DMH (Juca et al., 2014) can prove promblematic for a small budget 
research centre.   
Tumour xenograph model: 
An alternative CRC model involves the subcutaneous implantation of HT29 or other CRC 
cancer cells  on to the flank of an immunocompromised mouse (Britten et al., 1999). This 
is a popular model for directly measuring the effects of a drug on a tumour. This is because 
the tumour is grown on the back of a mouse and changes to growth can be easily seen and 
quantified. Although a very popular tool in human drug discover – it has one large 
limitation – the human cell line is grown in a different host and is not influenced by the 
normal colonic environment (Richmond et al., 2008).  
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Table  A1.1 – Data sheet to score animal behaviour during 
treatment 
 
Cage number:                                                                                                                   
Study number: 
Dead 
In nest 
Weight 
Fur appearance 
•         Normal
•         Pilo-erection
•         Bald
•         other
Walking 
•         Normal
•         Circles
•         Unable to stand on 4 legs
•         other
Ears open 
Eyes open 
Posture  
• Normal 
• Huddled 
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• Other 
Reaction to cage opening  
•         Active
•         Hyperactive
•         No response
Reaction of handling. 
•         None
•         Irritation/biting
•         Fear ( faeces/urine)
Cleaning aggression (+/-) 
Whister chewing (+/-) 
Comment 
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Background: Sophorolipids (SL), are amphiphilic biosurfactant molecules which consist 
of a sophorose molecule with 2 variable chain length (C10 - C22) They contain double 
bonds at the 3” 4” positions and fatty acids at the 1” positions. SL exist in either a lactonic 
(SLL; closed ring) or acidic (SLA; open ring) forms. SL is produced in crude mixtures by 
the yeast Candidia bombicola in economically viable amounts, with variable levels of 
anti-proliferative activity on tumour cell lines in vitro. As biosurfactants are well tolerated 
in the GI tract and currently used in a variety of food products, we tested the hypotheses 
that purified forms of either SLL or SLA have differential effects on colo-rectal tumour 
versus “normal” cells as well as in a well-established model of pre-cancerous lesions; viz 
the Apcmin+/− mouse. 
 
Methodology: The colo-rectal cancer cell lines HT29, HT115, HCT116, Caco-2 in 
addition to CCD-841 colonic epithelium and MRC5 lung fibroblasts were exposed to 10 
- 100 μg/ml of either SLL or SLA (96% or 94%) pure respectively by HPLC/MS analysis) 
for 24 hours following serum starvation and an MTT assay performed. The mechanism 
of cell death in cell lines was assessed by acridine orange/ethidium bromide staining 
followed by microscopic examination. Five-week old Apcmin+ mice or wild-type 
littermate mice were treated orally with 50mg/kg of either SLL or SLA, or vehicle-only 
control every other day for 14 weeks. Weights, water and food consumption were 
measured on a daily basis. On completion of the experiment, mice were euthanized, the 
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digestive tract was excised, washed and fixed with 10% BFS. Polyp size, number and 
location were recorded and samples were blocked for paraffin embedding, sectioning and 
H&E/immunofluorescence staining and analysis. 
 
Results and Discussion: In vitro, SLL caused a decrease in colorectal cancer cell viability 
at >70μg/ml. However, it also caused an unfavourable effect on the colonic epithelium 
and lung fibroblast cell lines by reducing cell viability at a lower concentration 
(<10μg/ml). In-vivo, SLL treatment exacerbated the growth of polyps along the digestive 
tract of Apcmin+ mice. SLL treatment resulted in an increase in polyp number and size 
compared to vehicle treated Apcmin+/- mice. SLL treated mice presented with reduced 
haematocrits (28.5% vs 34.5% p<0.03) and increased spleen weights (0.56g vs 0.70g 
p<0.01) compared to vehicle treated control Apcmin+ mice. 
SLA induced a dose dependent decrease in cell viability of colo-rectal cancer cell lines 
(20μg/ml) without affecting the viability of the colonic epithelial and lung cell lines. 
SLA selectively induced cell death in the colo-rectal cancer cells by means of necrosis. 
However, the effects of SLA in vivo are yet to be established. 
 
Contrary to current literature, purified SLA appears to have an advantage over the 
SLL form in vitro. To date, this is the first study investigating anti-cancer effects of 
sophorolipids in vivo. 
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